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1. Obesity: a world-wide disease 
 
 
1.1 Historical view 
 
In the comedies of the ancient Greeks a fat character was perceived as a flawed and 
glutton figure, and was a subject of mocking. Hippocrates recognized corpulence as a disease but 
also a harbinger of others, health being the greatest human blessing. Together with his quote that 
“What is food to one man is bitter poison to others”, the meaning of obesity has changed 
throughout history. About three centuries later, the Roman emperor Julius Caesar suggested that 
higher body weight correlated with a well-balanced mental disposition 1. Back then, and until the 
Middle Age and the Renaissance, obesity was not considered a medical risk factor, but was rather 
viewed as a sign of wealth and prosperity. 
It was not until the end of the 19th century and the onset of the industrial revolution that 
food scarcity was considered to play a major role in the economic development of industrialized 
societies, contributing to low survival, strength and productivity of the young generations, where 
the soldiers and workers were drawn from. Thus, weight, together with height, increased 
progressively in the developed world 2,3. 
By the 21st century was achieved a historical milestone in human evolution, according to 
which the number of adults with excess weight equaled the number of those who were 
undernutritioned 3. Spare body weight is nowadays widely recognized as one of the most 
important risk factors in health, increasing the social and economic burden worldwide. WHO ranks 
obesity and overweight in the fifth highest position for global deaths, contributing moreover to 
other major health burdens, such as diabetes, hypertension, ischaemic heart disease and cancer. 
In 2008, more than one in ten of the world’s adult population was obese. It is a fact that 
overweight and obesity are rapidly upsurging/emerging in low- and middle- income countries, 
particularly in urban settings, and are linked to more deaths worldwide than underweight. 
Nevertheless, obesity is preventable and as a medical disorder that also leads to many 
comorbidities should not be neglected 4. 
 
 
1.2 Definition and causes of obesity 
 
Obesity is defined as abnormal or excessive adipose tissue accumulation that may impair 
health 4. The obese state designates a disproportionate increase in weight with respect to height, 
sex and age. A simple quantification of this relationship commonly used to classify overweight and 
obesity is the body mass index (BMI), calculated by dividing a person’s weight in kilograms (kg) by 
the square of his height in meters (m).   
 
BMI= kg / m2  
 
Undoubtedly, BMI provides the most useful population-level measure of overweight and 
obesity as it is the same for both sexes and for all ages of adults. Nevertheless, it should be 
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considered a rough guide because it may not correspond to the same degree of fatness in different 
individuals.  
The World Health Organization (WHO) has established a series of criteria according to 
which high or low body weight in humans is classified as follows:  
 
 
Classification BMI (kg / m2) 
Underweight <18.5 
Normal 18.5 -24.9 
Overweight 25 – 29.9 
Obesity class I 30.0 – 34.9 
Obesity class II 35.0 – 39.9 
Obesity class III ≥ 40.0 
Extreme obesity > 50 
 
 
After the WHO classification, there are a number of causes for obesity, being the 
fundamental one the energy imbalance between calories consumed and calories expended. 
Globally, there has been an increased intake of energy-dense foods that are high in fat, salt and 
sugars, but low in vitamins, minerals and other micronutrients, as well as a decrease in physical 
activity due to the augmented sedentary nature of many forms of work, changing modes of 
transportation and increasing urbanization.  
 
 
1.3 Just a matter of genes? 
 
Scientists acknowledge that multiple factors contribute to obesity including dietary, 
economic, psychosocial, reproductive, cultural and pharmacologic impacts. The contribution of 
each of those elements has been subject of intensive studies.  
Genetic heritability of BMI or body fat phenotype has been validated by different research 
techniques, recognizing more that 50 genes (LPL, UCP's, PPAR, Ob, LepR, POMC, etc.) linked 
straightforwardly or not with obesity heritability 5. As an example, monozygotic twin pairs showed 
a higher obesity concordance rate than dizygotic pairs (~ 0.68 vs ~ 0.28) 6,7,8,9. In cases of adoption, 
the adopted subjects exhibited a BMI closer to the one of their biological parents, supplementing 
the role of the genetic factors over a shared familial environment 10,11. 
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Some forms of monogenic obesity (mutations in obesogenic genes as leptin, POMC, 
Prohormone Convertase 1, Neurotrophin Receptor TrkB, melanocortin 4 receptor deficiency 12 and 
endocrine forms of secondary obesity (i.e. Cushing syndrome) exist in humans. But obesity remains 
predominantly a complex polygenic disease, that, under the influence of an obesogenic 
environment (food excess, lack of exercise), modifies signals of caloric intake and energy 
expenditure. One hypothesis for that is that genes that once provided an evolutionary advantage 
(by allowing maximum efficiency of nutrient storage) are severely challenged when exposed to 
obesogenic environments 13, although this remains to be formally tested and proved. There is also 
the case of the pleiotropic syndromes, where obesity forms part of a variety of physical and 
developmental anomalies within the clinical syndromes (Prader Willi, Bardet-Biedl syndromes 
etc.), for the moment reported around 30 of them. A plausible cause of those syndromes is an 
intracellular protein produced by the defective gene, which is present throughout the body and 
has an unidentified function 12. 
Therefore, the impulse to eat, that at extremity can result in hyperphagia, should not be 
considered a fully voluntarily controllable phenomenon and as the sin of gluttony, but rather as a 
genetic defect driven by biological signals. Many patients who develop early-onset obesity inherit 
it in a Mendelian way, or present subphenotypes that are similar to those of monogenic obesity 
characteristics. This proves the fact that a lot more genes still need to be identified in order to 
understand the roots of the disease completely. It is also very frequent in consanguineous families 
to have obese members in whom severe obesity segregates in an autosomal recessive manner and 
where mutations in known obesity genes are not found 14. 
Moreover, many complex diseases are nowadays attributable to epigenetic changes, 
translated into inherited changes in gene expression that take place without changes in the DNA 
sequence. Epigenetic events like a prolonged, inappropriate diet determine cell fate by introducing 
strong environmental influences to the genome. In this sense recent researches have 
demonstrated that obesity is associated with an impaired adipogenesis. Thus, epigenetic 
mechanisms could explain the alterations that undergoes a preadipocyte when growing under a 
hypertrophic environment, generated by his already hypersized companions. The contribution of 
this mechanism in the development of obesity is still under study. 
 
 
1.4 Epidemiology 
 
Awareness on obesity has been attracted by the mass media during the last decades. It is a 
fact though, that the prevalence of obesity in industrialized countries began to increase gradually 
early in the last century.  
Starting from the 1950s and continuing to the 1970s and on, surveys in the U.S. population 
emphasized alarming trends in obesity rates 15,16. By the year 2000, 65 percent of the same adult 
population had a BMI above 25, 30 percent were obese and 5 percent were extremely obese 17. 
Nowadays the U.S. belongs to the countries with the highest obesity rates in the world.  
Undeniably, obesity started as a public health problem in societies with high 
socioeconomic status, primarily the United States and Europe in the developed world. But as soon 
as dietary changes in developing countries underwent significant changes (particularly in respect 
to fat, caloric sweeteners and animal source foods) and physical activity was shifted away from 
high-energy expenditure activities (like farming, mining and forestry), the burden of obesity moved 
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towards the poor. Countries as diverse as Mexico, China, Thailand and South Africa are shown with 
dramatic increases in obesity 18. The WHO statistics pointed out 400 million obese people in the 
world, estimating an increase to 700 million by 2015.  The transition stage of nutrition linked with 
a high level of obesity is finding most lower- and middle-income countries unprepared 19.  
The biggest large-scale study conducted for Europe was the WHO MONICA (Multinational 
MONItoring of trends and determinants in CArdiovascular disease) project. In this study were 
collected data from 34 populations in 21 countries from the early 1980s to the mid-1990s. 
Participating subjects aged 35-64 years. According to the results obtained, Mediterranean 
countries, Spain, Italy, and France had lowest energy intake proportion from all sweeteners 20.  
Other studies revealed obesity prevalence up to 28.3% in men and 36.5% in women. 
Overall obesity prevalence rates were higher in the central, eastern, and southern regions of 
Europe than in the western or northern ones, a geographic pattern partly explained by the 
negative impact of new lifestyle factors on the traditional Mediterranean diet 21.  
Regarding Spain, the most recent data come from a study conducted by the Spanish 
Society for the Study of Obesity (SEEDO), that incorporate diverse epidemiologic studies 
performed in the country at the time period 1990-2000. Data base analysis of the DORICA study 
for people 25 to 60 years old revealed a total obesity prevalence of 15.5%, which appears to be 
more prominent in women (17.5%) than in men (13.2%). Overweight frequency is though more 
elevated in men at 46.4% in respect to 32.9% of the women, summing up a 39.2% of the 
population 22.  
 Obesity is not only a trend of the adults, but also of the young. Youth overweight has 
increased in the 1990s to 25.6% in the United States, 14.3% in Brazil and 7.7% in China, with 
annual increasing rates from 0.2-0.5% 18. Overweight differs across children (ages 7–11 years) from 
Spain (34%), Italy (36%), and Malta (35%) in Southern Europe 23 and France (19%), the United 
Kingdom (20%), Sweden (18%), and Denmark (15%) in Western and Northern Europe, to Russia 
(10%) and Poland (18%) in the Eastern bloc. Adolescent (14–17 years) overweight is similar, with 
particularly high levels in the United Kingdom (21%) and Southern Europe (Spain (21%), Greece 
(22%), and Cyprus (23%)) 18. According to the DORICA study about children and young people in 
Spain, overweight and obesity is related to absence of breastfeeding, low consumption of fruit and 
vegetables, high consumption of cakes, soft drinks and butchery products, low physical activity 
levels and a positive association with time spent watching TV 24.  
 
 
1.5 Clinical diagnosis and Measurement of fat distribution 
 
Fat distribution is an important factor to be taken on account, and measuring visceral fat is 
a better prediction factor of health risks than total body fat. Vague 25, in 1948, came first to the 
notion that android or male fat distribution was connected to diabetes and heart disease, a 
perception nowadays widely accepted. Until the present, plenty of techniques have been 
established for the solid measurement of body fat distribution 26. The employment of a concrete 
technique relies on the equilibrium between practical and financial considerations and the aim of 
the study 27. 
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Body Mass Index 
BMI has traditionally been the preferred index by which to measure body size and 
composition, and to diagnose underweight and overweight 4. Generally, the BMI correlates with 
the accumulation of fat mass. However, this is not the case in severely obese patients due to the 
central accumulation of adipose tissue, which leads to a greater accumulation of adipose tissue for 
the same BMI. 
Nonetheless, BMI measurement underlies the important limitation of being unable to 
distinguish between fat mass and fat-free mass, a relationship opposed with health risk 28. 
Moreover, BMI is a restrictive method also in the case of elderly people 29, that have decreased 
fat-free mass even without a change in overall weight 30. 
Alternative measures that reflect abdominal adiposity, such as waist circumference, waist–
hip ratio and waist–height ratio, have been suggested as being superior to BMI in predicting CVD 
risk4. 
 
Waist Circumference 
In contrast, waist circumference (WC) represents a measure of adiposity that takes into 
account the accumulation of abdominal fat. WC is simple to measure and interpret and it is highly 
correlated with visceral fat as assessed by computed tomography 31. The potentially greater 
relevance of WC than BMI for predicting adverse health conditions in the elderly is underscored by 
the observation that fat mass accumulates intra-abdominally with age 32. Older age groups have 
experienced a greater increase in abdominal obesity than younger age groups 33. 
The ratio of waist circumference to hip circumference (WHR) was started to get used in the 
1980s as another way to assess risk development of heart disease, diabetes, and other chronic 
problems associated with obesity 34-36, proceeding from central fat location. However, the 
preferred method remained waist circumference, measured according to National Heart, Lung, 
and Blood Institute/North American Association for the Study of Obesity (NHLBI/NAASO) 
guidelines 37. 
 
Other Anthropometric Techniques  
 Central fat estimation has been accomplished in some epidemiologic studies by other 
phenotypical measurements getting subscapular skinfold values, a method not clinically valuable. 
Moreover, techniques like bone dimensions and limb circumference are based on the assumption 
that the subcutaneous adipose layer reflects total body fat, but this association may vary with age 
and gender. 
  
Bioelectrical Impedance  
Bioelectrical impedance analysis (BIA) is an indirect technique that estimates body 
composition via comparison of fat-free mass and total body water 38, by release of a low electrical 
current through the body, which passes through the fluids contained in muscle tissue more easily 
than through fat tissue. The resistance encountered in the latter is termed 'bioelectrical 
impedance', and is characteristic for a person's height, gender and weight. Adipose tissue (AT) 
mass is calculated by the subtraction of the free AT mass from the total body weight 38. BIA can 
evaluate the AT content better than the BMI, but loses sensitivity for a BMI>35kg/m2, 
overestimating AT free mass and underestimating AT 39. 
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Hydrostatic Weighing (HW) and Air Displacement Plethysmography (BOD-POD) 
Hydrodensitometry, or hydrostatic weighing (HW), is considered to be the gold standard of 
the densitometric methods 40. Based on the Archimedes principle, body volume is determined by 
measuring the difference between a subject's weight in water and that in air and thus determining 
whole-body density. A prerequisite for this technique is to submerge the subject completely 
underwater while exhaling maximally 41. As a consequence, several limitations apply with this 
method, such as time and labor intensity, subject discomfort, and inaccessibility for many special 
populations.  
Plethysmography refers to the measurement of size, usually volume. In air-displacement 
plethysmography, the volume of an object is measured indirectly by measuring the volume of air it 
displaces inside an enclosed chamber (plethysmograph). BOD-POD (Life Measurement, Inc, 
Concord, CA) is the only commercially available system for air-displacement plethysmography 42. 
This technique offers established reference methods, including a quick, comfortable, automated, 
noninvasive, and safe measurement process, and accommodation of various subject types (e.g. 
children, obese, elderly, and disabled persons). Moreover, it is reasonably precise, accurate, and 
easy to use, but still expensive 43. 
 
Computed Tomography (CT) and Magnetic Resonance Imaging (MRI)  
 The primary advantage of these imaging modalities is the ability to quantify adipose tissue 
within distinct regions of the body. Computed tomography can provide information about the 
spatial arrangement of tissues within specific regions of the body based on how those tissues 
attenuate the energy from the X-ray. Fat and muscle can be primarily distinguished because of 
their widely different attenuation characteristics. Adipose tissue is less dense than water and 
displays attenuation values in the negative range (-190 to -30 HU) whereas muscle is denser than 
water and has a positive attenuation (0 to 100 HU), thus muscle and fat are in contrast on the 
computed tomography image. 
 Although its application to regional fat distribution is more common, MRI can be used to 
quantify whole body adipose tissue through an electromagnetic field. An advantage of whole-body 
MRI over more conventional methods for determining whole body fat content or body 
composition is that regional differences or changes in fat or muscle can be assessed. The 
disadvantage of a whole body magnetic resonance scan is that considerable and fairly 
sophisticated image analysis software is required 44. 
MRI does not expose patients to ionizing radiation as CT does, but both techniques are 
difficult to employ in the case of severe obesity due to the extended time of probing and the 
limitations regarding the explored surface. CT and MRI allow us to calculate the correlation 
between clinical parameters of cardiometabolic risk and the distribution of the adipose tissue, and 
thus are important tools for use in subjects at cardiometabolic risk 27,44. 
 
Dual Energy X-ray Absorptiometry (DEXA) 
The principle of DEXA consists in the generation of X-rays at dual energies, whose 
differential attenuation in a tissue-specific manner is used to estimate three body compartments 
with one measurement: adipose tissue, bone and other non-adipose soft tissue (lean) 45. The 
method is quick, safe, noninvasive, easy to use and has low operational costs, advantages that 
make it viable for clinical settings, clinical research and even large-scale population-based studies 
44,46. For that, DEXA use for assessment of body fat and body composition has become 
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progressively extensive, despite the fact that it does not provide information about the visceral or 
subcutaneous distribution of the adipose tissue, and the negative critics about the accuracy of the 
method for body-composition assessment and the different results exported by the different 
providers 47.  
 
 
1.6 Health consequences associated to obesity 
 
As obesity and overweight have reached unprecedented levels globally with a rise 
projected to continue, relevantly increscent have been associated-to them-comorbidities. Those 
are not rarely responsible for declining life quality of subjects dealing with those side effects and 
boosting economical and social costs, causing widespread concern.  
Obesity-associated comorbidities are due to the excess of adipose tissue itself, and to 
metabolic or/and psychosomatic alterations induced by the surfeit of adipose mass. A short 
classification of them is juxtaposed in Table 1 48,49. Since in chapter 4 we will provide more insights 
into some of them, subsequent aspects are briefly portrayed. 
  
 
Reduced life expectancy 
In an analysis of the effects of obesity on longevity in 16 countries it was estimated that 
obesity reduced longevity in all countries ranging from half a year for females in Switzerland to 
more than a year and a half for U.S. males. These effects have been more severe in the United 
States than in other countries, featuring a BMI distribution that distinguishes it from the 
comparison countries: an unusually high rate of obesity in younger age groups and significantly 
higher rates of severe obesity 50. 
 
Arterial Hypertension 
 Hypertension is due to increased intravascular volume and secondary to an increase in 
peripheral vascular resistance and activation of the rennin-angiotensin system 51. Obesity most 
commonly leads to hypertension, where it appears up to five times higher than in normoweight 
people 52. 
 
Cardiovascular Diseases (CVD)  
 Obesity contributes importantly to the appearance of CVD. CVDs, including heart disease, 
vascular disease and atherosclerosis, are the most critical global health threat, contributing to 
more than one-third of the global morbidity. At the present time, systemic atherothrombosis is 
recognized as a chronic condition determined by the interplay between the chronic inflammation  
of the vessel wall and lipid overcharge. It is likely that inflammation induced by obesity accelerates 
atherosclerosis.  
 
Alteration of carbohydrates and lipid homeostasis  
 Impaired fasting glucose (IFG), impaired glucose tolerance (IGT) and furthermore type 2 
diabetes are associated with obesity (especially abdominal or visceral obesity).  The risk of 
diabetes is greatly increased by weight gain.  These alterations are frequently associated to various 
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forms of dyslipidemia with high triglycerides and/or low high-density lipoprotein (HDL) cholesterol 
or high low-density lipoprotein (LDL) cholesterol and hypertension.   
Moreover, obese individuals commonly have elevated plasma free fatty acids (FFAs, 
probably due to increased FFA release from expansion of the fat mass) and so do type 2 diabetic 
people 53. 
 
 
Table 1. Obesity-associated comorbidities 
Cardiometabolic alterations 
 Atherothrombotic coronary and 
cerebral disease 
 Arterial hypertension 
 Congestive heart failure 
 Dyslipidemia  
 Diabetes mellitus 
 Hyperuricemia 
Digestive alterations 
 Non-alcoholic steatohepatitis 
 Gastroesophageal reflux disease 
 Colelithiasis 
Renal alterations 
 Microalbuminuria 
Respiratory alterations 
 Asthma 
 Sleep apnea 
 Restrictive respiratory insufficiency 
Neoplasms/Cancers  
 Breast 
 Endometrium 
 Prostate 
 Colon  
Others 
 Daytime somnolence 
 Depression 
 Polycystic ovary syndrome 
 Peripheral venous insufficiency 
 Arthritis  
 Gallbladder disease 
 Binge-eating disorder 
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 Psychological impacts 
 In today’s western societies, beauty standards praise cachectic bodies to a level that 
individuals not fulfilling those standards, especially women, tend to feel anxious, margined in 
interpersonal relationships and depressed, being prone to develop obsessive behaviors as they 
attempt to deal with their excess weight. Thus, discrimination and bias spread unrestrained 54. 
Special attention has to be applied in order to distinguish the social from the pathophysiological 
consequences of weight gain. Stigma and discrimination toward obese persons are pervasive and 
pose numerous consequences for their psychological and physical health.  
 
 
 
2. Type 2 Diabetes Mellitus  
 
 
2.1 Definition of Diabetes Mellitus 
 
According to the American Diabetes Association (ADA), Diabetes mellitus (DM) is defined 
as a group of metabolic disorders characterized by chronic hyperglycemia resulting from defects in 
insulin secretion and/or action. The prolonged hyperglycemia of diabetes is associated with long-
term damage, dysfunction, and failure of various organs, especially the heart, vascular and nervous 
systems and eyes, kidneys.  
 
 
Table 2. Criteria for the diagnosis of diabetes 
1 
A1C ≥ 6.5%. The test should be performed in a laboratory using a method 
that is standardized to the DCCT assay.* 
OR 
2 
FPG ≥ 126 mg/dl (7.0 mmol/l). Fasting is defined as no caloric intake for at 
least 8 h.* 
OR 
3 
Two-hour plasma glucose ≥ 200 mg/dl (11.1 mmol/l) during an OGTT. 
The test should be performed as described by the World Health 
Organization, using a glucose load containing the equivalent of 75 g 
anhydrous glucose dissolved in water.* 
OR 
4 
In a patient with classic symptoms of hyperglycemia or hyperglycaemic 
crisis, a random plasma glucose ≥ 200 mg/dl (11.1 mmol/l). 
*In the absence of unequivocal hyperglycemia, criteria 1–3 should be confirmed by repeat testing. 
Adapted from the American Diabetes Association, Diabetes Care 2011 55. 
18 | I n t r o d u c t i o n  
 
The origin and the development of diabetes is attributable to multiple causes, starting 
from autoimmune destruction of the insulin producing pancreatic β-cells and the consequent 
insulin deficit, to abnormalities in the metabolism of carbohydrates, fat and proteins resulting 
from insufficient insulin secretion and/or a diminished insulin response in the target tissue 
(muscle, adipose tissue, liver, etc). 
The principal symptoms of overt diabetes are excess thirst, polyuria, hunger, unexplained 
weight loss, fatigue and blurring of vision. 
Diabetes can be diagnosed clinically or by the application of laboratory methods. The 
current diagnostic criteria for diabetes are summarized in Table 2. 
 
 
2.2 Classification of Diabetes Mellitus 
 
The classification of diabetes includes four clinical classes 55:  
 
 
Type 1 Diabetes Mellitus 
Type 2 Diabetes Mellitus 
Gestational Diabetes Mellitus 
Other Specific Types of Diabetes 
 
 
I. Type 1 Diabetes 55 
 
Type 1 DM results from destruction of the beta cells in the pancreas and usually leads to 
absolute insulin deficiency. Although it can occur at any age, type 1 DM is more common in 
persons less than 30 years of age. The rate of pancreatic destruction is variable and is generally 
more rapid in infants and children and slower in adults. Patients tend to be acutely symptomatic at 
onset. The primary characteristic of type 1 DM is absolute dependence on exogenous insulin to 
prevent ketoacidosis 56. 
There are two forms of type 1 DM: 
 
a) Immune-mediated diabetes 
This form of diabetes is a result of the autoimmune destruction of the pancreatic β-cells 
and accounts for only 5–10% of the diabetes cases and for the majority of cases of type 1 diabetes. 
Previously termed as insulin-dependent diabetes or juvenile-onset diabetes, it appears with 
variable β-cell destruction rates: rapid mainly in young individuals (infants, children and 
adolescents) and slow in adults. Commonly it is diagnosed in the first category of patients, but 
subjects in their latter years can also be affected. Autoimmune destruction of β-cells is based on 
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multiple genetic predispositions, as well as on environmental factors, yet poorly defined. Patients 
tend also to develop other autoimmune disorders such as Graves’ disease, vitiligo, autoimmune 
hepatitis, myasthenia gravis, and pernicious anemia. 
 
b) Idiopathic diabetes 
The existence of some forms of type 1 diabetes has no known etiologies. Some patients 
belonging to this category undergo permanent insulinopenia and are prone to ketoacidosis 
without any evidence of autoimmunity. Patients falling in this category of type 1 diabetes are of 
African or Asian ancestry, accounting on total for a minority of patients. Episodic ketoacidosis and 
varying degrees of insulin deficiency between episodes are frequently present in those individuals. 
Inheritance seems to be the main reason for the transmission of this form of diabetes, which lacks 
immunological evidence for β-cell autoimmunity. Affected patients might depend on insulin 
replacement therapy with a con-coherent frequency. 
 
 
II. Type 2 Diabetes 55,56 
 
Type 2 diabetes, which accounts for about 90–95% of those with diabetes, presents an 
increasing prevalence. There are probably many different causes of this form of diabetes. Although 
the specific etiologies are not known, autoimmune destruction of β-cells does not occur.  
Ketoacidosis seldom occurs spontaneously in this type of diabetes; when seen, it usually arises in 
association with the stress of another illness such as infection. Previously referred to as non-
insulin-dependent diabetes, type II diabetes, or adult-onset diabetes, underlies defects that can 
vary from predominant insulin resistance with relative insulin deficiency to a predominant insulin 
secretory defect of beta cells with insulin resistance 55. 
Type 2 DM occurs more frequently in adults than in children, and the incidence increases 
with age (especially after age 40), obesity, lack of physical activity, in women with prior gestational 
diabetes mellitus and in individuals with hypertension, dyslipidemia or of different racial/ethnic 
subgroups. However, the prevalence of type 2 DM in children is increasing, especially in the high-
risk ethnic groups, such as Native Americans, Hispanic Americans, African Americans, and Asian 
Americans. There have been studied many candidate genes as possibly implicated in the etiology 
of DM2. Recent research reported interesting results regarding the effect of TCF7L2 as a primary 
type 2 diabetes genetic risk mediator in African Americans 57, but the actual evidence indicates 
that type 2 DM is a complex genetic disease.  
Because the onset is frequently insidious (hyperglycemia develops gradually and at earlier 
stages is often not severe enough for the patient to notice any of the classic symptoms of 
diabetes), many patients with type 2 DM are asymptomatic and remain undiagnosed for years. 
Nevertheless, such patients are at increased risk of developing macrovascular and less 
microvascular complications. At least initially, and often throughout their lifetime, patients do not 
require insulin therapy to survive.  
Among type 2 DM diagnosed patients 80% are overweight 58. Obesity itself causes some 
degree of insulin resistance. Patients who are not obese by traditional weight criteria may have an 
increased percentage of body fat distributed predominantly in the abdominal region. Generally, 
upper body obesity is a recognized risk factor because it results in a significantly increased 
peripheral muscle and hepatic insulin resistance. Initially, beta cells compensate for this resistance 
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by increasing insulin secretion, inducing a relative hyperinsulinemia and maintaining normal 
glucose tolerance. In time, maybe due to a genetic predisposition in some individuals, beta cells 
fail to maintain an increased insulin secretion. This leads to the instauration of chronic 
hyperglycemia and overt diabetes. With the evolution of the disease, the hyperglycemia worsens, 
glucose toxicity ensues, and insulin secretion and action decrease. Ultimately, the loss of beta cell 
mass can lead to insulin dependency. Thus, insulin secretion is defective in these patients and 
insufficient to compensate for insulin resistance. Insulin resistance may improve with weight 
reduction and/or pharmacological treatment of hyperglycemia, but is seldom restored to normal.  
Abdominal obesity, as depicted in chapter 4, associates with a broad range of metabolic 
and cardiovascular complications. Besides the toxic effect of hyperglycemia per se, the 
instauration of chronic hyperglycemia and diabetes exponentially potentiates the traditional 
visceral obesity associated cardiometabolic risk factors like hypertension; increase of the 
plasminogen activator inhibitor (PAI-1), dyslipidemia and increase and maintain systemic 
inflammatory state in obese subjects. Therefore the evolution of type 2 DM is marked by 
macrovascular disease, atherosclerosis and CVD and in a lesser extent by the microvascular 
angiopathy.  
 
 
III. Gestational Diabetes Mellitus (GDM) 55,56 
 
GDM is defined as any degree of glucose intolerance with onset or first diagnosis during 
pregnancy, regardless of whether it persists after giving birth and can be a predictor of late 
dysfunction of beta cells. It occurs in approximately 4% of pregnancies in the U.S.  
 
 
IV. Other specific types of diabetes due to other causes 
 
DM can also occur secondary to monogenetic defects in β-cell function or insulin action, 
pancreatic diseases or other endocrinopathies, medications, toxic chemicals, or uncommon forms 
of immune-mediated diabetes, e.g., "stiff man syndrome" or the presence of anti-insulin receptor 
antibodies. The defects in beta cell function are better characterized as follows 59: 
  
a) Genetic defects of the β-cell 
Frequently existing is onset of hyperglycemia at an early age (generally before age 25), 
referred to as maturity-onset diabetes of the young (MODY), which is characterized by impaired 
insulin secretion with minimal or no defects in insulin action. There are various forms of MODY 
described at the time. Mostly, the inheritance here happens in an autosomal dominant pattern, 
commonly associated with mutations of hepatocyte nuclear factor (HNF)-1α and in the glucokinase 
gene. Some families have been identified with the inability to convert proinsulin to insulin and 
others with mutant insulin molecules, presenting mild glucose intolerance. 
 
b) Genetic defects in insulin action 
Rarely diabetes can result from genetically determined abnormalities of insulin action, as 
mutations of the insulin receptor may range from hyperinsulinemia and modest hyperglycemia to 
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severe diabetes. Individuals may have acanthosis nigricans and adult women enlarged, cystic 
ovaries. Leprechaunism and the Rabson-Mendenhall syndrome are two pediatric syndromes that 
have mutations in the insulin receptor gene with subsequent alterations in insulin receptor 
function and extreme insulin resistance. 
 
c) Diseases of the exocrine pancreas 
Any process that diffusely injures the pancreas can cause diabetes. Acquired processes 
include pancreatitis, trauma, infection, pancreatectomy, cystic fibrosis and hemochromatosis and 
pancreatic carcinoma. With the exception of that caused by cancer, damage to the pancreas must 
be extensive for diabetes to occur. This implies a mechanism other than simple reduction in β-cell 
mass. 
 
d) Endocrinopathies 
Several hormones (e.g., growth hormone, cortisol, glucagon, epinephrine) antagonize 
insulin action. Excess amounts of these hormones (e.g., acromegaly, Cushing's syndrome, 
glucagonoma, pheochromocytoma, respectively) can cause diabetes. This generally occurs in 
individuals with preexisting defects in insulin secretion, and hyperglycemia typically resolves when 
the hormone excess is resolved. Somatostatinoma- and aldosteronoma-induced hypokalemia can 
cause diabetes, at least in part, by inhibiting insulin secretion. Hyperglycemia generally resolves 
after successful removal of the tumor. 
 
e) Drug- or chemical-induced diabetes 
Many drugs can impair insulin secretion, precipitating diabetes in individuals with insulin 
resistance. Certain toxins such as Vacor (a rat poison) and intravenous pentamidine can destroy 
pancreatic β-cells. There are also many drugs and hormones that can impair insulin action like 
nicotinic acid and glucocorticoids. Patients receiving α-interferon have been reported to develop 
diabetes associated with islet cell antibodies and, in certain instances, severe insulin deficiency.  
 
 
f) Infections 
Certain viruses as congenital rubella coxsackievirus B, cytomegalovirus, adenovirus, and 
mumps have been associated with β-cell destruction or autoimmunity.  
 
g) Uncommon forms of immune-mediated diabetes 
The stiff-man syndrome is an autoimmune disorder of the central nervous system 
characterized by stiffness of the axial muscles with painful spasms. Patients usually have high titers 
of the glutamic acid decarboxylase (GAD) autoantibodies, and approximately one-third will 
develop diabetes. 
Anti–insulin receptor antibodies syndrome (type B insulin resistance) can cause mostly 
diabetes by binding to the insulin receptor, thereby blocking the binding of insulin to its receptor 
in target tissues.  
 
h) Other genetic syndromes sometimes associated with diabetes 
Many genetic syndromes, like Down's syndrome, Klinefelter's syndrome, and Turner's 
syndrome are accompanied by an increased incidence of diabetes mellitus. Wolfram's syndrome is 
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an autosomal recessive disorder characterized by insulin-deficient diabetes and the absence of β-
cells at autopsy.  
  
 
2.3 Epidemiology of Type 2 Diabetes Mellitus 
 
Over the last three decades the number of people with diabetes mellitus worldwide has 
more than doubled 60. Data for 2010 estimated 285 million people worldwide with diabetes 
mellitus, out of which 90% with type 2 DM 61,62. By 2030 the prediction of global diabetes mellitus 
rises to 439 million, representing a 7.7% of the world’s total adult population aged 20–79 years 62 
(Fig.1). In many zones of the World DM2 appears in epidemic proportions. The global prevalence is 
rapidly increasing in populations that have been industrialized in a short period of time, or, in 
other words, where the traditional lifestyle has given way to the occidental one.  Factors that 
contribute to the increase in type 2 DM are therefore the increase in obesity urbanization and 
consequent lifestyle changes  with decreased physical activity and hypercaloric diets, aging, 
urbanization/ lifestyle changes, and aging. Other risk factor for type 2 DM are the pertinence to 
particular ethnic race, family history, longevity, migration and fetal/neonatal nutrition.  
 
 
           
 
 
Besides age and sex linked to diabetes, people with a low educational level were 28% more 
prone to develop it than the ones that had received better schooling throughout their lives. That 
was also the case in people with low socioeconomic level and poorer state of health, which 
moreover presented higher rates of mortality and cardiovascular disease 63. Abdominal obesity, 
high blood pressure, low HDL cholesterol, high triacylglycerols and a family history of diabetes 
were accompanied by the presence of diabetes. 
There are also particular cases regarding the diabetes incidence in some populations. The 
groups known to have the highest prevalence are the Pima Indians and the inhabitants of Nauru 
Fig.1 Epidemiology of type 2 DM. In each box, top and middle values represent the number of people with DM (in 
millions) for 2010 and 2030, respectively. Bottom value is the percentage increase from 2010 to 2030. Bigger left box: 
worldwide the number of people with DM is estimated to rise from 285 million in 2010 to 439 million by 2030, a 54% 
increase. Adapted from Chen et al, Nature Reviews Endocrinology 2012 69. 
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(located in the Pacific Ocean), where diabetes affects 20% of the settlements. The basis for the 
genetic susceptibility to obesity and DM2 has been unclear but could be the result of an 
evolutionary advantageous “thrifty” gene, which promoted fat deposition and storage of calories 
in times of abundance and provided a positive selective advantage during periods of food shortage 
and starvation, but due to environmental changes during early development the selected 
trajectory became inappropriate and resulted in adverse effects on health 64. Besides the racial 
propensity to DM2, there are also ethnic groups relatively protected from diabetes, such as the 
Melanesians (subregion of Oceania). Since DM2 occurrence reaches a maximum in higher age 
groups, ethnic groups with short life expectancy may present falsely low diabetes prevalence. 
There is a racial predisposition to DM2 with some ethnicities relatively protected, like the 
Melanesians 65. 
Type 2 DM was relatively rare in developing countries some decades ago. However, the 
major burden of diabetes mellitus is now taking place in developing rather than in developed 
countries, representing an 80% of cases of diabetes mellitus worldwide 62. Asia has emerged as the 
'diabetes epicenter' in the world, as a result of rapid economic development, urbanization and 
nutrition transition over a relatively short period of time 66. Among the 10 countries with the 
largest numbers of people predicted to have diabetes mellitus in 2030, five are in Asia (China, 
India, Pakistan, Indonesia and Bangladesh) 62. In addition to Asia, the Gulf region in the Middle 
East 62 and Africa 67,68 are other hot spots for diabetes mellitus. Compared with developed 
countries, the proportion of young to middle-aged individuals with type 2 DM is higher in 
developing countries 62. 
 
 
In the last two decades, type 2 diabetes, once thought to be a metabolic disorder 
exclusively of adulthood, has become increasingly more frequent in obese adolescents 70.  
In this sense, although a very high prevalence of type 2 diabetes has been observed in non-
Caucasian groups (African Americans, Native Americans, Hispanics), type 2 diabetes occurs in all 
races 71,72. In the SEARCH study 72, the incidence rate (per 100,000 person/year) of type 2 diabetes 
among children and adolescents varies greatly by ethnicity, with the highest rates observed among 
youths aged 15–19 years in minority populations. In particular, the reported incidence rate was 
49.4 for Native Americans, 22.7 for Asian/Pacific Islanders, 19.4 for African Americans, 17 for 
Hispanics, and 5.6 for non-Hispanic whites. 
The increased prevalence of type 2 diabetes in the obese pediatric population is paralleled 
by an increased prevalence of the prediabetes conditions. In particular, 25% of children and 21% 
adolescents with severe degree of obesity, irrespective of ethnicity, were found to have IGT 73. 
Similar high prevalence rates in Hispanic obese children and adolescents were subsequently 
reported by Goran et al 74. Surprisingly, very high prevalence rates of IFG were reported in children 
from the Studies to Treat or Prevent Pediatric Type 2 Diabetes 75. In Europe the scenery is not 
encouraging either. The prevalence of DM in European countries is estimated to rise in the next 10 
years (Table 3).  
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Table 3. Prevalence estimates of DM in the European Region 
 DM prevalence 2003 DM prevalence 2025 
Country % % 
Andorra 7.7 9.5 
Austria 9.6 11.9 
Bulgaria 10.0 11.6 
Croatia 5.8 6.7 
Cyprus 5.1 6.3 
Finland 7.2 10.0 
France 6.2 7.3 
Germany 10.2 11.9 
Greece 6.1 7.3 
Ireland, Republic of 3.4 4.1 
Italy 6.6 7.9 
Netherlands 3.7 5.1 
Norway 6.7 8.2 
Portugal 7.8 9.5 
Romania 9.3 10.6 
Russian Federation 9.2 10.9 
Slovenia 9.6 12.0 
Spain 9.9 10.1 
Sweden 7.3 8.6 
Switzerland 9.5 12.6 
Turkey 7.0 9.1 
United Kingdom 3.9 4.7 
Modified after the Diabetes Atlas, International Diabetes Federation, 2003. 
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Spain is one of the European countries with the lowest prevalence increase within a time 
period of 20 years. According to the very recent cross-sectional population-based study published 
in 2012, being the first national one, almost 30% of the study population had any kind of glucose 
disturbance. The total prevalence of DM was shown under age and sex adjustments at 13.8%, out 
of which 6.8% were not aware of it until the moment of the study. DM and impaired glucose 
regulation was amplified with age (p < 0.0001) and essentially higher in men than women (p <
0.001). Obesity was more probable to appear in people with DM and impaired glucose regulation; 
so were high blood pressure, raised triacylglycerol and low HDL cholesterol levels. Besides age and 
sex linked to diabetes, people with a low educational level were 28% more prone to develop it 
than the ones that had received better schooling throughout their lives. That was also the case in 
people with low socioeconomic level and poorer state of health, which moreover presented higher 
rates of mortality and cardiovascular disease 63. Abdominal obesity, high blood pressure, low HDL 
cholesterol, high triacylglycerols and a family history of diabetes were accompanied by the 
presence of diabetes.  
 Though this study was based on a representative sample of the whole national territory 
and the diagnosis of diabetes was mostly made by OGTT, it lacked of high number of participants 
(around half of the selected population attended for examination) and of a better sex and age 
distribution (more women and older people took part), making age and sex corrections inevitable 
for the analysis. Another limitation was the people’s self-report on the information, something 
that is common in large epidemiological surveys though 76. 
  
 
2.4 Principal complications and treatment of Type 2 Diabetes Mellitus  
 
Diabetes mellitus (DM) type 2 is a chronic disease with long-term macrovascular and 
microvascular as well as neuropatic complications (Fig.2) 56. Yet, patients undergoing regular 
checkups and correct treatments are often able to minimize the consequences.  
Whilst type 1 DM complications are marked from the evolution of the microangiopathy, 
type 2 DM patients are prone to developing macrovascular complications (depicted in chapter 3), 
respectively disseminated atherothrombosis. Cardiovascular morbidity and mortality is the first 
line complication in type 2 DM. Importantly, risk factors for coronary heart disease have to be 
looked into regularly. A1C, regular capillary glucose measurements, blood pressure and cholesterol 
levels reflect the possibilities of a stroke, cardiomyopathy and congestive heart failure. 
Macrovascular complications are definitely dominating the clinical picture of the disease by 
conditioning acute and chronic disease prognosis, life expectancy and quality of life. 
Moreover, patients with type 2 diabetes are at increased risk of diabetes-associated eye 
complications. Patients are 40% more likely to suffer from glaucoma than healthy people (the 
longer the diabetic status, the more common the glaucoma is), and 60% from cataracts. Diabetic 
retinopathy, although less frequent than in type 1 diabetes, can also occur.  Microalbuminuria and 
an impaired renal function can also be a complication of type 2 diabetes, amplifying the renal 
effects of hypertension.  
Many different foot problems can appear in diabetic people, starting from neuropathy, 
skin changes, ulcers and calluses, ending to poor circulation and eventual amputation of the 
affected member. Skin complications like bacterial and fungal infections, itching, dermopathies, 
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allergic reactions and acanthosis nigricans are very common in diabetic patients, appearing at a 
rate of 33% among those.  
Not neglectable is the mental health of people with diabetes, which can vary between 
anger, denial and depression. Other associated complications comprise of oral problems, loss of 
hearing, ketoacidosis, nephropathy, stress, etc 77. 
 
 
 
Fig.2 Major diabetes- associated complications. 
Adapted from the Diabetes Atlas, International Diabetes Federation, 2003. 
 
 
Treatment of type 2 DM apart from medication requires the patient’s devotion in changing 
daily habits. Medical nutrition therapy, exercise and weight loss are at the onset of the disease and 
for the further control as essential as a correct insulin and noninsulin treatment. Patients with 
improperly controlled type 2 DM or unresponsive to diet and medications require insulin therapy, 
as type 1 DM patients do. The therapy’s aim is to maintain as normal as possible the blood glucose 
levels throughout the day. 
 
For the treatment of type 2 DM, six classes of oral agents are available on the international 
market 78:  
• Biguanides, such as metformin, block hepatic glucose production and are thought to have insulin 
sensitizer proprieties (effects of metformin are detailed in chapter 5). Metformin is worldwide 
employed as first line agent in the treatment of type 2 diabetes after the failure of the diet. 
• The sulfonylurea compounds do mainly stimulate the secretion of insulin from the pancreatic 
islets. Their use also results in reduction of hepatic glucose production, and diminution of insulin 
I n t r o d u c t i o n | 27 
resistance through reversal of the post-receptor defect, and increase in the number of insulin 
receptors. 
• The nonsulfonylurea insulin secretagogues repaglinide and nateglinide bind to a specific site on 
the sulfonylurea receptor and increase insulin secretion. 
• Glucosidase inhibitors, as acarbose and miglitol, block starch, sucrose, and maltose absorption. 
• Insulin sensitizer: Thiazolidinediones, like pioglitazone and rosiglitazone, have the capacity to 
decrease insulin resistance by enhancing insulin-mediated glucose disposal by muscle. Because of 
idiosyncratic liver damage and liver failure, the Food and Drug Administration (FDA) removed one 
of the thiazolidinediones, troglitazone, from clinical use in the United States in 2000. Another 
agent, rosiglitazone, has been associated in clinical studies with an increased risk of cardiac 
insufficiency, angina or myocardial infarction, but others have excluded this risk, rendering the 
conclusions uncertain 79. 
• Incretin mimetic agents: are either inhibitors of dipeptidyl peptidase-IV (DPP-IV) like sitagliptin, 
vildagliptin, linagliptide, saxagliptin or analogous of glucagon-like peptide-I (GLP-I) like exenatide, 
liraglutide. Generally, incretin mimetic agents are increasing insulin secretion, suppress 
hyperglucagonemia, delay gastric emptying, and depress appetite. 
In a study published in 2008 in the Journal of the American Medical Association were 
presented data analyzing medications prescribed between 1994 and 2007 for all U.S. office visits 
among patients 35 years and older with type 2 diabetes. The source was the U.S. National Disease 
and Therapeutic Index and the researchers were lead to the conclusions that apart from the 
increasing diabetes population, a great rise was applied in the complexity and the cost of the 
diabetes treatments. New data are awaited with respect to the period after the introduction of 
incretin mimetics 80. 
The actual golden standard in diabetes treatment represents the achievement, following 
the treatment strategies presented above, of an A1C of ~7%, a blood pressure of ~130/80 mmHg 
and total cholesterol of below 175 mg/dl 55.  
 
 
 
3. Atherothrombosis 
 
 
3.1 The endothelium 
 
The vascular endothelium forms the inner cellular lining of the blood vessels and is 
considered the largest organ of the human body. It has emerged as a key regulator of vascular 
homeostasis, since endothelial cells are not inert and don’t function only as a barrier between the 
blood and the tissues, but rather present a vast metabolic activity.  
Thereby it plays an important role in many physiological functions, including the control of 
vascular tone, blood cell trafficking, haemostatic balance, the interchange of fluids and cells 
between blood and tissues, the development and resolution of inflammatory processes as well as 
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innate and adaptive immunity. Moreover, it acts as a signal transducer for metabolic, 
hemodynamic and inflammatory factors that modify the function and morphology of the vessel 
wall.  
Due to its great activity the endothelium either is a primary determinant of a disease state 
or a victim of a collateral damage. Alterations in the function of the endothelial cell can lead to 
dysfunctions like atherosclerotic changes and the progression of vascular lesions 81,82. 
 
3.2 Endothelial and subendothelial activation 
  
The subendothelium is the connective tissue between the endothelium and the inner 
elastic membrane in the intima of arteries. It involves the extracellular matrix synthesized by the 
endothelial cells, which contains numerous proteins, like collagen, von Willebrand factor (VWF), 
laminin, metalloproteinases (MMPs) and tissue factor (TF).  The subendothelium acts as a 
supporter of the endothelial cells and as a secondary barrier if the endothelium is disrupted. When 
the subendothelium is exposed to rapidly flowing blood upon vessel damage, platelets adhere 
rapidly to the exposed surface, decelerate, and aggregate to arrest bleeding. Platelets are the 
major components of the blood responsible for initiating the coagulation cascade and the 
formation of the repairing thrombus at sites of blood vessel damage 83. 
Under the term endothelial cell activation are understood the changes that the 
endothelium undergoes in order to respond to inflammatory stimuli proceeding by agents, such as 
interleukins, chemokines, etc. The terms activated and active do not indicate a condition alike. 
Generally, the endothelial cells are highly active as mentioned before 82.    
Five principal changes occur during endothelial cell activation:  
a) Loss of vascular integrity: the subendothelium gets exposed and the efflux of fluids 
from the intravascular space is possible to occur. 
b) Expression of leukocyte adhesion molecules: adhesion molecules such as E-selectin, 
ICAM-1 and VCAM-1 when upregulated adhere to the endothelium and move into the 
tissues 84. 
c) Phenotypic change from antithrombotic to prothrombotic: loss of surface 
anticoagulant molecules, reduced fibrinolytic capacity, loss of the platelet 
antiaggregatory effects, production of platelet activating factor, nitric oxide, and 
expression of tissue factor are included 85. 
d) Cytokine production: Local cytokines are synthesized, including interleukin 6 which 
regulates the acute phase response, as well as chemoattractants such as interleukin 8 
and monocyte chemoattractant protein 1 86. 
e) Upregulation of human leukocyte antigen (HLA) molecules: their expression allows 
endothelial cells to act as antigen presenting cells, especially important in transplant 
rejection 87. 
 
There are two stages of endothelial cell activation 85. The first one takes place rapidly since 
it does not require gene upregulation or de novo protein synthesis. Effects include the retraction of 
endothelial cells, expression of P-selectin, and release of von Willebrand factor. During the second 
response are stimulated gene transcription and protein synthesis, therefore it is a time requiring 
stage. The genes involved are those for adhesion molecules, cytokines and tissue factor.  
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On the other hand, endothelial cell dysfunction is by definition maladaptive. Under an 
environmental persistence of severe damaging stimuli, the dysfunction of endothelial cells evolves 
irreversibly with loss of cell integrity and the damage of the underlying tissue. Endothelial cell 
dysfunction has been implicated in advanced atherosclerosis following an abnormally 
hyperadhesive endothelial cell surface 82. 
Nevertheless, an adaptive reaction can be beneficial in one case but deleterious in 
another, like in the case of monocyte adhesion that leads to atherosclerosis when it takes place in 
the coronary artery, but is a potent defense in pulmonary arteries 82. 
 
Cell adhesion is an essential process required for the correct functioning of multicellular 
organisms. Cellular adhesion molecules (CAMs) are involved in a variety of processes: cell-cell and 
cell-matrix adhesion, cell migration 88, activation of lymphocytes and initiation of the immune 
response. Inflammatory stimuli inducing transmigration towards the subendothelial tissues lead to 
the expression of CAMs by the endothelium, or at the surface level, or in the matrix, or as soluble 
receptors in the bloodstream 89,90. 
Five families of adhesion receptors have been identified: 1) the selectins, 2) the 
immunoglobulins (Ig), 3) the cadherins, 4) the integrins, 5) the homing receptors 91. 
Out of those families, the selectins and the immunoglobulins have an expression relevant 
to the presence of an inflammatory environment. 
 
 
 
Fig.3 Leukocyte migration through the blood vessels. Leukocytes initially rotate, become activated, adhere to the 
endothelium and migrate by crossing it. Adapted from Robbins and Cotran, Pathologic Basis of Disease 2005 93. 
 
 
The selectins are responsible for the initial interaction of circulating leukocytes with the 
activated vascular endothelium. Leukocytes roll along the vessel wall before firm adhesion and 
diapedesis at sites of tissue injury and inflammation. The selectin family includes three members 
with nomenclature according to the cell type on which it was originally identified: E-selectin 
(endothelium), P-selectin (platelets), and L-selectin (leukocytes) 92. 
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The Ig gene superfamily consists of cell-surface proteins that are involved in antigen 
recognition, complement-binding or cellular adhesion, and are implicated in the final phase of the 
cellular adhesion of granulocytes and monocytes to the endothelium. Five members of this family 
expressed by endothelial cells are involved in leukocyte adhesion: intercellular adhesion molecules 
-l and –II (ICAM-1= CD54, ICAM-2= CD102), vascular cell adhesion molecule-l (VCAM-1= CD106), 
platelet-endothelial cell adhesion molecule-l (PECAM-1= CD31) and the mucosal addressin 
(MAdCAM-1) 94. 
 
 
3.3 The endothelium in arterial thrombosis  
 
The human coronary artery consists of endothelial cells that form the layer in contact with 
the blood. The endothelium is based on the intimal layer that contains smooth muscle cells 
diffused within the intimal extracellular matrix. The next adjacent stratum is the media, comprising 
of multiple layers of smooth muscle cells much more densely present than in the intima, and 
surrounded by a matrix rich in elastin and collagen.  
Atherothrombotic arterial disease, atherosclerosis, consists of the progressive diminution 
of the caliber of the vessel wall as a consequence of the local accumulation of cholesterol and 
formation of the atherosclerotic plaques. It occurs mostly at bifurcations of arteries, regions 
characterized by a disturbed blood flow 95,96. 
A lesion begins as a fatty streak and can develop into an intermediate lesion and then into 
a lesion that is vulnerable to rupture and, finally, into an advanced obstructive lesion. In the first 
stage it is characterized by the progressive accumulation of atherogenic lipoproteins such as low-
density lipoproteins (LDLs), constituting the asymptomatic “fatty streaks” within regions of the 
arterial intimae. The evolution of these lesions depends on further activation and dysfunction of 
the endothelium accompanied by inflammation of the vessel wall; increased lipoprotein oxidation 
and accumulation of lipid-rich material in activated macrophages (the so called foam-cells). 
Although they cause no clinical pathology, fatty streaks are widely considered to be the initial 
lesion leading to the development of complex atherosclerotic lesions 95. Further development of 
the true atherosclerotic plaques with diminution of the vessel diameter (stenosis) is the 
consequence of fibrous tissue accumulation, smooth cell proliferation and extracellular matrix 
deposition around foam cells. In addition to monocytes, other types of leukocytes, particularly T-
cells, are recruited to atherosclerotic lesions and help to perpetuate a state of chronic 
inflammation. As the plaque grows, compensatory remodelling takes place, such that the size of 
the lumen is preserved, while its overall diameter increases. Smooth muscle cells form a fibrous 
cap beneath the endothelium, and these walls off the plaque from the blood. This process 
contributes to the formation of a necrotic core within the plaque and further promotes the 
recruitment of inflammatory cells 95,97,98,99. 
This nonobstructive plaque can abruptly rupture or the endothelium can erode, resulting 
in the exposure of thrombogenic material, including VWF and TF, and the formation of a thrombus 
in the lumen (Fig.4). If the thrombus (clot) is large enough, it blocks the artery finally inducing an 
acute coronary syndrome or myocardial infarction or a stroke. Ultimately, if the plaque does not 
rupture and the lesion continues to grow, the lesion can encroach on the lumen and consequently 
the quantity of blood supplied to the adjacent tissue is reduced, leading to symptomatic hypoxia of 
the adjacent tissue when the stenosis is >75% of the vessel diameter or in conditions of increased 
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oxygen consumption 95,98,100. Initiation and progression of the atherothrombotic lesions are highly 
complex processes, and many aspects of atherogenesis are still under study. 
 
 
 
Fig.4 Formation of an atheroma. Upper boxes adapted from Libby, Nature 2002 101. Rest of the picture modified after 
McLaren et al, Progress in Lipid Research 2011 102. 
 
 
3.4 Role of inflammation in atherogenesis 
 
High plasma concentrations of cholesterol accumulating within the artery, and particularly 
LDL cholesterol, have been considered for long time the principal risk factors for atherosclerosis. 
However, it is now known that atherosclerosis is not only due to hypercholesterolemia, but that a 
complexity of factors contributes to this process, chronic hyperglycemia and local and systemic 
inflammation playing a major role.  
In endothelial dysfunction and formation of the atherosclerotic plaque are involved, 
besides elevated LDL, hypertension, diabetes mellitus, genetic alterations and free radicals caused 
by cigarette smoking. There has been also reported association between elevated plasma 
homocysteine concentrations, infectious microorganisms such as herpesviruses or Chlamydia 
pneumoniae and atherosclerosis 97. 
These pathogenic causes of local and systemic inflammation have been underestimated 
for a long time, even though their significance is in our times important as well. Hence, the 
presence of systemic inflammation is evident even before the detection of myocardial infarction. 
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Patients with autoimmune diseases (as rheumatoid arthritis), untreated infections (like 
periodontal disease), chronic extravascular infections (eg, gingivitis, prostatitis, bronchitis) or even 
chlamydial infection have been shown to present elevated possibilities of atheroma 
formation95,103,104. 
 
 
3.5 Role of inflammation in atherothrombosis  
 
It has been assumed that atherosclerosis is the consequence of the excessive inflammatory 
and prothrombotic response of the endothelium to activators like diet compounds, 
hypercholesterolemia, elevated free fatty acids, factors secreted from the obese adipose tissue 
and chronic hyperglycemia 105,106,107,108,109. This causes endothelial and smooth muscle cells of the 
large arteries to synthesize proinflammatory proteins, including chemokines, CAMs and cytokines, 
growth factors and thrombogenic substances 95,110. 
Development of atherothrombotic plaques in the bifurcation regions is facilitated by the 
turbulent blood flow, which reduces the activity of endothelial atheroprotective molecules such as 
the endothelium-produced nitric oxide (NO), and favours regional VCAM-1 expression under the 
presence of circulating inflammatory stimulus. Nitric oxide maintains the vasodilatory properties of 
the endothelium, and opposes the effects of vasoconstrictors like endothelin-1 (ET-1) and 
angiotensin II (AGT II). Reduced production of NO and increased synthesis and secretion of 
endothelin-1 enhances the vasoconstrictor tone and increases synthesis and release of 
proinflammatory cytokines maintaining endothelial activation 107,108. On the other hand, diabetes- 
and obesity-associated elevated FFA levels decrease NO activity by activating innate inflammatory 
pathways. 
The development of atheromatous plaques is a major health problem that is becoming an 
even greater issue when it comes to plaque rupture and thrombosis, triggering acute life-
threatening cardiovascular events, as stroke or myocardial infarction. According to studies, an 
arterial narrowing of <50% is usually produced before the acute event, responsible for unstable 
angina and myocardial infarction 111. Atherosclerotic lesions trigger acute life-threatening 
cardiovascular events such as myocardial infarction or stroke only when an occlusive thrombus (or 
clot) forms. The initial step for arterial thrombosis comes when the superior layer of the 
atherosclerotic plaque gets disrupted, and blood comes in contact with the lipid core of the 
thrombogenic subendothelium. Plaque rupture under the pressure of the blood flux would take 
place depending on plaque fragility, plaques with a lower content in lipids being more susceptible. 
The consequent events that lead to the arterial occlusion after plaque injury are: the contact of 
blood with the prothrombotic subendothelial components, the activation and aggregation of 
platelets and dynamic changes in cellular adhesion to the atheromatous plaques 95,97. 
Plaque rupture is associated with local inflammation and degradation of the collagen and 
elastin in the extracellular matrix (ECM) by extracellular proteases present in the subendothelium. 
Endopeptidases, like MMPs, secreted by cytokine-activated macrophages and smooth muscle cells 
play an important role in plaque rupture. Besides ECM degradation, MMPs can promote 
macrophage invasion and angiogenesis 112. 
The platelets are disc-shaped cell fragments that circulate in the blood as sentinels of 
vascular integrity and rapidly form a primary haemostatic plug at the site of vascular injury. When 
atherosclerotic plaque ruptures, platelets are rapidly recruited to the lesion site through the 
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interaction of specific platelet cell-surface receptors with collagen and VWF 113,114. After adhesion 
to the vessel wall, platelets aggregate to one another, determining a rapid growth of the provisory 
thrombus. The formation of the final thrombus is induced by the activation of the coagulation 
cascade. The ultimate result is thrombus formation and the acute coronary or cerebral 
atherothrombotic event 100. 
To conclude, inflammation initiates the atherosclerotic lesion and contributes to the 
formation of the complex plaque, weakens the fibrous cap (which causes easy plaque rupture) and 
enhances the thrombogenicity of the lipid core 115. 
 
 
3.6 Endothelial activation and inflammation markers in atherothrombotic 
cardiovascular risk prognosis  
 
Inflammation plays an essential role in the initiation and progression of atherosclerotic 
lesions, and plaque disruption. A good perception of the inflammatory mechanisms contributes to 
the prediction of potentially useful markers of CVD. Clinically, those markers have to complete a 
number of conditions in order to be able to be utilized as such. Those are 116:  
(1) the ability to standardize the assay and to control the variability of the measurement 
(2) the independence from established risk factors 
(3) their association with CVD clinical end points in observational studies and clinical trials 
(4) the presence of population norms to guide interpretation of results 
(5) the ability to improve the overall prediction beyond that of traditional risk factors  
(6) the generalization of results to various population groups 
(7) un acceptable cost of the assays.  
 
A good sample of studies has examined the connection between inflammation and CVD 
through measurement of a variety of analytes 116. 
 
Cellular Adhesion molecules (CAMs) 
 Cells interact collectively and this is mediated partially by different families of adhesion 
molecules. Patients with coronary artery disease possess higher serum levels of CAMs than lean 
subjects 108,117. Plasma concentrations of soluble adhesion molecules may be higher in patients 
with atherosclerosis 118,119 and hyperlipidemia 120,120. Out of those we are going to focus our 
analysis on two of them, which were also used in the methodology of this thesis. 
 Intercellular Adhesion Molecule 1 (ICAM-1), also known as CD54, is a membrane receptor 
of 80-114 kDa of size, structurally related to the immunoglobulins (Ig). It is expressed by various 
cell types, like epithelial cells and fibroblasts. But constitutively expressed it can only be found, at 
low levels, on vascular endothelial cells and on some lymphocytes and monocytes. Several 
cytokines, as the inflammatory interleukin (IL-1), tumor necrosis factor (TNF-α), and interferon 
gamma (IFN-γ) or lipopolysaccharides (LPS) can induce elevated ICAM-1 expression 121. Its role has 
been found to be in inflammatory cells trafficking, in T-cell mediated host defense system 122 in 
microbial pathogenesis, and in signal transduction pathways 121. Circulating ICAM-1 levels were 
found to be higher in patients with stable or unstable angina and acute myocardial infarction, 
compared with control patients 123. In another study, CVD risk factors and BMI were associated 
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with systemic inflammation, determined by ICAM-1 levels. Thinking of the heritability of ICAM-1, it 
was suggested that systemic inflammation could have a genetic background 124. 
 Vascular Adhesion Molecule 1 (VCAM-1), alternatively CD106, weights 80-100 kDa 94. It is 
a sialoglycoprotein whose expression is restricted to the endothelium of small and large vessels, 
and permits the binding of monocytes, lymphocytes, eosinophiles and basophiles to the activated 
endothelium. VCAM-1 is not constitutively expressed by endothelial cells, but is only synthesized 
by induction of inflammatory stimuli and its synthesis depends on the persistence of the 
deleterious input 125. The promoter region of VCAM-1 gene presents binding sites for nuclear 
factor-κB (NF-κB)126. VCAM-1 plasma levels were increased in diabetic patients with 
microalbuminuria, giving to VCAM-1 the important role as a marker of ongoing vascular 
dysfunction and progressive vascular disease 127. 
 
High sensitive C-reactive protein (hs-CRP) 
CRP is a protein synthesized mainly in the liver, participating in innate host defense by 
recognising and further mediating elimination of pathogens and apoptotic cells. Thus, injured 
tissues are restored and their normal structure and function redeemed. IL-6 and TNF-α are 
inflammatory cytokines inducing the secretion of C-reactive protein in the liver 128. CRP inter-
relates with fibrinogen, a factor that has been found to double the risk of coronary attack and 
stroke in high-risk men 129. Harmful effects of CRP have been found to be implicated in 
arteriosclerotic lesions 130,131 and in the tissue damage that accompanies acute myocardial 
infarction.  
 Abnormally high CRP levels can be caused by various reasons, since it is a protein involved 
in the mechanisms of the immune system. For that, it can not be considered as a specific 
prognostic indicator of systemic chronic inflammation in obesity and atherothrombotic disease. A 
better quantification of such conditions is achieved by measuring the high-sensitivity CRP (hs-CRP), 
which measures lower CRP levels with the help of laser nephelometry. The reliability considering 
hs-CRP a systemic marker of chronic low-grade inflammation present in atherothrombotic disease 
and obesity has been shown in various studies 132,133. Many physicians consider hs-CRP levels as an 
add-on to overall cardiovascular risk prediction, and intensive research targeting vascular anti-
inflammatory agents for the treatment and  prevention of coronary disease is being conducted 133. 
  
Interleukin-6 (IL-6) 
 IL-6 is a pleiotropic cytokine relating to inflammation, host defense, and tissue injury. 
Many factors contribute in the production of IL-6, including infection, IL-1, interferon-γ, and TNF. 
IL-6 is a central mediator of the acute-phase response and a primary determinant of hepatic 
production of CRP. Moreover increases fibrinogen and plasminogen activator inhibitor-1 (PAI-1) 
concentrations.  
 IL-6 is being produced by vascular endothelial and smooth muscle cells, has been found 
expressed in human atherosclerotic lesions, and may have procoagulant effects. Healthy 
individuals with elevated levels of IL-6 are prone to developing coronary and cerebrovascular 
events 134. 
 
Interleukin-1β (IL-1β) 
 IL-1β is a critical early mediator of inflammation. Its natural receptor antagonist (IL-1Ra) is 
also released during inflammation and may limit the potential deleterious effects of IL-1. Thus, 
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such balance may determine the progression of inflammation. Relative absence of IL-1Ra is 
suggested to play a role in the pathogenesis of some inflammatory disorders 135. 
  
Monocyte chemoattractant protein (MCP-1) 
 Monocyte chemoattractant protein is a chemokine being given the role to recruit 
monocytes into the developing atheroma and may contribute to atherosclerotic disease 
development and progression. Plasma levels of MCP-1 are associated with prognosis in patients 
with acute coronary syndromes, but few population-based data are available from subjects in early 
atherosclerosis 136. 
 
Tumor necrosis factor-alfa (TNF-α) 
 TNF-α is a multifunctional circulating cytokine, that enhances monocyte recruitment at 
atherosclerotic lesions, and is expressed by endothelial, smooth muscle cells and macrophages 
associated with coronary atheroma. TNF-α levels are noticeably elevated in proximal coronary 
events 137. 
 
Interleukin-8 (IL-8)  
 IL-8 has been directly linked to the development of early atherothrombotic lesions since its 
production starts when phagocytes and mesenchymal cells get exposed to inflammatory stimuli, 
for example IL-1 or TNF-α. The activation of neutrophils with induction of chemotaxis, exocytosis 
and respiratory burst is triggered. In fact, IL-8 produces an immense neutrophil accumulation at 
the site of injection, believed to originate mainly by stimuli such as infection, inflammation, 
ischemia, trauma etc 138. Moreover, it has been demonstrated that IL-8 is fundamental in 
monocyte capture 139.  
 
Interleukin-10 (IL-10) 
 IL-10 is produced by T cells, B cells, monocytes, and macrophages, and inhibits a variety of 
immune parameters 140. Besides that, it presents anti-inflammatory properties that inhibit the 
production of proinflammatory cytokines. Anti-inflammatory cytokines have been shown to have 
antiatherogenic properties 141. In a study was demonstrated that IL-10 was able to downregulate 
ICAM-1 and VCAM-1 expression on HUVECs having been activated by IL-1 142, and decrease IL-8 
and IL-6 production in irradiated HUVECs 143. 
 Impediment of atherosclerosis development due to the protective effect of IL-10 could 
also be credited to inflammatory cell deactivation 144,145.  Expression of IL-10 in the atherosclerotic 
lesion is associated with low iNOS expression by macrophages and low levels of cell death 144.  
 
Interleukin-12 (IL-12p70) 
 IL-12 is a cytokine consisting of two chains, one of 35 and another of 40 kDa, resulting in 
the biologically active 70 kDa (p70) form. IL-12 has been proven critical in several pathogeneses, 
whereas high IL-12 levels have been described in autoimmune diseases and chronic inflammatory 
reactions, such as osteoarthritis, rheumatoid arthritis and atherosclerosis 146. 
 
Extracellular matrix (ECM) biomarkers 
             Being under normal conditions, the vascular endothelium produces a number of substances 
that contribute to hemostasis, fibrinolysis and regulation of vessel tone and permeability.  
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 One such substance is the large glycoprotein von Willebrand factor (VWF), whose 
production is undertaken mainly by endothelial cells and its presence can also be found in 
platelets.  It is very important in the coagulation cascade, having the ability to enhance platelet 
adhesion and aggregation. Plasma levels of VWF are found elevated in different states of 
endothelial damage and are therefore candidates as useful markers of endothelial dysfunction.  
Stimulated release of VWF in humans is achieved by blockade of nitric oxide 147. People with 
inherited deficiencies of von Willebrand factor may suffer a bleeding disorder, von Willebrand 
disease, while substantially increased levels are associated with thrombotic disorders.  
 Tissue factor (TF) is the key initiator of the coagulation cascade and thereby crucially 
involved in the maintenance of vascular hemostasis. As an ultimate step it can lead to fibrin and 
clot formation. TF is actively expressed and detectable in vascular smooth muscle cells and 
fibroblasts and its action can be provoked by various stimuli including cytokines. Apart from 
triggering coagulation extracellularly, TF also functions as a transmembrane receptor, regulating 
the expression of genes involved in cellular responses such as proliferation and migration. For that, 
it is apparently involved in the pathogenesis of neointima formation and tumor growth, and 
increased levels of TF have been detected in patients with cardiovascular risk factors or coronary 
artery disease in addition to those with cancer 148. 
 Elevated levels of TF are observed in patients that suffer under cardiovascular risk factors, 
i.e. hypertension, diabetes, dyslipidemia, and smoking, as well as in those with acute coronary 
syndromes, where TF may indeed promote thrombus formation besides migration and 
proliferation of vascular smooth muscle cells 149. 
 
 
 
4. Factors contributing to the cardiovascular disease in obesity and type 2 
diabetes mellitus  
 
 
4.1 Classical and emerging cardiovascular risk factors in obesity and type 2 diabetes. 
 
Traditional cardiovascular risk factors of atherothrombotic disease in obesity, as partially 
depicted in Chapter 1, are hypertesion, hyperglycemia, hyperinsulinemia and insulin resistance, 
elevated levels of circulating free fatty acids and abnormalities in the lipid profile. 
 
Arterial hypertension 
Hypertension is the cardiovascular pathology most attributed to obesity, and especially to 
central obesity. The percentage of hypertensive people among the obese is around 35% 150,151, 
with even more elevated levels in obese females. In the National Health and Examination Survey 
(NHANES) III, the prevalence of hypertension according to body mass index (BMI) and adjusted for 
age was about 14% in participants with a BMI less than 25 kg/m2 versus about 40% in participants 
with a BMI greater than 30 kg/m2  152.  Hypertension appears up to five times more among obese 
people than among those of normal weight 52. Increased blood pressure due to excess weight gain 
occurs due to the enhanced intravascular blood volume connected to greater body mass and a rise 
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in blood viscosity, an increased peripheral vascular resistance and adipose tissue release of 
angiotensinogen 153. 
 
Lipid profile alterations 
 Obesity observed abnormalities in the lipid profile consist of an atherogenic lipid profile 
with increased triglycerides (TGs) 154, LDL-, VLDL cholesterol, decreased HDL cholesterol 155,156,157 
and increase in the circulating free fatty acids (FFAs). These modifications result from various 
actions: increased production by the hepatocytes, enhanced release of FFAs from the AT 158, 
reduced clearance of TGs-rich lipoproteins due to a reduced activity of lipoproteinlipase (LPL) and, 
therefore, a decreased HDL synthesis, diminished expression of the LDL receptor followed by lower 
very low-density lipoprotein (VLDL) clearance 159,160, and therefore, weakened synthesis of HDL. 
The levels of FFAs are elevated in obesity. Raised cellular levels of FFAs can produce insulin 
resistance in skeletal muscle and liver, and reduce beta-cell function, in what has been referred to 
as lipotoxicity 161. Clinical evidence suggests that FFA levels in obese subjects may also accelerate 
atherosclerosis and predict cardiovascular mortality. FFAs may induce inflammatory processes, 
possibly through the activation of the Toll-like-receptor family. They may also induce endothelial 
apoptosis and impair endothelial-dependent vasodilatation 106. 
 
Hyperinsulinemia and insulin resistance 
Insulin resistance is known as the state in which a target cell or a whole organism act with 
reduced responsiveness to the insulin concentration to which they get exposed. Compensatory 
hyperinsulinemia contributes to the maintenance of normal glucose levels, not seldom for 
decades, until the beta cells become unable to overcome insulin resistance through 
hypersecretion, and chronic hyperglycemia, respectively diabetes, instaurates 162. 
Obesity is most commonly linked to insulin resistance. It has been reported 163 that insulin 
resistance is a potent predictor of a wide range of serious illnesses, including stroke, type 2 
diabetes, cardiovascular disease, hypertension and cancer. Regardless of whether the insulin 
resistance or the basal hyperinsulinemia came first, the hyperinsulinemia itself might perpetuate 
the insulin resistance. In other words, hyperinsulinemia is often both a result and a driver of insulin 
resistance164. 
Insulin sensitivity is quantified ideally by the euglycemic hyperinsulinemic clamp, a test 
that cannot be used in the clinical practice due to its length and complicated protocol. Alternative 
well-correlated methods are not substantially simpler than the clamp and unsuitable for clinical 
practice. The Homeostatic Model Assessment (HOMA): HOMA-IR=Insulin mU/l x Glycemia 
(mmol/l)/22.5 remains the most popular one among other calculation models based on glucose 
and insulin levels in the fasting state. HOMA data on insulin sensitivity correlate well with data 
obtained from the glucose clamp, and are able to predict future development of diabetes. 
However, it remains a surrogate marker, and has a poor reproducibility across laboratories and 
populations, cut-off values for HOMA insulin resistance (HOMA-IR) being dependent from this 
variables 165.  
 
Hyperglycemia  
 Diabetes sets up after a period following a long phase of asymptomatic hyperglycemia. 
During this prediabetic state 166, which falls between normal glucose tolerance and diabetes 167, 
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fasting blood glucose can be maintained at an almost normal range for years, on the contrary to 
postprandial or postglucose levels that are gently elevated 166.  
 Hyperglycemia is responsible for the induction of numerous harmful effects that 
contribute to atherothrombosis. It is therefore linked to elevated oxidative stress 168, enhanced 
interaction between leukocytes and endothelial cells 169, and glycosylation of a plentiful of proteins 
such as lipoproteins, apolipoproteins, and clotting factors. Ultimately, a number of dehydration 
and oxidation reactions leads to the formation of advanced glycosylation end products (AGEs) 170 
that promote atherothrombosis through their effect on endothelial cell function 171.  
 
Inflammation 
It is widely appreciated that adipose tissue has important endocrine functions under both 
physiological and pathophysiological conditions. The proteins recognized to be secreted from the 
obese adipose cells, both adipocytes and stromal cells, are known collectively as adipokines (or 
adipocytokines) and their main functions are to participate in various processes as inflammation, 
blood pressure control, lipid metabolism and immunity, appetite and energy balance, insulin 
sensitivity and angiogenesis 172. The conversion from the lean to the obese state demands high 
triglyceride storage, so that the adipose tissue undergoes hyperplasia and hypertrophy. During and 
after this process, as consequence of the activation of stromal cells, infiltration with inflammatory 
immune cells and adipocytes hypertrophy, the obese adipose tissue produces an increased 
number of inflammatory adipokines and demonstrates an altered pattern of adipocyte secretion. 
Data have shown that initiation and integration of pathways of inflammation and insulin action in 
obesity and moreover in type 2 diabetes, depend critically on endoplasmic reticulum (ER) stress. 
The ER, as an organelle of protein modification and distribution, might be a sensor of the high 
metabolic stress induced by adipocyte hypertrophy and its conversion into signals of inflammatory 
response 173. 
This results in a systemic maintained low-grade inflammation, endothelial activation and 
development of atherothrombotic disease 105,174. The detailed role of local and systemic 
inflammation in the development of atherothrombosis has been detailed in chapter 3 Waist 
circumference correlates significantly with systemic inflammatory response 175. 
Conceptually, inflammation is described as the principal response of the body attempting 
to deal with injuries and trying to integrate many complex signals. Whereas this reaction takes 
place as a short-term response, the long-term consequences of prolonged inflammation are often 
not beneficial, as seen in metabolic diseases, including obesity and diabetes. In the chronic low-
grade inflammation associated with metabolic disease, few of the classic features of inflammation 
have been observed; the response is lower in intensity and more heterogeneous 173. 
Low grade inflammation is characterized by activation of the immune system and 
increased levels of various sera cytokines. Despite this, due to the great variability, only the high-
sensitivity C reactive protein (hs-CRP) 176, synthesized in the liver as response to the activation of 
the inflammatory cascade, and the increased count of leucocytes 177 have been validated as 
systemic markers for chronic inflammation. In atherothrombotic disease and obesity these 
markers are also utilized for the evaluation of the degree of systemic inflammation.  
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4.2 Obesity-associated atherosclerotic risk based on regional adipose tissue 
distribution  
 
In mammals, the adipose organ consists of several subcutaneous and visceral depots, 
some areas of which are brown and correspond to brown adipose tissue (BAT), while many are 
white and correspond to white adipose tissue (WAT).   
 
 
4.2.1 Brown and white adipose tissue and cardiometabolic risk 
 
 The Brown Adipose Tissue (BAT)  
BAT is a thermoregulatory organ. Heat production in BAT is under central control from the 
hypothalamus, where the outgoing signal is transmitted via the sympathetic nervous system to the 
brown adipose tissue 178. Being a heat regulator, it utilizes as a substrate FFAs in order to produce 
thermogenesis 179. BAT is equipped with a great number of mitochondria that give to the tissue its 
distinctive dark color. Brown adipocytes express the uncoupling protein-1 (UCP-1), that generates 
heat at the expense of ATP 180. 
Initially believed to be present only in young subjects/newborns, BAT is known nowadays 
to be active in various adult groups, as outdoor workers, northern populations, and less active in 
obese or overweight people, making it a suspect for obesity prevalence and a target for obesity 
treatment.  
In humans, brown adipose tissue surrounds the heart and great vessels in infancy but 
tends to disappear over time. Metabolically active BAT is identified by 18F-fluorodeoxyglucose (18F-
FDG) positron emission tomography scans (FDG-PET) combined with computed tomography (CT). 
Several studies have documented that the metabolically active areas detected on PET-CT actually 
are UCP-1-positive brown adipocytes 181,182,183 and have reached the conclusions that, irrespective 
of age and gender, metabolically active BAT is found in adult humans in the cervical–
supraclavicular region and upper-chest regions 184. 
 
The white adipose tissue (WAT) under normal and obesogenic conditions 
 On the contrary to BAT, WAT is active as an energy storage site. Dispersed all over the 
human body as part of the connective tissue and embedding muscle and nervous tissue, white 
adipocytes are the main storage depot for triacylglycerides (TAGs), leading to eventual release of 
FFAs.  
 Traditionally, WAT was attributed a role as a simple energy storage organ, that was 
accumulating triglycerides (TGs) and releasing FFAs and glycerol when energy intake was 
significantly lower than the fuel needed. However, nowadays it has proven to possess a complex 
metabolic role, which is to secrete and release a variety of proteins and biomolecules, therefore 
interacting with other tissues and organs 185,186. 
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Fig.5 Adipose tissue as an important endocrine organ. 
 
 
On its total, the adipose tissue (AT) is not composed of only adipocytes. Other types of 
cells to be found within this tissue are the stromo-vascular cells, formed by blood cell, leukocytes, 
macrophages, fibroblasts, preadipocytes, endothelial cells, holding one with another with collagen 
and elastic fibres 187,188,189,190. WAT has significant endocrine functions and is well vascularized and 
innervated. 
Human weight increase is due to the excessive accumulation of WAT. The white adipocyte 
is crucial for energy homeostasis and has significant endocrine functions, secreting hundreds of 
factors like enzymes, cytokines, hormones and growth factors 191,192 with autocrine, paracrine and 
endocrine actions. In obesity there is a misbalance in the secretion of these biomolecules that 
leads to a disrupted crosstalk between WAT and the other tissues inducing. WAT has the ability to 
grow and expand itself under positive energy balance and decline when energy expenditure is in 
excess of intake.  
 
Obese AT as source of circulatory atherothrombotic cytokines. Cellular origin.   
White adipocytes are nucleated cells comprising a lipid droplet which occupies most of the 
cell and a thin cytoplasm displaced to the periphery. Adipocytes derive from mesenchymal stem 
cells (MESCs) 193. MESCs initially develop into preadipocytes, cells that are morphologically 
indistinct from MESC precursors but meant to convert into WAT or BAT 193.  Finally they 
differentiate into mature adipocytes under well known regulations.  
The number and size of adipocytes generates the WAT mass, and cell death contributes to 
that together with the development and differentiation of progenitor cells, namely the 
preadipocytes. The growth of adipocyte mass occurs by elevated differentiation of the progenitors 
or by hypertrophy of the already existing adipocytes, precisely enhanced intracellular lipid 
deposition 188,194,195. 
Studies performed during the last years demonstrated that adipokines and bioactive 
peptides released by the adipose tissue are not only secreted by the mature adipocytes, a fact that 
is true in the case of some proteins only, like leptin or adiponectin.  
The theory about the inflammatory state of the obese adipose tissue emerged in 1993. 
Scientists were lead to this by the observation that TNF-α expression was upregulated in adipose 
tissue of obese mice 196. Mice fed a high-fat diet had a weight gain allied to the activation of 
various inflammatory pathways, being 59% of the total adipose tissue mRNA linked to 
inflammatory genes197. Additionally, mRNA levels and protein secretion of IL-6, TNF-α, PAI-1, TF, 
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angiotensinogen (AGT), complement factor C3 and other inflammatory, angiogenic and 
prothrombotic cytokines have been found elevated in adipose explants from obese patients 107. 
More recently 196,198, activation of a proinflammatory cell phenotype was suggested in the 
obese adipose tissue. According to evidence, adipose tissue dysfunction, resulting from fat 
accumulation in obesity, starts from the increase in both number and size of adipocytes, the 
associated hypoxia 199 and the defects in the accumulation and storage of lipids. Therefore, an 
imbalance of secreted cytokines and extracellular lipids is being generated, which further induces 
intracellular endoplasmic reticulum (ER) stress, produces an excess of reactive oxygen species 
(ROS) by the mitochondria and activates inflammatory signaling pathways 174,200. Once the initial 
impulse has been generated by hypertrophic mature adipocytes, further cellular activation in the 
obese AT involves mostly other cell types. Most factors secreted by the adipose tissue of morbidly 
obese humans derive from the non-adipocyte stromal cell fraction 201.  
Although macrophages embody only 5-10% of the adipose tissue’s cell population, weight 
gain induced by diet causes a significant macrophage infiltration, resulting in macrophages 
representing up to 50% of all cells found in adipose tissue 202,203. Studies performed on humans 
reported that insulin action is mostly connected to macrophage activation rather than the 
content204. For that, suggestions have been made linking inflammatory stimuli, generated by 
mature adipocyte-derived factors, to the polarization of the resident anti-inflammatory M2 
macrophages to a proinflammatory M1 phenotype, secreting chemoattractant biomolecules 205. 
This determines supplementary transmigration of circulatory monocytes and obese adipose tissue 
infiltration with proinflammatory macrophages, maintaining a vicious proinflammatory cycle 
197,202,205. 
In relation to this, our group has recently reported that the stromo-vascular cell fraction is 
responsible on majority for the secretion of cytoadipokines with endothelial injury potency 206. Fair 
enough has been also proposed that the number of committed preadipocytes able to undergo 
adipogenesis is reduced in obesity due to the proinflammatory environment 200,207,208. 
While less evidenced, worth mentioning are various other theories about inflammation 
onset in obesity. One of them 174 postulates that obesity itself is a stress condition comparable to 
that of an infection, explaining therefore the activation of similar pathways. Moreover, activation 
of inflammatory pathways could represent a catabolic defense response to the anabolic 
accumulation of adipose tissue.  
All these occurrences may then interact in order to generate a nasty cycle, maintaining the 
obese adipose tissue inflammation and intensely disturbing the secretion of adipose tissue-derived 
cytoadipokines. Consequently, an amplified number of inflammatory and thrombogenic 
proteins/peptides enter the central circulation and induce systemic low-grade inflammation, 
endothelial activation and development of atherothrombotic disease 105,109.  
 
 
4.2.2 Visceral versus subcutaneous adipose tissue in atherothrombotic disease 
 
Evidently, changes in the adipose tissue’s size and metabolism that define its pass from the 
lean to the obese state, but also changes within the very same obese condition (e.g. obese to 
morbid obese), determines an altered adipocytokine synthesis pattern, proinflammatory and 
prothrombotic ones getting dysregulated. Table 4 presents a summary of the till date most studied 
cytoadipokines emerged from the inflamed obese adipose tissue and their presumed actions.  
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Table 4. Adipokines and their functions 
Adipokine Metabolism 
Inflammation 
(Adhesion, 
Chemotaxis ) 
Extracellular 
Matrix Growth 
Fibrinolysis , 
Hemostasis 
Adiponectin (ADIPOQ) √ √  √  
Adipocyte fatty acid 
binding protein (FABP4) √ √    
Adipsin (CFD)  √ √    
Alpha 1 acid 
glycoprotein (ORM)  √    
Alpha 2 macroglobulin 
(A2M)   √   
Angiopoietin 1, 2    √  
Angiotensinogen (AGT); 
Angiotensin II  √ √  √ 
Apelin (Apln)  √ √    
Apolipoprotein E √     
Cathepsin (CTSD)   √   
Chemokine ligands and 
chemokines: 
CXCL5,CXCL10, CCL4-5, 
CCL14,CCL23, CXCL3, 
XCL1,CXCL12 LIF, LYVE-
1   
 √    
Collagen I, III, IV, VI   √   
Fibronectin (FN)   √   
Insulin-like growth 
factor 1 (IGF-1), IGF- 
binding proteins (IGFBP 
1-7) 
√   √  
Interleukines: IL-1β, IL-
4, IL-6, IL-6sR, IL-7, IL-8 
IL-10,IL-18 
√ √  √ √ 
Leptin(Lep) √ √  √  
Lysyl Oxidase   √   
Lipoprotein lipase (LPL) √     
Macrophage 
chemoattractant 
proteins (MCP1, MCP2) 
 √    
Macrophage migration 
inhibitory factor (MIF)  √    
Macrophage colony 
stimulating factor 
(MCSF), Monocyte 
differentiation antigen 
(CD14) 
 √    
MMP1-3, 7, 9-12, 14,15, 
19 
TIMP 1- 4 
  √   
Omentin (ITLN) √     
Oncostatin M (OSM)  √  √  
Resistin (RETN)  √ √    
Retinol binding protein 
(RBP4) √     
Secreted frizzled-
related protein 5 (Sfrp5) √     
TNFα,sTNFαRI, sTNFαRII  √    
Visfatin (NAMPT)  √     
Vaspin (serpin) √ √    
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Serum amyloid A3 
(SAA),C-reactive 
protein(CRP), 
Complement factors 
(C3-4, C7) , Haptoglobin 
(Hp)  
 √    
Angiogenin (ANG), 
Angiopoetin(ANGP), 
Fibroblast Growth 
Factor (FGF), Hepatic 
growth factor (HGF), 
Nerve growth factor 
(NGF),Stromal derived 
factor (SDF-1), Vascular 
endothelial growth 
factor (VEGF), Tumor 
growth factor (TGF-ß), 
Platelet derived growth 
factor (PDGF), 
Thrombopoietin (THPO) 
   √  
Tissue factor (TF), 
VCAM-1, ICAM-1, E-
selectin 
 √  √ √ 
Plasminogen activator 
inhibitor (PAI-1), 
Antithrombin (SerpinC) 
Trombospondin (Tsp)  
√    √ 
 
  
Both increased adiposity and reduced physical activity are strong and independent 
predictors of CHD 209 and death 210,211,212,213. Depending on the regional distribution on the human 
body, excess WAT has been correlated to cardiometabolic complications (accelerated 
atherothrombosis and premature cardiovascular death 214,215. There is widespread support in the 
literature for the conclusion that central adiposity (fat in the trunk and/or abdomen) confers more 
cardiovascular risk than peripheral adiposity (i.e., that present in the hips and thighs) 106. To the 
first form of adipose tissue accumulation is also referred as android obesity, whereas to the 
subcutaneous deposition of fat at the hips and thighs as the gynoid form of obesity.  
The waist-to-hip ratio reflects abdominal fat in predicting type 2 diabetes, stroke, myocardial 
infarction and cardiovascular mortality in middle-aged individuals. The Nurses’ Health Study 
confirmed these findings using the waist circumference 216. There is an independent curvilinear 
association between visceral adiposity and mortality 217, suggesting that a large amount of visceral 
fat is required for an increased risk of mortality. 
In general, for each unit of BMI increment, the risk of CHD increases by 8% 209. On the 
other hand, each 1 h-MET (metabolic equivalent) increase in activity score is associated with an 8% 
decrease in CHD risk. Most heart attacks can be predicted from easily measurable and modifiable 
factors, including abdominal adiposity and regular physical activity 214,217,218,219,220. 
AT is not structured out of one component only and is separated to the visceral and 
subcutaneous one. Both store excess calories while visceral AT supplies the inner organs with 
energy. There is 3 to 4 times more subcutaneous than visceral AT 221, and it appears that the two 
tissue types can interact in a coordinated and compensatory manner. An increase in total body fat, 
particularly in the visceral deposit, takes place with age and is associated with insulin resistance, 
dyslipidemia and increased risk for diabetes and CVD 220,105. 
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Compared with the subcutaneous AT, visceral AT is more cellularized, vascularized  and 
innervated, and contains a larger number of inflammatory and immune cells, a lesser preadipocyte 
differentiating capacity and a greater percentage of large adipocytes. Visceral AT cells are more 
metabolically active, more sensitive to lipolysis and more insulin resistant than subcutaneous 
adipocytes 187,222. Several proteomic studies have revealed significant differences in many 
proteins/peptides secreted from the visceral versus subcutaneous fat pads in obese versus lean 
individuals 223,224.  Interestingly, a current comparative proteomic study in lean subjects suggests 
significant differences between the secretomes of visceral and subcutaneous stromal cell fraction, 
but not between the secretomes of adipocytes isolated from the same fat pads 225. 
Thus, visceral AT has a greater capacity to generate free fatty acids and to take up glucose 
than subcutaneous AT, and is more sensitive to adrenergic stimulation. On the other hand, 
subcutaneous AT is more ardent in the absorption of circulating FFA and triglycerides. The 
subcutaneous fat is a more active storage depot, being more responsive for the anabolic actions of 
insulin and demonstrating a greater readiness for proliferation and expansion 222. In this sense, AT 
inflammation and macrophage infiltration is higher in obese visceral AT than subcutaneous AT 
197,202, which may be due to the reduced expandability of the former. Accordingly, data from 
various clinical ex vivo studies of different AT depots in humans indicate that visceral fat 
accumulation represents the highest risk factor for CVD, hypertension, insulin resistance and type 
2 diabetes 105,220. Visceral AT mass is also a more important predictor of myocardial infarction than 
the total body mass in women226.  
Therefore the increased secretion of deleterious adipokines in obesity has been attributed 
to visceral AT, suggesting that proinflammatory and prothrombotic protein secretion increases 
proportionally to the BMI 201,227. However, subcutaneous AT from obese subjects with a 
BMI>40kg/m2 also presented an altered cytokine secretion pattern 201,228. Thus, recently there 
have been reports that increased circulating hs-CRP associates with enlarged visceral AT mass in 
patients with vascular disease, apparently as a consequence of the induction of CRP synthesis by 
IL-6 secreted by the visceral AT 229. By that has been demonstrated the connection between the 
visceral AT secreted cytokine IL-6 and systemic inflammation. Circulating levels of IL-6 were 
associated with visceral adiposity, whereas TNF-α showed an association with overall obesity. 
These results support the hypothesis that IL-6 mediates the hyperinsulinemic state related to 
excess visceral fat while TNF-α contributes to the insulin resistance of overall obesity 230. Overall 
adiposity has also been found to be responsible for plasma levels of CAMs, being ICAM-1 and E-
selectin the most relevant ones231,232.  
In this sense, previous results from our group showed in a translational study model that in 
both lean and obese subjects the secretome of the visceral stromal cell fraction determines a 
higher proinflammatory and prothrombotic injury in macroendothelial cells, being highest the one 
induced by the visceral obese adipose tissue secretome 206. 
On the other hand, pericardial or perivascular ectopic AT depots associated with visceral 
obesity, have also been associated with increased CV risk in a paracrine manner, although to a 
lesser extent than the intra-abdominal AT 220. Nevertheless, the relationship between CVD and 
visceral AT is not straightforward, as racial and ethnic differences do exist. For example, African 
Americans demonstrate greater insulin resistance with less visceral fat as compared with 
Caucasians 233. Moreover, earlier studies in humans showed a stronger association between 
subcutaneous abdominal fat and insulin resistance 234,235. Thus, the role of anatomical location in 
mediating the deleterious effects of visceral AT, remains unresolved. 
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4.2.3 State of the art: Atherothrombotic disease in obesity and type 2 diabetes; the 
hyperinsulinemia- hyperglycemia- inflammation ensemble 
 
 Evidence demonstrates that increased adipose tissue mass contributes directly to an 
increase in systemic inflammation. The earliest indications of this phenomenon were reported in 
1985, when an article noted positive correlations between body mass and peripheral leukocyte 
count 236. Neutrophil activation increases with the grade of obesity. As neutrophils have a short life 
span, this indicates that the chronic inflammatory condition associated with morbid obesity is 
characterized by a continuous activation of the innate immune system 177. Further research in the 
‘90s has evidenced, as previously mentioned, that obese adipose tissue is infiltrated with 
proinflammatory immune cells that activate local non-adipocyte AT cells inducing profound 
alteration in the secretory pattern of the AT 196.   
 Since then, a large number of studies have found that increased BMI correlates with 
increases in systemic circulating levels of inflammatory, prothrombotic proteins and markers of 
endothelial activation, such as hs-CRP, IL-6, PAI-1, VWF and vascular cell adhesion molecules like 
VCAM-1, ICAM-1, P-selectin, fibrinogen and AGT 106,107,201,237,238. Moreover, endothelial activation 
and expression of ICAM-1 and E-selectin seems to be determined more by the obese AT grade of 
overall adiposity than insulin resistance 231. Further investigation confirmed that the obese AT 
secreted cytokines, especially the visceral ones, reach systemic circulation and determine directly, 
or by inducing the hepatic synthesis of other proinflammatory proteins like hs-CRP, the modulation 
of the sera prothrombotic and proinflammatory biomolecules 196,198,229,239. 
 
 
 
Fig.6 Local, portal, and systemic effects of inflammation in insulin resistance and atherogenesis. 
Increasing adiposity activates inflammatory responses in fat and liver, with associated increases in the production of 
cytokines and chemokines. Portal delivery of abdominal fat–derived cytokines and lipids contributes to hepatic 
inflammation and insulin resistance. Proinflammatory and proatherogenic mediators are produced in the adipose tissue 
and liver and associated immune cells. This creates a systemic inflammatory diathesis that promotes insulin resistance in 
skeletal muscle and other tissues and atherogenesis in the vasculature. FFA= free fatty acids. Adapted from Shoelson et 
al, J Clin Invest. 2006 240. 
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The “chicken or the egg” question.  As a result of the above, we can see that obesity is 
able to encourage both chronic inflammation and insulin resistance development. But there is still 
a blurred vision of whether insulin resistance leads to or results from systemic inflammation.  
Considerable studies on this field have been made on animals. Therefore, insulin resistance 
can be provoked in lean animals by infusion with inflammatory cytokines or lipids. Mouse obesity 
models were protected against insulin resistance when inflammatory mediators or pathway 
components by genetic manipulation were removed 174. Additionally, insulin resistance was caused 
in animals when infused with inflammatory cytokines or lipids and at the absence of obesity 174. 
In humans, the facts are that subjects with chronic inflammation are predisposed to CVD 
and diabetes 174,237. Insulin sensitivity is improved by salicylates 240, and obese patients with insulin 
sensitivity present a lower risk of cardiometabolic complications and a higher degree of adipose 
tissue inflammation 241,242. The same studies suggest activation of insulin resistance associated with 
obesity depends on the activation of inflammatory cascades and that IL-6, IL-1b and NF-κB seem to 
be important effectors, mediating the inflammation effects promoting insulin resistance 242. The 
inflammatory state can be reverted by weight loss, which is essentially a reduction in AT mass. 
Weight loss induces the constant decrease in CRP levels and other systemic inflammatory 
cytokines107, with the exception of adiponectin, which rises.  
Significant source of endothelial dysfunction can be considered insulin resistance and the 
effects proceeding hyperinsulinemia, even though evidence suggests that the roots of endothelial 
activation and at least the first crucial step of leukocyte adhesion to the endothelium are the 
consequences of the systemic inflammation associated with obesity 239.  
 
Promising experimental data are suggesting that insulin has a beneficial effect on the 
endothelium 243. Anyway debate persists as follows. 
 
Anti-inflammatory effect of insulin. Another possible reason why obesity and type 2 diabetes are 
associated with inflammation is that the state of insulin resistance promotes inflammation. This is 
due to the fact that insulin exerts an anti-inflammatory effect at the cellular and molecular level in 
vitro and in vivo. A low dose infusion of insulin (2.5 IU h21) reduces ROS generation by 
mononuclear cells, suppresses NADPH oxidase expression and intranuclear NF-κB binding, induces 
I-κB expression and suppresses plasma intercellular adhesion molecule-1 (ICAM-1) and monocyte 
chemotactic protein-1 (MCP-1) concentrations. It also suppresses plasma tissue factor, PAI-1 and 
MCP-1 concentrations 244,245. An interruption of insulin signal transduction would prevent the anti-
inflammatory effect of insulin from being exerted 246. 
An important implication in the relationship between inflammation, obesity, insulin 
resistance and type 2 diabetes, is that atherosclerosis, which is responsible for the major cause of 
death (acute myocardial infarction) in this patient population, is itself an inflammatory process 97. 
An increase in the plasma concentration of inflammatory mediators, such as CRP and IL-6, 
increases the risk of atherosclerotic complications, such as acute myocardial infarction. Thus, 
inflammation underlies both insulin resistance and atherosclerosis. One mechanism that might 
connect these features is the anti-inflammatory and potential anti-atherosclerotic effect of insulin, 
which in the presence of resistance will lead to a proinflammatory state. It is interesting in this 
light that insulin sensitizers as thiazolidinediones are also anti-inflammatory and potentially 
antiatherogenic 247,248,249. Thus, insulin and thiazolidinediones (TZDs) exert a suppressive effect on 
ROS generation, NADPH oxidase expression and intranuclear NF-κB binding, and a stimulatory 
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effect on I-κB expression along with a reduction in plasma concentrations of ICAM-1, MCP-1 and 
PAI-1. TZDs also suppress the plasma concentrations of TNF-α and CRP 246. 
 
Proinflammatory and other proatherogenic effects of insulin. Intriguingly, results from in vitro 
studies in the HUVEC-established macroendothelial model, mostly from the group of Madonna et 
al, reported that prolonged pathologic concentrations of insulin induce the endothelial expression 
of adhesion molecules VCAM-1, ICAM-1 and activation of NF-κB pathways in endothelial cells 
through stimulation of the p38 MAP kinase 250,251,252. Moreover, recent researches regarding insulin 
growth factor potential have reported that high concentrations of insulin stimulate angiogenesis in 
the atherosclerotic plaque, making it more vulnerable and prone to an acute rupture 253. 
  
Hyperglycemia, glucose variability and inflammation in the atherothrombotic disease related to 
type 2 diabetes-associated obesity.  
Earlier we referred to hyperglycemia as causative of cardiovascular complications which 
constitute the major source of morbidity and mortality in patients with diabetes.  
These have been linked to hyperglycemia-induced oxidative stress and to the formation of 
advanced glycosylation end products (AGEs), that promote atherothrombosis through their effect 
on endothelial cell function 254,255,256.  
However, there is a considerable debate about the range of glucose adjustment. It is a fact 
that glucose control in DM treatment undergoes strict lines, since intensive glycemic control 
prevents the development and progression of microvascular complications in patients with type 1 
or type 2 diabetes. Nonetheless, recent studies demonstrated that intensive glycemic control to 
near normoglycemia also can result unworthy, having no deriving benefit on cardiovascular 
outcomes. Apart from this, prejudicious intensive glucose-lowering therapy was reported to have 
an effect on mortality 257. 
An interesting theory suggests that glucose variability is more important than hyper- or 
hypoglycemia per se. Exposure of human umbilical vein endothelial cells (HUVECs) to oscillating 
glucose revealed its damaging effects compared to constant high glucose, inducing a metabolic 
memory even after glucose normalisation, most probable due to hyperactivation of p53 during 
glucose oscillation 258. With the term “metabolic memory” has been described the ability of 
hyperglycemia to leave a mark in the cells of the vasculature and therefore supporting 
forthcoming complications even at moments of good glycemic control 259. Hence, a very early 
aggressive treatment of hyperglycemia has been suggested as mandatory 255. 
Data remains unchanged when comparing effects of high glucose, hypoglycemia and 
glucose variability on the acute and chronic CV disease. Both high values of glycemia and 
hypoglycemia and high oscillation seem to predict endothelial apoptosis and prothrombotic short 
term complications260.  
Moreover it has been observed that systemic inflammation increases in obesity once 
diabetes is restored 261. The effect of high glucose concentrations (varied doses and time of 
exposure) on the activation of inflammatory endothelial pathways has been studied in various in 
vitro models of endothelial injury with contradictory results 262,263,264,265,266,267,268. Most evidence 
indicates that chronic hyperglycemia is not sufficient to directly promote endothelial inflammatory 
activation. At clinical level, inflammatory activation of endothelial cells in acute myocardial 
infarction is related to glucose impairment in diabetic subjects 269, but as mentioned above, no 
relation has been established in the evolution of chronic CVD. These findings are highlighting the 
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pivotal role of a proinflammatory environment in type 2 diabetes associated to obesity, suggesting 
it as a critical factor conditioning the early pro-atherosclerotic actions of hyperglycemia.  
 
Till date no study was performed on the direct concomitant effect of glucose and adipose 
tissue secreted molecules on the endothelium. Our group has previously demonstrated in an in 
vitro model the capacity of cytokines secreted from the adipose tissue to directly activate 
endothelial injury mechanisms. How glucose, insulin and type 2 DM change the effect of the 
adipokines secreted from the obese adipose tissue has therefore been one of the three goals of 
this thesis.   
 
 
4.3  Metabolism products as emerging cardiovascular- and diabetes-predictor factors 
in obesity and diabetes mellitus  
 
 
4.3.1 Metabolomics, the concept 
 
Since the 1990s, there has been a revolution in the techniques and approaches used in 
molecular biology culminating with the development of system biology and of the -omic 
sciences270. Among “-omics” sciences, metabolomics is of the youngest, but its use has been 
rapidly increased, accounting for its great impact. It shows a great potential in identifying possible 
biomarkers for drug discovery, involving the bio-chemical profiling of all the metabolites in a cell, 
tissue, or organism.   
In reality it depicts the comprehensive and simultaneous systematic profiling of multiple 
metabolite levels and their systematic and temporal changes caused by factors such as diet, 
lifestyle, environment, genetic effects and pharmaceutical effects, both beneficial and adverse, in 
complex systems and whole organisms. Actually metabolomics focuses on the measurement of the 
physiological state of an organism’s metabolites through the combination of data-rich analytical 
techniques and multivariate data analysis 271,270. 
The objective of systems biology is to obtain an integrative model of systems and their 
interactions. Genomics’, transcriptomics’, metabolomics’ and proteomics’ data are integrated for 
construction and validation of models. The value of metabolomics is justified by the straight 
correlation between the metabolome and the phenotype, since the metabolites reflect the 
activities of the cell at the phenotypic level. It is worth to note that a large variety of metabolites 
change far faster than nucleic acids or proteins, reflecting more adequate changes in cell functions. 
Differently from genomics and transcriptomics, metabolomics is sensitive to both the genetic and 
the modifying environmental influences that determine the metabolic pattern of an organism. 
Metabolic analysis observes the biochemical effects in a system being close to the biological end-
point.  
Metabolomics applies techniques suitable for a high throughput analysis of metabolites in 
fluids (mainly blood and urine) and tissues. The product is the metabolic profile, whose 
comparison with others, from different phenotypes, is used to recognize precise metabolic 
changes. The latter leads to understanding of biochemical pathways, complex biomarker 
combinations, toxic effects and disease progression. Metabolomics is mainly functional in 
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mammalian systems in phenotyping, discovery of biomarkers, diagnosis of diseases and 
therapeutic efficacy, toxicology (pre-clinical drug candidate safety assessment), etc. 
 
 
4.3.2 Detection techniques 
 
There are two basic different approaches to metabolomics: targeted and untargeted.  
Targeted metabolomics refers to the identification and quantification of defined sets of 
structurally known and biochemically annotated metabolites. It has the chief advantage to 
generally provide quantitative data (the concentrations of the involved metabolites) and facilitate 
the instantaneous understanding of deviations from normal. Interpretation of the data is 
straightforward, regardless of the cohort investigated, for example, healthy vs. diseased or treated 
vs. untreated. A further advantage of targeted metabolomics is that it is well suited for high-
throughput and routine applications 272. Another major benefit of the targeted method is speed, 
since minimal effort and resources are required to profile the specific metabolites over a large 
number of samples 273. 
On the other hand, untargeted metabolomics involves comparison of total relative 
quantities of the metabolome in samples without previous identification.  The objectives of 
untargeted metabolomics are to determine metabolomic profiles in relation to complex sets of 
genomic and proteomic changes. This method is a potent technique for identifying and quantifying 
relative changes in complex samples, since identification of the peaks found to be dysregulated in 
the untargeted data still remains a challenging determination 273. In contrast to targeted 
metabolomics, where ions from known metabolites are being measured, untargeted 
metabolomics records all ions within a certain mass range, including those of structurally novel 
metabolites 274. 
 
The main analytical techniques that are employed for metabolomic studies are nuclear 
magnetic resonance (NMR) spectroscopy and mass spectrometry (MS), thanks to their sensitivity 
and resolution capabilities. The latter technique requires a connection to another technique for a 
pre-separation of the metabolic components, for instance gas chromatography (GC) after chemical 
derivatization, or liquid chromatography (LC), with the newer method of ultra-high-pressure LC 
(UPLC) gaining more and more use. The use of capillary electrophoresis (CE) coupled to MS has 
also shown to be promising. Other more specialised techniques as Fourier transform infra-red 
(FTIR) spectroscopy and arrayed electrochemical detection have been used with less extent 270.   
 
 
NMR spectroscopy 
 NMR spectroscopy is a non-destructive technique that supplies detailed information on 
the molecular structure of pure compounds and complex mixtures, as well as on absolute or 
relative concentrations. The NMR spectroscopic methods are employed in the survey of 
metabolite molecular dynamics and mobility in addition to substance concentrations through the 
interpretation of NMR spin relaxation times and by the determination of molecular diffusion 
coefficients 270. 
 
50 | I n t r o d u c t i o n  
 
Fig.7 A proton NMR spectrum of a solution containing a simple organic compound, ethyl- benzene. Each group of signals 
corresponds to protons in a different part of the molecule. Adapted from http://www.nobelprize.org. 
 
 
 The benefits and weaknesses of the technique, with respect to its use in metabolomics, are 
depicted in Table 5. In the pros are included the high throughput, the minimum sample 
preparation, the non-destructive nature of the technique and the possibility for in vivo application 
on whole live subjects, among others. The cons are allied to a relatively poor resolution as far as 
complex samples are concerned, a reduced sensitivity compared to MS, and the need for a fairly 
high sample volume, as being the most important ones.   
 
 
Table 5. Advantages and disadvantages of metabolomics-applied NMR 
Advantages Disadvantages 
o Rapid and simple sample preparation 
required.  Poor sensitivity and selectivity. 
o Does not require chromatographic 
separation. 
 
 Relatively poor resolution in complex 
samples. 
o High reproducibility.  Difficult automatization despite robotized systems. 
o Relatively high throughput in 1DNMR 
experiments. 
 Very low throughput in 2D-NMR 
experiments. 
o Useful for identification purposes.  Difficult to unequivocally assign 
signals. 
o Versatility. Possibility of direct 
analysis of solids and in-vivo studies.  Less suitable for targeted analyses. 
o Non-destructive. 
 Large sample volume (0.5 ml). 
Adapted from http://www.tdx.cat. 
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Targeting NMR analysis is gaining attention owing to the wide range of applications that 
has emerged lately. Interestingly enough there have already been studied and published 
biomarkers related to diseases or human metabolism, including schizophrenia 275, multiple 
sclerosis 276, diabetes 277, organ rejection 278, and rheumatoid arthritis 279. Moreover, NMR-based 
serum-lipoprotein quantification is now an ordinary clinical diagnostic tool, since in vivo 
identification and quantification is currently well practiced.  
 
 
Mass spectrometry (MS) 
Being currently the most reliable platform for identification, MS is a detection technique 
based on the differential displacement of ionized molecules through vacuum by application of an 
electrical field. The ions are separated according to their mass-to-charge ratio (m/z) and are this 
way detectable. A general prior separation of the complex mixture sample is required, being mass 
spectrometers usually joined to a separation unit such as a chromatograph or capillary 
electrophoresis equipment 271. For example, connection to a UPLC (UPLC-MS) provides better 
chromatographic peak resolution and increased speed and sensitivity in complex mixture 
separation 270.  
 
 
 
Fig.8 Example of a mass spectrum. Each peak shows a component of unique m/z in the sample, and heights of 
the peaks indicate the relative abundance of the various components in the sample. Adapted from 
http://www.broadinstitute.org. 
 
 
The use of MS is extensive in metabolic fingerprinting and metabolite, as well as in the 
identification and quantitation of drug metabolites, since it is considerably more sensitive than 
NMR spectroscopy 270. In fact, MS-based metabolomics offers quantitative analyses with high 
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selectivity and sensitivity and the potential to identify metabolites with high mass accuracy. On the 
contrary, quantification requires suitable internal standards, MS measurements can vary in time 
requirement, and sample preparation might cause metabolite losses. For more information see 
Table 6. 
 
 
Table 6. Advantages and disadvantages of metabolomics-applied MS 
Advantages Disadvantages 
o Highly sensitive in its different 
modes. 
 Detection depends on ionization 
efficiency. 
o Accurate m/z measurements ideal for 
identification of metabolites. 
 Limited to liquid samples or extracts 
isolated from solid samples. 
o Suitable for quantitative target 
analysis. 
 Destructive, particularly complicated 
for analysis of valuable samples. 
o Very selective.  More efficient when coupled to 
separation techniques. 
o Structural information throughout 
fragmentation patterns. 
 Quantification requires chemically-
related internal standard. 
o Excellent resolution (improved by 
separation). 
 Difficult sample preparation 
protocols. 
Adapted from http://www.tdx.cat. 
 
 
Mass spectrometry is the preferred technique for targeted analysis in several areas, 
including pharmaceutics, clinics, forensics, food, agriculture, etc., being a great tool for molecular 
identification. The recently introduced highly accurate mass spectrometers (Orbitrap and TOF 
analyzers) have enabled the use of MS for global profiling with a relatively high throughput. Mass-
spectrometric metabolic profiling has been used broadly in the diagnosis of metabolic disorders by 
sampling diverse biofluids; as an example, the urinary metabolome that has been evaluated by 
Kuhara 280 in the diagnostics of metabolic disorders using GC–MS. Additionally, MS has become 
valuable in assessing disorders of amino acids metabolism, fatty acids, organic acids biosynthesis, 
etc271.  
 
 To summarize, NMR and MS approaches are highly complementary, and mutual use is 
frequently necessary for global molecular characterisation. The lower detection limits of MS 
constitute it more sensitive, provided the substance of interest can be ionised, but NMR 
spectroscopy is particularly functional for distinguishing isomers, for the obtention of molecular 
conformation information and for studies of molecular dynamics and compartmentation 270. 
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4.3.3 Applications on obesity and type 2 diabetes mellitus 
 
Nowadays’ scientists are confronting themselves with the discovery of treatment or 
prevention of diseases. Development of obesity-associated metabolic disease, cardiometabolic 
complications and diabetes are among them 271. 
Alterations of carbohydrate and lipid homeostasis in obesity have been widely recognized 
281 but the role of specific metabolites remains under study, with controversy surrounding the 
question of whether protein metabolism is affected in human obesity. Metabolomic sera studies 
performed till now in obese humans have provided important evidence about the role of obese 
adipose tissue emerged metabolites in the systemic metabolic disease have been performed till 
date various study in animal models and in obese humans. Adipose tissue-secreted metabolites 
are not only indicative of the obesity-induced psychopathological state but may also act as 
initiators of pathological cascades and play endocrine roles as regulatory signals 282. 
   Metabolic markers for insulin resistance, development of the cardiometabolic disease and 
diabetes have been a constant motive of investigation.  
As far as animal models are concerned, the Zucker obese rat has been widely used for 
metabolomic studies. Considering male and female Zucker rats as models for diabetes, 
metabolomic analysis has been applied on urine samples of those animals, with the help of 
capillary HPLC 283. Chromatographic separation using capillary HPLC-MS provided higher sensitivity 
than simple HPLC-MS, as well as a greater peak count (ca. 3000 ions compared to 1500 for HPLC) 
for the same analysis time. From the data resulted also markers of diurnal variation, for both male 
and female rats. 
Moreover, the relationship between visceral adiposity and intramyocellular lipid levels 
associated with the development of type 2 diabetes was surveyed in animal models of insulin 
resistance, induced by diet or glucocorticoids 284, applying metabolomic measurements as well as 
in vivo and plasma NMR spectroscopy.  
In humans, the first metabolomic studies applied NMR spectroscopy in the urine and 
plasma of diabetic patients 285. Insulin removal lifted plasma levels of ketone bodies and glucose, 
whose levels, together with the ones of lactate, valine and alanine, were in agreement as when 
measured by standard clinical chemistry methods, confirming NMR accuracy. This, in addition to 
some later studies, demonstrated the usefulness of NMR spectroscopy in the diagnosis of 
diabetes, the monitoring of the development of the disease and the monitoring of patient therapy 
in a fast and non-destructive way.  
It was not until recently that capillary gas chromatography was applied in the diagnosis of 
type-2 diabetes mellitus based on serum lipid metabolites, suggesting that serum fatty acid 
profiles might distinguish type 2 diabetic patients from healthy subjects 286.  
Kim et al identified three lyso-phosphatidylcholine derivates as potential plasma markers 
and confirmed eight known metabolites for overweight/obesity men. Overweight/obese subjects 
showed higher levels of lysoPC C14:0 and lysoPC C18:0 and lower levels of lysoPC C18:1 than lean 
subjects. Moreover they present an abnormal metabolism of two branched-chain amino acids 
(BCAA), two aromatic amino acids, and fatty acid synthesis and oxidation 287.  
   In a functional study in obese humans, Huffman et al observed that elevated 
concentrations of large, neutral amino acids were independently associated with insulin resistance 
and fatty acids were inversely related to the pancreatic response to glucose, suggesting that these 
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metabolites might play a role in the progression of type 2 diabetes by inducing insulin resistance 
and pancreatic injury 288. 
   Hypercaloric high fat and BCAA containing diets (mainly leucine) contribute to 
development of obesity-associated insulin resistance by chronic phosphorylation of mTOR 
(mammalian target of rapamycin), JNK (c-Jun N-terminal kinase), and IRS1Ser307 (insulin receptor 
substrate 1), and by accumulation of multiple acylcarnitines in muscle 289. Plasma long-chain 
AcylCN species are increased in obesity and type 2 DM, suggesting that more fatty acids can enter 
the mitochondria. In type 2 DM, many shorter species accumulate, suggesting an extended 
oxidation defect 290. 
   Moreover, butyrate and propionate protect against diet-induced obesity and regulate gut 
hormones via free fatty acid receptor 3-independent mechanisms 291. 
   Other small study on serum from young obese, nondiabetic women reports that, serum 
acetate was negatively associated with visceral adipose tissue and insulin levels 292.   
 Interestingly, other scientists proposed that a high glutamine to glutamate ratio would 
exert a preventive role on the cardiometabolic status 293. 
   Moreover, recent clinical evidence from the Framingham offspring study indicated 
increased levels of a group of five BCAA and aromatic amino acids (namely isoleucine, leucine, 
valine, phenylalanine and tyrosine) as candidate metabolic risk markers for diabetes in obesity, 
predating the clinical onset of diabetes by years 294. 
In summary, up to date have been reported notable differences in the metabolic sera 
signatures of obese, mild insulin resistant but nondiabetic and lean individuals, while a decrease in 
certain metabolites has been found to predict improvement in insulin resistance (HOMA-IR) 
independent of the weight loss. Moreover, specific plasmatic metabolites are emerging as strong 
predictors of insulin resistance. What is more important, very recently have been described 
predictive sera metabolites of the onset of diabetes in obesity.  
Despite all this extensive sera basal and functional metabolite study, until nowadays the 
contribution of the metabolites produced by the different obese adipose tissue depots to the 
systemic altered metabolite pool has not yet been defined. Hence, as in the present thesis one of 
our aims was to study the particularity of regional adipose tissue depots, we comparatively 
analyzed the secretome pattern of subcutaneous and visceral obese and nonobese adipose tissue 
using an untargeted metabolomics approach. Our goal was to decipher how obesity affects the 
metabolic profile of adipose tissue secretomes.  
 
 
 
5. Metformin role in the treatment of type 2 diabetes  
 
 
5.1 History 
 
Back in the 18th century, the British botanist Sir John Hill, briefly illustrated in his work a 
plant named Goat’s Rue (Galegus officinalis), a description that still stands until today: ‘This is a 
perennial, native of Spain, and Italy; of Greece and Africa. A specious plant, of a yard high, that 
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flowers in August. The stalk is juicy, and green: the leaves are of a fine fresh green: the flowers are 
purple; sometimes white 295. 
Goat’s Rue, also known as French Lilac or Italian Fitch, is the natural source of guanidine, 
the active component of galega. Guanidine was popular in the 1920s for the synthesis of several 
antidiabetic compounds, out of which in the 1950s were introduced metformin and phenformin, 
two main biguanides 296. 
Whereas phenformin presented a connection with lactic acidosis and was withdrawn from 
clinical use in many countries in the 1970s, metformin got not related with such associations and it 
is still used in more than 90 countries as the most widely prescribed oral antidiabetic agent. 
Metformin has an efficacy of glycemic control similar to that of the sulfonylureas, even if with a 
different mode of action. It is administered as first line therapy in patients with type 2 diabetes, 
with a special indication in obese patients. Metformin acts as an insulin sensitizer lowering blood 
glucose concentrations, improving insulin sensitivity and thus decreasing insulin resistance 296. 
 
 
5.2 Metformin as antidiabetic drug: mechanisms of action  
 
Fig.9 shows the structure of metformin and in Table 7 are delineated its pharmacokinetics. 
The main mode of action of metformin relies on the hepatic suppression of gluconeogenesis, fatty 
acids and cholesterol biosynthesis and on the reduction of the glucagon-stimulated 
gluconeogenesis296. This reduces the levels of circulating glucose, increases hepatic insulin 
sensitivity, and reduces hyperinsulinemia associated with insulin resistance. Metformin performs 
effectively only in the presence of insulin296. Most type 2 diabetic patients have three times the 
normal rate of gluconeogenesis and metformin treatment reduces this by over one third.  
 
 
                                      
Fig.9 Structure of Metformin.  
Adapted from Bailey et al, NEJM 1996 296. 
 
 
Several other actions may contribute to the positive actions of metformin, such as 
increased intestinal use of glucose and reduced fatty acid oxidation.  
Peripheral tissues, for instance skeletal muscle, increase insulin-mediated glucose uptake 
due to metformin, predominantly after meals. Metformin activates the adipose tissue AMPK 297. 
Therefore it increases the activity of anaerobic glucose metabolic pathways with the formation of 
lactate and the suppression of lipolysis. This sinks the availability of substrates for 
gluconeogenesis296, a process linked to its antilipolytic effect by lowering serum free fatty acids. 
Metformin increases therefore the uptake and oxidation of glucose by the adipose tissue and the 
lipogenesis 298.  Consequently, glycemic control gets enhanced and serum insulin levels diminish. 
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However, the actions of metformin on peripheral tissues in vitro require high concentrations and 
are slow in onset. Tissues acutely insensitive to insulin, like the brain, the renal medulla and the 
skin, show ineffectiveness to metformin 296.  
 
 
Table 7. Pharmacokinetic Aspects of Metformin 
About… Observations 
Bioavailability - 50-60%  
- absorbed mainly from the small intestine 
 - estimated absorption half-life 0.9-2.6 hours 
Plasma concentration - 1-2 μg/ml 1-2 hours after an oral dose of 500-
1000mg 
- negligible binding to plasma proteins 
Plasma half-life - 1.5-4.9 hours 
Metabolism - not measurably metabolized 
Elimination - ~ 90% is eliminated in urine in 12 hours 
- multiexponential pattern involving glomerular 
filtration and tubular secretion 
Tissue distribution - distributed in most tissues at concentrations 
similar to those in peripheral plasma  
- higher concentrations in liver and kidney 
- highest concentrations in salivary glands and 
intestinal wall 
Table adapted from Bailey et al, NEJM 1996 296. 
 
 
As much as is known, the molecular mechanism by which metformin acts is to inhibit liver 
cell glucose production by activation of AMP-activated protein kinase (AMPK), a liver enzyme 
important in insulin signalling, whole body energy balance and metabolism of glucose and fats. 
Metformin’s regulation of AMPK works through liver kinase B1 (LKB1), a tumor suppressor, and 
activation of AMPK through LKB1 may play a role in inhibiting cell growth. Hence, metformin 
seems to exert its cell-growth inhibitory effects through two distinct mechanisms: a direct 
mechanism that inhibits the mTOR pathway and an indirect mechanism depending on insulin 
levels. For that, metformin use has been observed to decrease cancer incidence 296.   
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Interestingly, besides pathways dependent from the activation of AMPK, it has been 
stipulated that metformin increases insulin sensitivity by increasing the affinity of insulin to its 
receptors and the phosphorylation and tyrosine kinase activity of these receptors in vivo, but the 
actions have been irreproducible in vitro. Moreover, metformin increases the cellular translocation 
of GLUT-1 and GLUT-4 isoforms of glucose transporters.  In vitro, cultured hepatocytes and 
adipocytes exposed for long periods to high insulin concentrations are prevented from developing 
insulin resistance by metformin treatment 296. 
The decrease in the fatty acid oxidation induced by metformin rises up to 10-20% 296, 
resulting in a following reduction in plasma glucose concentrations by means of the glucose–fatty 
acid cycle. Metformin affects overall faintly the oxidative metabolism, since it causes a small 
decline in fatty-acid oxidation and a small augmentation in glucose oxidation, implicating glycogen 
formation as an important part of the increased glucose disposal.  
Another characteristic of metformin is that it increases basal and postprandial blood 
lactate levels at small, but within normal, degrees. The explanation of these ascends needs to be 
searched between obesity and diabetes, which have the ability to slightly raise blood lactate 
concentrations. The latter effect is probably due to metformin-induced conversion of glucose to 
lactate by the intestinal mucosa. Continuously, the lactate enters the portal circulation and gets 
degraded by the liver, where it serves as a gluconeogenic substrate. After a meal, when liver gets 
immersed in loads of fuel, greater quantities of lactate enter into the systemic circulation. In 
animals, metformin administration contributes to the conversion “glucose–lactate–glucose” and 
the overall increase in glucose turnover 296.  
 
 
5.3 Safety and tolerability 
 
Metformin is being used widely in Europe, Latin America, Canada and the United States for 
its antidiabetic action, as well as in the rest of the world. Even so, historically its use has been 
through adverse prohibitions, due to an affected safety profile compared to other biguanides. 
Being lactic acidosis the most severe reaction to biguanides, as it leads to fatal results in 50% of 
the cases, phenformin, a member of the family, had to be withdrawn from the market due to its 
high incidence of lactic acidosis, making the use of metformin considerable of approval in the U.S. 
299. 
Lactic acidosis is defined as the accumulation of lactate and lowering of the pH in body 
tissues and blood, occurring when the body regenerates ATP without oxygen (tissue hypoxia) 
300,301. It is rare but a serious effect in metformin therapy, with an incidence of 9.7 episodes per 
100,000 patient-years among patients with type 2 diabetes, translated to 3 cases per 100,000 
patient-years with metformin therapy 299. In the vast majority of the cases it occurs because one or 
more contraindications were overlooked, precipitating the reaction. Moreover, causal 
consideration of metformin to lactic acidosis has been present in patients with renal insufficiency, 
and thus at risk for metformin accumulation, or in patients going through hypoxic states, as 
hypotension with low tissue perfusion, liver disease, alcohol abuse, heart failure and surgical 
procedures, which increase the risk for developing lactic acidosis 296,299. The risk of death from 
lactic acidosis in metformin-treated patients is similar to that of hypoglycemia in sulfonylurea-
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treated patients296. Metformin-attributable lactic acidosis can be confronted by removal of the 
drug with hemodialysis 296. 
 More commonly, adverse effects occurring during metformin therapy are of 
gastrointestinal nature and are dose dependent. In a lesser extent, around 7% of patients under 
metformin treatment present reductions in serum vitamin B12 and folic acid, probably in relation 
with impaired gastric absorption of these vitamins. Other events include hypoglycemia episodes, 
but occur at lower rates similar to those of other antidiabetic drugs 299.  
 
 
5.4 Metformin and the cardiometabolic risk factors associated with type 2 diabetes 
and obesity 
 
As suggested by data from clinical trials, metformin, compared with any other oral 
diabetes agents or placebo, dicreases the cardiovascular mortality and also the cardiovascular 
morbidity due to its glucose lowering effect 302,303. Sustained evidence from animal and in vitro 
studies suggests also a beneficial, but glucose-lowering, independent effect of metformin on the 
CV outcome in type 2 diabetes. This effect has been stipulated to rely initially basically on its 
insulin sensitizer proprieties. 
Nowadays there has been provided evidence about pleiotropic actions of metformin in the 
reduction of the CV risk. The United Kingdom Prospective Diabetes Study (UKPDS) reported that 
metformin was associated with a 32% reduction in any diabetes related endpoint (p<0.002), a 39% 
reduction in myocardial infarction (p<0.01) and a non-significant 29% fall in microvascular 
complications 304.  
Interestingly, metformin therapy has been also observed to decrease platelet sensitivity to 
aggregating agents 305, most probably due to reduced blood glucose levels. Moreover, there has 
been an association with increased fibrinolytic activity and small reductions in plasma 
concentrations of the fibrinolytic inhibitor PAI-1 296. 
Moreover metformin seems to modulate, although discrete, the lipid profile, by decreasing 
fatty acid oxidation. Patients receiving long-term metformin treatment show a moderate reduction 
in plasma triglyceride concentrations (10-20%) because of decreased hepatic synthesis of very low 
density lipoprotein 296. 
Very recent reports from in vitro experiments suggest that metformin suppresses the 
metabolic memory of high glucose in diabetic retina by targeting Sirtuin 1 (SIRT1). This fact, 
although focusing on a microarterial complication in diabetes, raises questions about the 
importance of this mechanism in macrovascular disease, as SIRT1 exerts an important 
antiatherogenic role 306,307. 
Interestingly, also in vitro has been provided sustained evidence on its capacity to improve 
nitric oxide endothelial dysfunction and prevent nitrosative and oxidative stress under basal 
conditions, as well as alter exposure of EC to high glucose and lipids 308,309,310,311,312,313. Metformin 
also ameliorates proliferation and apoptosis of human coronary artery endothelial cells 314. 
From other in vitro and animal model experiments, we have evidence that metformin 
independently reduces carotid arterial wall thickness and improves arterial dilatation in type 2 
diabetes and other insulin resistant models 315,316. 
Recently has been questioned the role of metformin on the chronic systemic 
inflammation, an important CV risk factor associated to obesity and type 2 diabetes. In in vitro 
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experiments on an established macroendothelial study model (HUVEC), metformin has been 
observed to inhibit cytokine-induced NF-κB activation via PI3K-dependent AMPK activation in 
vascular endothelial cells 317,318,319. In this sense, some sera studies on the hs-CRP inflammatory 
marker report the decrease of systemic inflammation in metformin-treated patients 320,321,322. 
Contrarily, a recent study in obese children with normal glucose tolerance and the PIOCOMB study 
on type 2 diabetic patients report that metformin does not improve inflammatory parameters 
323,324.  
 In vivo controversy persists on the beneficial role of metformin on CV outcomes beyond 
glucose control. In this sense, one recent meta-analysis concludes that treatment with metformin 
is not associated besides the glucose lowering effects with significant harm or benefit on 
cardiovascular events 325. Moreover, other recent meta-analysis of 26 trials on metformin and 
insulin versus insulin alone, reported that there was no evidence ore even a trend towards 
improved all-cause mortality or cardiovascular mortality in the metformin treated groups 326. 
These data strongly indicate that CV disease prognosis is not definitively determined by the 
amelioration of insulin resistance in the metformin-treated patients and moreover raise the 
question if really metformin acts or not on the systemic inflammation.  
Concerning the inflammation-related CV risk, in obesity and associated type 2 diabetes the 
driver of the low systemic inflammation is considered the crosstalk between the obese adipose 
tissue-emerged cytoadipokines and the hepatic response to the complex fatty acid and adipokine 
aggression 206. In humans with type 2 diabetes, metformin has been shown to activate AMPK in the 
adipose tissue and to enhance lipogenesis 297. In vitro, metformin decreases in human adipose 
tissue, adipocytes and stromal cells the expression of MCP-1 327. Recent studies on sera samples 
reported mostly that metformin does not influence adiponectin levels neither in humans 328 nor in 
db/db mice329. An animal study reported a decrease in chemerin expression (an adipokine known 
to influence adipocyte differentiation) and alleviation of the ER stress in the visceral adipose tissue 
of high fat diet-fed rats, when treated with metformin 330, proposing its use in obese, insulin 
resistant states. Nevertheless, in humans the effect of metformin on the deleterious inflammatory 
cytoadipokine secretion in obesity-associated type 2 diabetes has not been studied yet. 
 
In order to understand the effect of metformin on the obese adipose source of 
inflammatory cytokines one aim of the present thesis was to investigate the effect of metformin 
on the endothelial proinflammatory and prothrombotic response induced by the secretomes of 
visceral adipose tissue fat pads obtained from obese subjects with established type 2 diabetes 
under treatment with metformin.  
 
 
 
 
 
 
 
 
 
 
 
II. Aims 
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As depicted in the introduction, obesity is a strong predictor for the development of 
cardiometabolic disease. Type 2 diabetes and atherothrombotic disease are the milestones of the 
evolution of obesity.  
New paradigms are under debate nowadays.  On the one hand there is still under debate 
which is the importance of chronic inflammation associated to obesity in the interplay of 
hyperinsulinemia and hyperglycemia in atherothrombosis. Moreover, the impact of metformin, 
the worldwide first-line treatment agent in type 2 diabetes associated to obesity, on the 
endothelial atherothrombotic dysfunction induced by the obese adipose tissue-secreted cytokines 
has not been yet investigated. 
One the other hand, sustained by the evolution of recent investigation tools, beside cytokines, 
metabolites are emerging as new endocrine key players in the genesis and evolution of diseases. 
The changes in the obese adipose tissue metabolism have not been studied yet.  
Previous studies in our group206 have reported that cytokines present in the secretome of 
simple obese subjects without other cardiometabolic risk than their BMI determine the direct 
proinflammatory and prothrombotic activation of endothelial cells. On the contrary, secretomes of 
normo-weight subjects do not injure the endothelium.  
Parting from this previously acquired knowledge, in order to advance in the understanding of 
pathophysiological processes involved in atherothrombosis and type 2 diabetes in obesity, we 
have proposed the following aims:  
 
 
1. To investigate the effects of physiological and pathophysiological concentrations of insulin and 
glucose on the proinflammatory and prothrombotic endothelial injury induced by the cytokines 
secreted from the visceral obese adipose tissue.  
 
2. To investigate the potential protective effect of metformin on the endothelial inflammatory and 
prothrombotic injury induced by cytokines originating from the visceral adipose tissue of obese 
subjects with established type 2 diabetes. 
 
3. To study the impact of obesity on the metabolism of the regional adipose tissue depots, namely 
visceral and subcutaneous ones, by comparing the metabolite profile of obese visceral and 
subcutaneous adipose tissue secretomes with similar ones isolated from lean subjects.   
 
 
NOTE: 
Obese patients with established diabetes have been submitted to bariatric surgery only 
after the initiation of the treatment of diabetes, respectively after the initiation of metformin. For 
this reason, although it would have been an important goal of our investigations, the study of the 
secretomes of visceral adipose tissue from obese patients with established diabetes without any 
treatment was for ethical reasons not possible. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
III. Materials and Methods 
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Experimental model for aims 1 and 2: Justification of choice 
 
 In order to accomplish our aims, we employed an established model of macroendothelial 
injury, respectively the HUVEC (human umbilical vein endothelial cell) model. For that we used 
primary human endothelial cells deriving from umbilical cords of various donors. This cell type has 
been utilized extensively in physiological and pharmacological investigations for the study of the 
regulation of endothelial cell function and the role of the endothelium in the response of the blood 
vessel wall to various stimuli, between them inflammatory activation pathways of endothelial cells 
being one of the most used. 
 
 
1. Cell handling and experimental techniques 
 
 
Umbilical cords from healthy neonates were maintained in physiological serum at 4oC until 
use within a maximum of 48 h after birth for EC isolation according to the protocol described in 
1.1. HUVECs are in general adherent and grow in a monolayer. They were cultured with 
appropriate culture medium in a humidified incubator under standard conditions (37oC and 5% 
CO2), expanded by tripsinization and media was changed every 48 hours, until reaching confluence 
at passage 2. Subsequently they were passed to culture plates (TPP) or glass coverslips, depending 
on the subsequent technique to use after stimulation: respectively for RNA extraction-targeted 
stimulation, and for immunohistochemical labeling and extracellular matrix reactivity experiments. 
RNA was further retrotranscribed and processed for/through real time analysis.  
 
 
Culture media preparation 
 
MEM 199 supplemented 
 To obtain the culture medium for the HUVECs, MEM 199 (Medium 199 EARLE, Gibco BRL, 
Life Technologies) was supplemented with pooled human serum at 20% (previously filtered, 
0.2μm), penicillin and streptomycin 5% (P/S, HyClone), mixed softly, and left at 37oC for 
immediate, or 4oC for future use.  
 The preparation was all set under sterile conditions.  
 
PBS Dulbeco’s and Hanks’ balanced salt solution (HBSS) were obtained from Gibco. 
 
 
Additional solutions 
 
The following solutions were prepared under sterile conditions and moreover used filtered 
through a 0.2μm filter (Millipore).  
   
Gelatin 
 The gelatin (Type B: from bovine skin, Sigma) is in a concentration of 2% and we diluted it 
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down to 0.1% in PBS for our experiments.  
 
Collagenase 
 The collagenase (Collagenase A from Clostridium histolyticum, Roche) arrives lyophilized. 
For use, we dissolved 0.5mg per ml (HBSS, MEM 199 or PBS). Each cord needs 15ml of collagenase 
solution. 
 
Trypsin-EDTA 
 The trypsin solution arrives concentrated (10x, Gibco) and was therefore diluted at 1x in 
HBSS for use. 
 
Glutaraldehyde  
The glutaraldehyde solution (Merck) arrives in a concentration of 25%, and we diluted it in 
PBS at 0.5%. 
 
 
Preparation of culture flasks with gelatin 
 
1. Prepare gelatin solution (see above). 
2. Filter it. 
3. Add 5ml per small flask, or 8ml in case of a medium flask. 
4. Keep flasks at 37oC for 30min until 1h. 
5. Aspirate the remaining gelatin. 
 
 
1.1 Isolation of Human Umbilical Vein Endothelial Cells 
 
Following procedure was performed in order to separate the ECs from the umbilical cord: 
1. Place the umbilical cord on the silver paper previously sprayed with alcohol. 
2. Spray the cord with alcohol and clean away the blood with a paper. 
3. Cut off one extreme of the cord with a scalpel. 
4. Dilate the cordon’s vein with the help of the forceps. 
5. Bind the cannula and the cord with a thread, and check that the cannula is well fixed. 
6. Clean the interior of the vein with 20ml of PBS (Gibco), using a syringe. 
7. Cut off the other extreme of the cord and bind the cannula. 
8. Introduce in this extreme of the vein 15ml of collagenase with a syringe, leaving the 
interior of the vein filled with the collagenase solution. 
9. Wrap the cord with a silver paper and incubate it at 37oC during 15min. 
10. Perform a soft massage to the cord for 2min. 
11. Remove the whole solution from the vein’s interior with the help of a syringe and pass it to 
a sterile falcon tube. Add 20ml PBS with a new syringe. 
12. Pass the solution from one syringe to another through the cord, various times. 
13. Collect the solution in a sterile falcon. 
14. Centrifuge 5min at 1,100 rpm. 
15. Aspirate the overflow leaving only a few microliters of it on the pellet. 
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16. Resuspend the cellular pellet in 4ml supplemented culture medium. 
17. Transfer the suspension to a small flask, previously treated with gelatin. 
18. Wash the perfusion tube with 3ml of medium and transfer it to the small flasks. 
19. Leave the flasks in the CO2 incubator for culture growth, with the lid slightly open for gas 
exchange. 
20. Carry on changing the culture medium until the cells reach confluence. Keep them for 
maximum 7 days in the flask. If by the end of this time they haven’t reached 80% 
confluence, discard the cells. Slow growth indicates that something is wrong with them 
and we’d better not use them.  
 
 
 
 
Fig.10 Isolation of endothelial cells from an umbilical cord. Gross procedure. 
 
 
Tripsinization 
 
 This method was performed maximum 7 days after having proceeded the umbilical cord, 
depending on each culture, and under sterile conditions. After transition of the first 48h in culture, 
cells were observed in the microscope for reaching confluence and in positive case tripsinized as in 
the next protocol: 
 
1. Aspirate medium (overflow). 
2. Add 4ml HBSS (Gibco), mix softly and aspirate. 
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3. Add 1.5ml Trypsin (Trypsin-EDTA 10x, Gibco). 
4. Leave small flask for 1-2min at 37oC (lid completely closed). 
5. Shake gently the flask in order to detach the monolayer and observe the cells in the 
microscope. 
6. Add to the cell suspension with the trypsin 4.5ml of culture medium and mix for breaking 
the cell aggregates. 
7. Transfer the cell suspension to a medium flask previously treated with gelatin for 1h and 
subsequently removed from the flask (add cell solution against the wall of the flask). 
8. Wash the small flask with 6ml culture medium and transfer them to the medium flask.  
9. Leave the flasks in the CO2 incubator for additional 48 hours. 
10. Keep changing the culture medium until the cells reach confluence.  
 
 
1.2 Planting and Culture of the Human Umbilical Vein Endothelial Cells  
 
 
1.2.1 Planting in 6-well plates 
 
Plates Preparation 
1. Add 1ml of gelatin 0.1% to each well and keep it for an hour. 
2. Aspirate and add 2.5ml culture medium per well.  
 
Procedure 
1. Aspirate the culture medium from the medium flask.  
2. Wash with 5ml HBSS, mix softly and aspirate. 
3. Add 2ml trypsin and leave 1-2min at 37oC. 
4. Hit gently the flask on the sides in order to detach the cell monolayer. 
5. Add on the cell suspension 4ml of culture medium and mix. 
6. Add 6ml culture medium and mix the total 12ml. 
7. Transfer 0.5ml cell suspension to the sterile culture plates containing 2.5ml of culture 
medium per well. 
8. Leave plates in the incubator. 
9. Maintain the cells changing the medium (3ml) every two days. 
 
 When cells obtained from one umbilical cord were not enough to cover all our conditions, 
we used 12-well plates for the fulfillment of the experiment, and during cell planting was utilized 
the same volume of cell suspension, but half the volume of culture medium per well. That results 
in reaching quicker the desired confluence. 
The use of those plates was destined only for RNA extraction. 
 
 
1.2.2 Planting in 6-well plates with coverslips 
 
1. Place a coverslip in each well and add alcohol 70% during 15min. 
M a t e r i a l s  a n d  M e t h o d s | 71 
2. Aspirate the alcohol and wash 3 times with PBS. 
3. Incubate the coverslips with 1ml gelatin 1% for 30min. 
4. Aspirate the gelatin and wash one time with PBS (try not to add it directly on the 
coverslip). 
5. Incubate coverslips with 1ml glutaraldehyde for 30min. 
6. Aspirate the glutaraldehyde and wash 3 times with PBS. 
7. In new sterile plates add 2.5ml culture medium/well. 
8. Transfer the coverslips to the new plates, with the treated surface looking up. 
 
 
 
2. Secretomes of the human adipose tissue 
 
 
2.1 Study participants  
 
 For reasons of simplification we describe once all included study groups of this thesis, 
independently of the aim inclusion. 
 To respond to aim 1 and 2 we performed a comparative analysis between patients of 
group 1 (Ob) and 2 (DMO). 
 Participants were recruited in the surgery unit of our hospital. Visceral adipose tissue 
samples in order to obtain the secretomes were obtained during laparoscopic surgery. Therefore, 
a total of n=16 morbid obese subjects (Ob and DMO, BMI=42-46 kg/m2) from the Obesity Unit of 
the Hospital Clínic about to undergo gastric bypass surgery were included in the experiments. Six 
nonobese age- and sex-matched subjects (NOb, BMI=24-26 kg/m2) undergoing elective procedures 
of digestive surgery to correct benign conditions (vesicular lithiasis and eventrations) served as 
controls. The study was approved by the hospital’s Ethics Committee. Written informed consent 
was obtained from all participants.   
 
The study groups included:  
1. Obese participants (Ob) without other cardiometabolic risk factors than their own 
BMI (n=8); diabetes was excluded after negative-resulting standard oral glucose 
tolerance test (OGTT) subsequent to oral administration of 75 g glucose 55. 
2. Obese subjects with established type 2 diabetes (DMO) on treatment with oral 
antidiabetic agents, namely metformin 850mg x 2 times/day for at least 1 year and 
maximum 3 years, at maximum 5 years of diagnosis of diabetes (n=8) 55. 
3. Nonobese subjects (NOb, n=6) served as controls.   
 
Exclusion criteria:  
1. Subjects receiving hormones (i.e. glucocorticoids, oral contraceptives, or other 
substitutive treatment), non-steroid anti-inflammatory drugs, immunosuppressive 
drugs, medications known to affect fat mass metabolism (i.e. thiazolidinediones, 
modulators of adrenergic receptors) were excluded.  
2. Insulin treated patients and patients with history of hypoglycemias were excluded 
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from the type 2 DM group. 
3. Subjects with major chronic illnesses or recent antecedents of neoplasias were also 
excluded. 
 
Biochemical phenotype of the study participants: 
Main biochemical parameters were measured in serum after an overnight fast in the 
hormonal and core unit of the central laboratory of our hospital, employing standardized methods 
for each parameter. Insulin resistance was estimated by calculating HOMA-IR index, with a 
threshold of 2.9, the reference value for the control population from our hospital.  
 
Clinical data from the study participants are resumed in Table 8. 
 
 
Table 8. Clinical and metabolic parameters of the studied subjects 
 1) Obese (Ob) 
Subjects  
n=8 
2) DM Obese (DMO) 
Subjects  
n= 8 
3) Nonobese (NOb) 
Subjects 
n=6 
Age (years) 41.4 ± 10 45.0 ± 4.2 44.4 ± 14 
Sex  (men/women) 2/6 1/7  2/4 
BMI (kg/m2) 44.1 ± 2.2 47.8 ± 2.6 24.6 ± 2.3 
Waist circumference  
(cm) 
126.3 ± 4.02 132 ± 3.01 82.9 ± 2.1 
SBP/DBP ( mmHg) 126.1/75.4 ± 2.7/1.8 135.2/75 ± 1.2/1.4 116.1/70.6 ± 1.5/1.3 
Fasting Glucose 
(mmol/l) 
5.5 ± 0.2 6.85 ± 2.65 4.8 ± 0.5 
2h–OGTT plasma 
glucose (mmol/l) 
7.5 ± 1.5 NA - 
Total Cholesterol 
(mmol/l) 
5.0 ± 1.1 4.8 ± 0.8 4.3 ± 1.3 
HDL/LDL (mmol/l) 1.3/3.3 ± 0.1/0.7  1.5/3 ± 0.1/0.5 
Triglycerides (mmol/l) 1.5 ± 0.2 1.7 ± 0.3 1 ± 0.3 
Leukocytes (x 109/l) 8.2 ± 1.7 9.01 ± 1.42 6.3 ± 0.8 
High Sensitive-CRP 
(mg/l) 
13.2 ± 4.5 16.2 ±  7.5 (<5)* 
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HbA1c  (NGPS/DCC) 5.2 ± 0.3 7.5 ± 0.05 (4.0 - 5.5)* 
Insulin (pmol/l) 201.9 ± 77.2 156.67 ± 57.6 (15.3 - 98.6) * 
HOMA-IR 5.7 ± 1.9 NA (<2.93)* 
Time from diagnosis 
of diabetes 
NA 1-3 years NA 
Time of treatment 
with metformin 
NA ≥1year NA 
Dyslipidemia on 
statin/fibrates 
treatment 
1/8 6/8 - 
Dyslipidemia without 
treatment 
1 1  
Hypertension on 
diuretic treatment 
2/8 4/8 - 
Data are presented as mean ± standard error of the mean (SEM) in international units; SBP: systolic blood pressure; DBP: 
diastolic blood pressure; CRP: C-reactive protein; OGTT: oral 75g glucose tolerance test; HOMA-IR: homa insulin 
resistance, NA: not applicable. *Laboratory age- and sex-matched normal parameter values. 
 
 
Note: Previous comparative study on HUVECs regarding inflammatory endothelial activation 
between the simple obese and the nonobese group has been recently published from our group.  
In the present thesis in order to respond to the proposed aims we comparatively investigated:  
a) The inflammatory activation of endothelial cells between the visceral obese adipose 
tissue isolated from participants of group 1 and 2. 
b) The metabolite compounds of groups 1 and 3. 
Further comparison of metabolites between groups 1 and 2 remains the goal for future 
investigation.  
 
 
2.2 Adipose tissue samples 
 
Visceral (VIS, omental) adipose tissue biopsies (fat pads, FP) from all obese and nonobese 
study participants mentioned above and subcutaneous (SC, periumbilical) adipose tissue biopsies 
(AT) from the morbid obese and nonobese individuals were obtained during the laparoscopic 
surgery in the surgical unit of our hospital. The samples were collected in non-fetal medium 
provided by us (DMEM, Sigma) and placed on ice, immediately transported to the laboratory and 
further processed.  
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2.3 Preparation of the secretome 
 
The following procedures were performed under sterile conditions provided by laminar 
airflow, according to the protocol of Fain and Rodbell 227,331 with minor modifications.  
The medium used for the incubation of the fat pads in order to obtain the conditioned 
medium, the secretome, was the MEM 199 with a preparation as described underneath.   
To note, the incubation media do not include fetal serum or other type of growth factors. 
 
Medium for adipose tissue incubation 
 MEM 199 (Sigma) arrives in powder and therefore has to be dissolved and adjusted for pH 
before use. Supplements can be added prior to filtration or introduced aseptically to the sterile 
medium; we preferred to follow the second option. 
 
Preparation Instructions (http://www.sigmaaldrich.com): 
1. Measure out 90% of final required volume (=1l) of distilled water. Water temperature 
should be around 15-20oC. 
2. While gently stirring the water, add the powdered medium. Stir until dissolved without 
heating it up. 
3. Rinse original package with a small amount of water to remove all traces of powder. Add 
to solution in step 2. 
4. To the solution in step 3, add 2.2g sodium bicarbonate or 29.3 ml of sodium bicarbonate 
solution [7.5%w/v] for each liter of final volume of medium being prepared. Stir until 
dissolved. 
5. While stirring, adjust the pH of the medium to 0.1-0.3 pH units below the desired pH 7.4 
since it may rise during filtration. The use of 1N HCl or 1N NaOH is recommended. 
6. Add additional water to bring the solution to final volume. 
7. Sterilize by filtration using a membrane filter of 0.2μm porosity. 
8. Aseptically dispense medium into sterile container. 
 
 The above medium was stored for longer periods at -20oC and at 4oC for shorter ones. It 
was supplemented with 1% P/S and 1% gentamycin (G, Sigma, 50 mg/mL in deionized water), and 
kept at 37oC before addition to the fat pads.  
 
Acquisition of the secretome 
Each experimental replication included tissue samples from distinct individuals. Once in 
the laboratory and under the laminar airflow, the visceral adipose tissue was washed from the 
blood with PBS, and the burnt parts from the laser operation as well as the coagulations were 
carefully removed with scissors and forceps, previously sterilized. Next, it was placed in a Petri dish 
and brought to the balance in order to record its weight. Back to the laboratory hood, the tissue 
was cut into small pieces (around 10mg) so as to have as much surface as possible in contact with  
the medium. The non-fetal medium (P/S+G) was added to the tissue in an analogy 5ml medium per 
1g of FP. The dish was subsequently positioned in the incubator, at 37oC and 5% CO2, for 2h. After 
transition of this time, the medium was cautiously separated from the FP pieces by aspiration, 
discarded and replaced by the same quantity. Incubation carried on for further 24h under the 
same conditions, in order to obtain the visceral obese (Ob-VIS FP) and nonobese FP (Nob-VIS FP) 
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secretomes.   
At the end of the 24h, the secretome was collected in a syringe, sterile filtered through a 
filter membrane of 0.2μm and stored at -80oC.  
 
 
 
 
Fig.11 Obtaining the secretome. Gross procedure. 
 
 
 
3. Experimental design for the in vitro studies  
 
 HUVECs, obtained and cultured as described above, were exposed to different secretomes 
on one hand, and control medium on the other. As control medium (Ctr) is referred to the 
standard culture medium for HUVECS, respectively the MEM 199 supplemented at 20% with 
human serum obtained from a pool of healthy donors.  
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Fig.12 Basic experimental design. 
 
 
 To the secretomes and the control medium were furthermore added progressively 
increasing concentrations of D-glucose: 5mM, 11mM and 16mM respectively (Merck) or insulin: 0, 
10-11, 10-9 and 10-7M respectively (Sigma), as illustrated in Fig.12.   
 Genetic changes and receptor expression were assessed after 24h stimulation, whereas 
protein expression on the extracellular matrix and its reactivity required a coculture of endothelial 
cells with the secretomes for 7 days. 
 The stimulations were made in order to assess changes in the expression and synthesis of 
(a) the cellular adhesion receptors VCAM-1 and ICAM-1 in endothelial cells, (b) the von Willebrand 
factor (VWF) and tissue factor (TF) expression in the endothelial cells and synthesis in the 
subendothelial extracellular matrix (ECM), (c) the expression of the transcription factor NF-κB and 
(d) the platelet adhesion to the ECM mentioned above. 
 Genetic changes and expression of receptors VCAM-1, ICAM-1 and VWF, TF and NF-κB 
were assessed after 24h stimulation, whereas adhesion of platelets to the ECM matrix by perfusion 
studies and protein synthesis of VWF and TF on ECM required an exposure to the experimental 
conditions of 7 days.  
 For the gene expression level we employed Real-Time PCR and for the quantification of the 
protein synthesis immunocytochemistry studies. The reactivity of the ECM was investigated 
through perfusion studies. Methods will be detailed in the following paragraphs. 
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Insulin facts and dilutions  
 Kinetics of the experiments and insulin concentration studies have been selected with 
regard to data previously presented in the literature. Insulin concentrations ranging from 10-11 to 
10-7M are spanning from 1.7mU/l to 1.7x104mU/l, covering pharmacological to pathophysiological 
levels of insulinemia. Moreover, those refer to far overwhelming insulin concentrations in fasting 
and postprandial states of obese hyperinsulinemia in the presence of insulin resistance 332. 
 Evidence of endothelial cell insulin receptors has been recognized long before by Lee et 
al333 and Bar et al 334. 
 Human insulin solution was obtained from Sigma, at 1.7mM. The desired concentrations 
for our experiments were 10-11, 10-9 and 10-7M.  
 Starting from the given 1.7mM= 1.7 x 10-3M, a dilution of 17 times (1/17) was made in PBS 
and filtered under the hood through a filter membrane (0.2μm), in order to reach the 
concentration 10-4M. That was subsequently diluted 100x, arriving to 10-6M, and further 100x, 
reaching 10-8M.  
 Those three dilutions served as stock solutions from which was obtained the planned 
insulin concentration, by picking out the corresponding 1/1000 of the medium volume added to 
the cells. Since for each stimulation was enough 1ml of secretome per well of a 6-well plate, 1μl 
from every insulin stock was added to the regarding wells. 
 
Scheme:  
from 10-4M → 10-7M 
from 10-6M → 10-9M 
from 10-8M → 10-11M 
 
 
Glucose stock preparation and addition 
 Glucose (Merck) was dissolved in as much PBS as necessary in order to prepare a stock 
solution of 1M, and sterile filtered through a filter (0.2μm).  
 It was to expect that even if the medium destined for secretome acquisition had a glucose 
concentration of 5mM, the adipocytes, after 24h of incubation, would consume glucose from it. 
Therefore, in order to perform the experiments under the same starting glucose concentration, 
the latter was measured before addition to the cells with a glucometer (both glucometer and 
stripes from Arkray Factory, Inc.) and the equation below was used for the calculation of the 
necessary glucose to be added: 
 
C1 x V1 = C2 x V2 
 
C1 = final glucose concentration in the secretome/control medium 
V1 = final secretome volume in each well (1ml) 
C2 = glucose stock concentration 
V2 = glucose stock volume to calculate in order to be added 
 
 Starting from the fact that C1 had to be from our experimental conditions 5mM, 11mM or 
16mM (corresponding to 90, 198 and 288 mg/dl respectively), and continuing with the 
consumption of glucose from the adipocytes, C1 was calculated by deduction of the measured 
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glucose from the desired concentration, i.e. C1 = (16mM – obtained measurement).  
 The glucometer gives values in a scale between 10 and 600mg/dl (both included). Our 
samples were not out of this range, but to ease our work they had to be calculated in the mM 
scale by division of the glucometer’s value by 18 (number obtained after simplification of the 
necessary calculations and taking on account the molecular weight of glucose). 
 
 
 
4. RNA  
 
RNA purification and manipulation requires certain precautions to be taken on account. 
The principal reason of RNA degradation is contamination from ribonucleases (RNases), enzymes 
very active and stable, which can generate important problems in RNA integrity. For that, all 
objects used such as gloves, pipettes, surface and corresponding material, has to be previously 
cleaned with RNaseZAP (Sigma) in order to ensure an RNase free environment. Moreover, the use 
of gloves is very important so as to avoid direct contact with skin, the main contamination source. 
 
 
4.1 RNA extraction 
 
Various methods have been developed for the extraction of RNA; the one that was used in 
this thesis was with TRIzol® (Invitrogen). The method consists in cell disruption and components 
dissolves, before separation into aqueous and organic phase, acquisition of the RNA in the 
aqueous phase and subsequent precipitation. 
 
 
Protocol 
Homogenization 
1. Aspirate culture medium from the plates and wash cells once with PBS. 
2. Add appropriate TRIzol volume to the plate. The volume does not depend on the number 
of cells, but on the area of culture (1ml per 10cm2). 
3. Mix with the pipette various times. 
Phase separation 
4. Incubate samples for 5 min at room temperature and transfer them into eppendorfs. 
5. Add 0.2ml of chloroform per 1ml of TRIzol in each eppendorf.  
6. Shake tubes vigorously by hand for a few seconds; then leave them still at room 
temperature for 2-3min. 
7. Centrifuge at 12,000g for 15min at 4oC. 
RNA precipitation 
8. Collect the aqueous phase to a fresh tube. 
9. Add 0.5ml of isopropyl alcohol per 1ml of TRIzol used initially. 
10. Incubate samples at room temperature for 10min. 
11. Centrifuge at 12,000g for 10min at 4oC. 
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RNA wash 
12. Remove the supernatant. 
13. Wash the RNA pellet once with 75% ethanol, adding at least 1ml of 75% ethanol per 1ml of 
TRIzol. Vortex. 
14. Centrifuge at 7,500g for 5min at 4oC. 
Redissolve the RNA 
15. Remove the supernatant. 
16. Dry the RNA pellet (air-dry). 
17. Dissolve RNA in RNase-free water, pipetting few times. 
 
In those experiments the RNA was dissolved in 8μl of RNase-free water. 
 
 
4.2 RNA quantification 
 
 RNA concentration was determined by Nanodrop (Thermo Scientific), analyzing the RNA 
absorbance of 1μl of sample at 260nm. The purity of the sample was observed through the ratio 
obtained by the sample’s absorbances at 260 and 280nm (Abs260/Abs280). Ratios greater than 1.8 
indicate optimal RNA quality. 
 
 
4.3 Retrotranscription (RT)  
 
 The obtained RNA was used to synthesize first-strand DNA (cDNA), using the enzyme 
SuperScript™ III (SS III, Invitrogen). 
 
Protocol 
- To a PCR-reaction tube add: 
 Random primers (3μg/μl)………………..0.5μl 
 RNA……………………………………………0.15-1μg 
 H2O (RNase free)……………………..up to 10μl 
- Incubate at 70oC for 10min.  
- Chill on ice. 
- Add to each sample: 
H2O (RNase free)……………………………...1.5μl 
First strand buffer (5x)...……………………..4μl 
DTT (0.1M)………………………………………….2μl 
dNTP mix (10mM)……………………………….1μl 
RNase OUT (40U/μl)…………………………0.5μl 
SS III (200U/μl)…………………………………….1μl 
- Leave at room temperature for 10min. 
- Incubate in a thermal cycler: 
 42 oC ….... 15min 
 50 oC ……. 90min 
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 55 oC ……. 15min 
 70 oC ……. 15min 
   4 oC ……. ∞ 
- Remove samples from the thermal cycler and store at -20 oC until further use. 
  
 
4.4 Primers design and validation 
 
The primers used in Real-Time PCR analysis (Table 9) were designed with the program 
Primer3 Input (v. 0.4.0), having previously obtained the related mRNA sequence in the webpage of 
NCBI (http://www.ncbi.nlm.nih.gov).  
 
 
Table 9. Primer sequences used 
Gene Forward Sequence (5’-3’) Reverse Sequence (5’-3’) 
VCAM-1 CAA ACA AAG GCA GAG TAC GCA A GCT GAC CAA GAC GGT TGT ATC TC 
ICAM-1 AGC CAG GAG ACA CTG CAG ACA TGG CTT CGT CAG AAT CAC GTT 
VWF ACA TAA CAG CAA GAC AGT CCG GA GCT GCG GCT ATC TCC AAG G 
TF GCC AGG AGA AAG GGG AAT CAG TGC AAT ATA GCA TTT GCA CTA GC 
NF-κB TCC ACA AGG CAG CAA ATA GAC GAG AAG CTG AGT TTG CGG AAG GAT GT 
Actin CCC CCA TGC CAT CCT GCG TCT G CTC GGC CGT GGT GGT GAA GC 
 
 
After reception, they were validated with known amplificated samples on an agarose gel 
1.5%, by comparing the resulting band with the expected amplicon size, and by ensuring that 
negative cDNA samples don’t present bands. Additionally, primers were tested for the presence of 
single-peaked-melting curves (see paragraph 4.5 for more details).  
 
 
4.5 Gene expression analysis by Real-Time PCR 
 
 Whereas in a conventional PCR can be detected the number of copies generated during 
the reaction, a Real-Time PCR, or quantitative PCR, enables data collection throughout the 
amplification cycles, rather than at the end of the reaction, with the use of fluorochromes.  
 In this thesis we have used the dye SYBR Green, which emits fluorescence when 
intercalated in the DNA helix. As the PCR reaction increases in amplicons, so does the 
fluorescence, and the PCR products are quantified after each completed PCR cycle. The cycle at 
which the fluorescence exceeds a detection threshold, the Ct (threshold cycle) correlates to the 
number of target cDNA molecules present in the added cDNA. Therefore, by comparison to a 
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calibration curve, it is possible to quantify in absolute amounts the number of target molecules in 
added cDNA samples.  
 The MESA GREEN qPCR MasterMix applied (Eurogentec) combines the fluorochrome 
SYBR® Green I with stabilizers, the DNA polymerase Meteor Taq, dNTPs including dUTP, MgCl2 and 
an appropriate reaction buffer. Real-Time PCRs were performed on Roche’s Light Cycler® 480 II. 
 
 
Protocol 
- Prepare appropriate cDNA dilutions, so as to have a final quantity of 15ng/sample. 
- To each well of a 96-well plate, add: 
SYBR Green Mix………………………………..10μl 
Primers mix (10μM)...………………….……..1μl 
cDNA……………………………………………….1-3μl 
dH2O………………………………………..up to 20μl 
- Centrifuge plate briefly so as for the content to descend. 
- Place plate into the thermal cycler under following conditions: 
 
 
Preincubation   95 oC ……. 5min 
Amplification    95 oC ……. 15s 
 60 oC ……. 1min 
Melting curve   95 oC ……. 5s 
 65 oC ……. 1min 
 97 oC ……. instantly 
Cooling              40 oC …….30s 
 
 
 At the end of each amplification cycle is created a melting curve for every sample, proving 
that the amplified product was unique. If this is true, the entire DNA from a sample gets separated 
at the same temperature and we obtain only one peak in the melting curve. The temperature 
where the two DNA strands are separated is detectable because SYBR Green does not emit 
fluorescence any more. 
 Quantification of results was performed by comparing the expression of our genes of 
interest with the expression of a control gene, that is, a gene being expressed alike in the variety of 
samples. Normalization of the results was achieved by calculating the ratio of the value of the 
studied gene in respect to the value of the control gene (ΔΔCt). Here, β-actin, the gene that 
codifies for actin, a multi-function protein present in all eukaryotic cells, was playing the role of the 
house-keeping gene (Act). 
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Fig.13 Melting curves (left) and amplification plots (right) of a Real-Time PCR. 
 
 
 
5. Generation of the extracellular matrix  
 
 In some experiments we evaluated the composition and reactivity of the ECMs. For this, EC 
monolayers grown on glass coverslips were treated with a 3% solution of ethyleneglycoltetraacetic 
acid (EGTA) to extract the cells and maintain the ECM on the coverslip as followed: 
1. Prepare the EGTA solution, 3% in Hank’s balanced salt solution (HBSS). Adjust the pH to 
7.4. 
2. Wash the monolayers of cells with HBSS. 
3. Add 3ml EGTA solution to each well, and apply mechanic action with a Pasteur pipette 
every 15min for 1 hour, leaving the plates at 37°C.  
4. Change the EGTA after the hour and continue the same way for another half an hour. Be 
careful not to go too far with the pressure and detach the matrix besides the cells, too. 
5. Aspirate the EGTA and leave the samples in HBSS until use in immunofluorescence or 
perfusion, the very same day. 
 
 
 
6. Immunohistochemistry 
 
 
6.1 Immunogold Labeling (IG) and Silver Enhancement 
 
 To evaluate the protein synthesis we performed the below described 
immunohistochemistry techniques. Glass coverslips coated with ECs and prepared as described in 
paragraph 1.2.2 were incubated with control medium, or secretomes only, or secretomes plus the 
highest insulin concentration, or secretomes plus the highest glucose concentration, for 24h. In 
continuation they were fixed to detect VCAM-1 and ICAM-1 adhesion receptor expression on ECs.  
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a) Cell fixation 
 This step was performed with paraformaldehyde (PFA) at 4%, diluted in PBS and filtered 
(membrane 0.2μm), so as to avoid the contact of possible formed crystals with the coverslips and 
thereby experimental background. Our PFA (Merck) stock solution is prepared at 8% and stored at 
-20oC.  
 
Procedure 
1. Remove the culture medium from the cells and add MEM 199, previously tempered at 
37oC. Mix softly. 
2. Remove the medium and add a tempered PFA solution 2%, prepared in MEM 199. Leave 
the plate for 10min at 4oC.  
3. Remove the solution and add PFA at 4%, diluted in PBS. Place the plate at 4oC for at least 
10min and maximum for one week. 
4. With the aim of neutralizing the aldehyde groups of the PFA, add glycine (BioRad) at 1% 
(diluted in PBS and filtered 0.2μm), and leave it for 10min with soft agitation.  
 
b) Cell wash 
 Wash the wells with PBS, 3 times of 5min each, and continuous agitation. 
 
c) Antibody incubation 
1. To avoid unspecific binding in the regions of our interest, after the last PBS wash incubate 
in continuous agitation for 15min with albumin (Sigma) solution at 1% in distilled water, 
filtered before addition. 
2. In 30ml of PBS add some drops (around 10) of the albumin solution and mix well. From this 
new solution is going to be prepared the antibody’s dilution. 
3. Perform the antibody incubation for 1 hour. Monoclonal antibodies against VCAM-1 
(Chemicon International) and ICAM-1 (Millipore) were diluted 1/100 in the solution 
prepared in step 2. Incubation in a humid environment is necessary, for that we prepared a 
petri dish of greater diameter (150mm) wrapped up in silver paper, in which we have 
placed humid filter paper and on top parafilm. On the parafilm we pipette 100μl of 
antibody solution and place the coverslips, the cell coating in contact with the drop. We 
close the petri dish and leave it still for the required time.  
4. Remove the excess of antibody by washing 3 times with PBS-BSA for 5min, coverslips being 
placed back to the plate wells and coated surface looking up. 
 
d) Incubation with colloid gold (Amersham) 
1. Incubate with colloid gold-conjugated goat anti-mouse IgG (dilution 1/200 in PBS-BSA) for 
1 hour, in the same system mentioned in paragraph c). At this point take out the silver 
staining from the fridge, in order for it to reach room temperature.  
2. Wash 3 times with PBS in constant agitation, each 5min, to eliminate gold particles not 
bound to the primary antibody. 
 
e) Intensification with silver staining 
1. Wash 3 times with distilled water for 5min in constant agitation. 
2. Prepare the intense silver enhancement reagent (Amersham), mixing 1:1 the intensifier 
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and the initiator. Treat samples in the same manner as for the primary antibody and the 
gold. Leave the incubation for 5 to 20min, checking out regularly for the intensity reached. 
The solution should not get a very dark color, since this results in increased background. 
Silver enhancement helps to visualize gold particles bound to the antigen. 
3. Wash 3 times with distilled water for 5min in constant agitation. 
 
f) May-Gruenewald-Giemsa staining 
1. Discard the water from the wells. 
2. Add 2ml May-Gruenewald staining, filtered with the help of a humid filter paper, for 
1.5min. 
3. Wash one time with tap water. 
4. Add 2ml Giemsa for 7-10min, diluted 1/5 in distilled water and filtered through a humid 
filter paper. 
5. Rinse off with tap water until color fades. 
 
g) Mounting 
1. Dry the coverslips overnight, coated part facing up.  
2. Stick them on an objective holder, coated surface facing down and in touch with the glue 
(DPX, Surgipath). 
3. Let them dry overnight at room temperature. 
4. Samples can be stored at room temperature. 
 
  
6.2 Immunofluorescence (IF) 
 
 Glass coverslips coated with ECs and prepared as described in paragraph 1.2.2 were 
stimulated with usual culture media for HUVEC (20% human serum), or culture medium (MEM 
199) containing 10% pooled human sera and 10% secretomes, alone or with highest insulin or 
glucose concentrations, for 7 days.  
 The protocol of the IF is similar to that of the IG. Since this technique was used to evaluate 
protein expression in the ECM, here the coated coverslips were processed without cells. 
Nevertheless, the ECM has to be fixed as well, following basically the same protocol described in 
6.1. After PFA 4%, cells can be stored in PBS at 4oC. Subsequent steps including washes, 
inactivation of aldehyde groups with glycine and BSA blocking at 1% and incubations with 
antibodies continue identical, as well as the regarding times.  
 The primary antibodies used here were the human Tissue Factor (American Diagnostics) 
and the human von Willebrand Factor (Dako), in dilutions of 1/100 and 1/1000, respectively. The 
secondary antibodies were correspondingly anti-mouse (Alexa 555) and goat anti-rabbit (Alexa 
488), both from Invitrogen, in the concentration of 2μg/μl.  
 Attention has to be paid to the manipulation of the samples once the secondary, 
fluorescence emitting antibody is in use. For maximum performance, samples have to be 
protected from light and kept covered. 
 Cell staining is not necessary, because theoretically the cells have been detached and what 
remains is only the ECM. Nevertheless, nuclei staining is achieved with DAPI (300nM) 1-5min 
under darkness. 
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 Coverslips have to be left drying before their adhesion (ProLong®, Invitrogen) on objective 
holders and afterwards being stored at 4oC. 
 See Fig.14 for a general overview of the technique. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.14 Immunofluorescence steps. Gross procedure. Ab=antibody, 1-ary=primary, 2nd-ary=secondary.  
For the rest of the abbreviations, see text. HUVEC picture by PromoCell. 
 
 
 
7. Platelet adhesion on the ECM: perfusion studies with whole blood 
 
 Glass coverslips coated with ECs were prepared as described in paragraph 1.2.2 and 
cultured as in the experiments of IF, for 7 days. The ECM was acquired with EGTA 3% as in 
paragraph 6, but was not fixed yet, since the objective was to evaluate platelet adhesion on ECMs. 
 In the meanwhile, 100ml of blood were extracted from healthy, normoweight donors in 
the Haemotherapy - Haemostasis unit of our hospital. 
 Perfusion studies were carried out in a parallel-plate perfusion chamber at a shear rate of 
800s-1 for 5 minutes. For each perfusion, two coverslips were inserted in separate receptacles of a 
parallel-plate perfusion chamber and perfused with 25ml-aliquots of whole blood anticoagulated 
with citrate (100mM sodium citrate, 16mM citric acid, 18mM sodium hydrogen phosphate, and 
130mM dextrose; final citrate concentration, 19mM) from a single healthy donor, and left until use 
at 37oC. 
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Fig.15 Platelet adhesion on the ECM. Gross procedure. For abbreviations, see text.  
HUVEC picture by PromoCell. 
 
 
Protocol 
1. Wash cell monolayers with HBSS. 
2. Obtain the ECM as described, EGTA 3%. 
3. Aspirate EGTA and leave the matrices in HBSS until perfusion. 
4. Apply blood perfusion 5 minutes, 800s-1, volume 25ml (blood kept in citrate phosphate 
dextrose solution, CPD). 
5. Between samples, wash the pump system with tap water, distilled water and saline buffer, 
respectively. 
6. Rinse off coverslips 4 times in falcons with PBS (1x). 
7. Leave coverslips in glutaraldehyde 0.5% in PBS, at 4oC for 24 hours to fix the matrices. 
8. Wash 4 times with distilled water. 
9. Stain with filtered toluidine blue (Merck), 0.02% in distilled water for 10min. It is very 
important to have the matrices well stained and distinguish the perfusion rail, that’s why 
staining concentration and time may vary. 
10. Rinse off with tap water, until color fades. 
11. Leave dry 24h at room temperature. 
12. Fix the coverslip on an objective holder with DPX (glue), coated surface facing down and in 
touch with the glue. 
13. Leave dry for 24h at room temperature. 
14. Samples can be stored at room temperature. 
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8. Microscopy 
 
 Regarding the IG technique, the density of gold particles bound was morphometrically 
analyzed in a light microscope (Polyvar) equipped with epipolarizing filters. Observation of the cells 
in the microscope can be performed without time limitation, immersing the objective/lens in oil.   
 Immunofluorescent images were acquired by means of an immunofluorescence 
microscope (Leica, Germany), within one week after performance of the technique since 
fluorescence is prone to fading away with time. 
 Platelet adhesion was detected on the optical microscopy lens of the same Leica 
microscope. Neither here did we have time limitation for obtaining the images.  
  
 
9. Measuring cytokines levels by flow cytometry 
 
 Pooled (n=7) secretome samples of each simple obese and diabetic obese patients were 
measured twice for cytokine analysis, using the Cytometric Bead Array (CBA) Human Inflammatory 
Cytokines Kit (BD). The kit can be used to quantitatively measure interleukin-8 (IL-8), IL-1β, IL-6, IL-
10, TNF and IL-12 protein levels in a single sample. 
 Principle of CBA assays: CBA assays provide a method of capturing one or more soluble 
analytes bound to beads, making their detection possible by recognizing the known size and 
fluorescence of the beads using flow cytometry. The capture beads in the kit have been previously 
conjugated with a specific antibody. The detection reagent in the kit contains a mixture of 
phycoerythrin (PE)-conjugated antibodies, which provide a fluorescent signal in proportion to the 
amount of bound analyte. When the capture beads and detector reagent are incubated with an 
unknown sample containing recognized analytes, sandwich complexes (capture 
bead+analyte+detection reagent) are formed. These complexes can be measured using flow 
cytometry to identify particles with fluorescence characteristics of both the bead and the detector. 
 Principle of this assay: Six bead populations with distinct fluorescence intensities have 
been coated with capture antibodies specific for IL-8, IL-1β, IL-6, and IL-10, TNF-α, and IL-12 
proteins. The six bead populations are mixed together to form the bead array that is resolved in a 
red channel (FL3 or FL4) of a flow cytometer (see Fig.16). 
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Fig.16 Red channel resolvation of a flow cytometer, including six bead populations.  
Picture from the original protocol. 
 
 
 During the assay procedure are mixed the inflammatory cytokine capture beads with the 
recombinant standards or unknown samples and incubated with the PE-conjugated detection 
antibodies to form sandwich complexes. The intensity of PE fluorescence of each sandwich 
complex reveals the concentration of that cytokine. After acquiring samples on a flow cytometer, 
FCAP Array™ software is used to generate results in graphical and tabular format.  
 
 
Protocol 
 The steps to follow are the ones being provided by the BD assay kit. The reagents and 
solutions referred to are as they appear in the original protocol. 
 
Preparation of the standards 
1. Reconstitute the lyophilized standard spheres with 2ml of Assay Diluent (this is the “Top 
Standard”). 
2. Allow the reconstituted standard to equilibrate for at least 15min at room temperature. 
3. Mix the reconstituted protein by gentle pipetting. 
4. Pipette 300μl of Assay Diluent in each of eight 12 × 75mm tubes that are going to be used 
as dilution tubes (1:2, 1:4, 1:8, 1:16, 1:32, 1:64, 1:128, and 1:256). 
5. Perform a serial dilution by transferring 300μl from the Top Standard to the 1:2 dilution 
tube and mix thoroughly by pipetting. 
6. Continue performing serial dilutions by transferring 300μl from the 1:2 tube to the 1:4 
marked tube and so on until the tube 1:256. 
7. Prepare one tube containing only Assay Diluent as the negative control 0 pg/ml. 
Mixing the capture beads 
8. Vigorously vortex each Capture Bead vial for 3 to 5 seconds before mixing. 
9. Add 10μl of each Capture Bead per assay tube to be analyzed into a single tube. 
10. Vortex the bead mixture thoroughly. 
Samples’ dilution  
11. Did not apply in our case. 
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Performing the assay 
12. Vortex the mixed Capture Beads prepared in step 9 and add 50μl to all assay tubes. 
13. Add 50μl of the standard dilutions to the control tubes, starting from the highest dilution 
tube. List them from the highest to smallest dilution (small to high concentration). 
14. Add 50μl of each unknown sample to the appropriately labelled sample tubes. 
15. Add 50μl of the PE Detection Reagent to all assay tubes. 
16. Incubate the assay tubes for 3 hours at room temperature, protected from light. During 
this time, the cytometer setup can be performed. 
17. Add 1ml of Wash Buffer to each assay tube and centrifuge at 200g for 5min. 
18. Aspirate and discard the supernatant. 
19. Resuspend the bead pellet by adding 300μl of Wash Buffer to each assay tube. 
20. Acquire the samples on the flow cytometer.  
 
 
Table 10. Concentrations correspondence to standard dilutions in the BD Cytokine Kit*  
Standard Dilution Concentration (pg/ml) 
no dilution/assay diluent 0 (negative control) 
1:256 20 
1:128 40 
1:64 80 
1:32 156 
1:16 312.5 
1:8 625 
1:4 1,250 
1:2 2,500 
Top Standard 5,000 
*Adapted from the original protocol. 
 
 
Setup of the cytometer can be performed during realization of the protocol and according 
to the manufacturer’s instructions.  
 Cytometry measurements were acquired on the BD LSRFortessa™ cell analyzer and 
analyzed on the BD FCAP Array™ v1.0.1 software.  
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Fig.17 A) Standards and positive control detectors; flow cytometric data. B) Characteristic standard curve  
from the BD CBA Human Inflammatory Cytokine Standards. Adapted from the original protocol. 
 
 
 
10. Enzyme-linked immunosorbent assay (ELISA) 
 
 Insulin concentration in the medium was measured applying the ELISA method, using 
Mercodia’s Ultrasensitive Insulin ELISA kit.  
 This is about a solid phase two-site enzyme immunoassay based on the direct sandwich 
technique in which two monoclonal antibodies are directed against separate antigenic 
determinants on the insulin molecule. During incubation, sample insulin reacts with peroxidase-
conjugated anti-insulin antibodies which are bound to microplate wells. Unbound enzyme labelled 
antibody is being removed with a simple washing step whereas the bound conjugate is detected by 
reaction with 3,3?,5,5?-tetramethylbenzidine (TMB). The reaction is stopped by addition of acid 
to give a colorimetric endpoint that is read spectrophotometrically.  
 
 
Test procedure 
 The protocol followed is according to the kit’s instructions. The reagents and solutions 
referred to are as they appear in the original. 
 All reagents and samples must be brought to room temperature before use and a 
calibrator curve is prepared for each assay run. 
 Before to start, prepare the Enzyme Conjugate 1X Solution and the Wash Buffer 1X 
Solution by diluting the reagents in Enzyme Conjugate Buffer (10 times) and distilled water (20 
times), respectively. After making some tries, the samples were in general diluted 0 until 1/10 with 
calibrator 0. 
 
A) 
B) 
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1. Pipette 25?l each of Calibrators and samples into sufficient wells provided by the kit. 
2. Add 100?l of Enzyme Conjugate 1X Solution to each well. 
3. Incubate on a plate shaker (700-900rpm) for 1 hour at room temperature (18?25°C). 
4. Discard the reaction volume by inverting the microplate over a sink. Add 350?l Wash 
Buffer 1X Solution to each well. Discard the wash solution, tap firmly several times against 
absorbent paper to remove excess liquid and repeat 5 times. Avoid prolonged soaking 
during washing. 
5. Add 200?l Substrate TMB into each well. 
6. Incubate for 30 minutes at room temperature (18?25°C). 
7. Add 50?l Stop Solution to each well. Place plate on a shaker for approximately 5 seconds 
to ensure mixing. 
8. Read optical density within 30 minutes at 450nm and calculate results. 
 
 
Table 11. Concentrations correspondence to Calibrators* 
Calibrator Concentration (mU/l) 
0 0 
1 0.15 
2 1 
3 3 
4 10 
5 20 
* According to the ELISA kit. 
 
 
Computerized calculation of results 
 The concentration of insulin is obtained by computerized data reduction of the absorbance 
for the calibrators, except for calibrator 0, versus the concentration, using cubic spline regression 
(Fig.18).  
 The detection limit is 0.07mU/l calculated as two standard deviations above the calibrator 
0. 
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Fig.18 A typical calibrator curve. 
  
 
 In our experiments, when the results obtained were under the detection limit of the 
lowest Calibrator, we considered in our calculations as a valid value the minimum of 0.07mU/l.  
 
 
Experimental model for aim 3: Justification of choice  
 
Methods applied for the metabolomic analysis of the adipose tissue secretomes:  
 
 In order to respond to aim 3 we were in the need to choose between the two available 
analysis methods present in our institution: magnetic resonance and gas chromatography- mass 
spectrometry. As magnetic resonance permits only a general landscape description of the samples, 
we preferred a more detailed approach utilizing the gas chromatography-mass spectrometry 
analysis. 
 
 
1. Subjects inclusion  
 
 Participants included in aim 3 are described in detail above (2.1). To make a first 
metabolomic analysis, due to the novelty of the approach, we have first analyzed the metabolites 
between lean and obese subjects. The metabolomic analysis of secretomes among diabetic obese 
and obese patients represents a further study, under work for the moment. 
 
 
 2. Sample conditioning and gas chromatography-mass spectrometry 
analysis (GC-MS) 
 
Samples 
 Visceral (VIS, omental) and subcutaneous (SC, periumbilical) adipose tissue biopsies (AT) 
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from the morbid obese (Ob, n=8) and nonobese (NOb, n=6) individuals were obtained and 
processed as explained earlier. Samples were transported on dry carbonic ice to the metabolomic 
platform of our institution. When ready to use, samples were thawed at 4oC. 
 
Sample conditioning/treatment 
 The whole GC-MS analysis was performed according to Agilent’s specifications 335 as 
followed:  
1. Spike 100μl-aliquots of each sample with 20μl internal standard solution (1μg/μl succinic-
d4 acid; Sigma-Aldrich). 
2. Add 900μl of cold methanol/water (8:1 v/v) in order to precipitate the metabolites. 
3. Ultrasonicate for 4 minutes and vortex 10 seconds. 
4. Centrifuge at 19,000g for 10min at 4oC. 
5. Prepare three technical replicates of each sample, transferring 200μl supernatant to a GC 
autosampler vial. 
6. Spike samples with 20μl myristic acid-d27 (Sigma-Aldrich), used as the internal standard 
for retention time lock (RTL system provided in Agilent’s ChemStation Software). 
7. Lyophilize overnight (Lyotrap freeze dryer). 
8. Derivatize metabolites in order to make them volatile and less polar and, by that, suitable 
to GC-MS analysis, in two different steps: 
a) Perform methoximation in order to prevent ring formation and stabilize carbonyl 
moieties. Thus, incubate lyophilized secretome residues with 50μl methoxyamine 
in pyridine (0.3μg/μl) for 16h at room temperature. 
b) Increase the volatility of the compounds. Silylate samples using 30μl N-methyl-N-
trimethylsilyltrifluoroacetamide with 1%trimethylchlorosilane (MSTFA + 1% TMCS, 
Sigma) for 1 h at room temperature. 
 
  
GC-MS analysis 
 
 Derivatized secretome samples were analyzed with a gas chromatography-mass 
spectrometry (GC-MS) system. All system components originated from Agilent Technologies (Santa 
Clara, USA) including the HP 6890 gas chromatograph coupled to a quadrupole HP 5973 mass 
spectrometric detector. The latter had a split inlet (split ratio 5:1) equipped with a J&W Scientific 
DB 5-MS+DG stationary phase column (30m × 0.25mm i.d 0.1μm film). Steps to follow were: 
1. Inject 1 μl of each derivatized sample in a gas chromatograph system. 
2. Set injector temperature at 250oC and keep the helium carrier flow rate constant at 1.1 
ml/min. 
3. Hold the column temperature at 60oC for 1min, then increase to 325oC at a rate of 
10oC/min and hold at this temperature for 10min. 
4. Maintain detector operation in the electron impact ionization mode (70 eV), and record 
mass spectra after a solvent delay of 4min with 2.46 scans/second (mass scanning range of 
mass-charge ratio: m/z, 50–600; threshold abundance value of 50 counts). 
5. Whilst, keep source temperature and quadrupole temperature at 230 and 150oC, 
respectively.  
 
94 | M a t e r i a l s  a n d  M e t h o d s  
 To reduce systematic error associated with instrumental drift, samples were entirely 
randomized. 
 
 
Statistical approaches 
 
a) Gene analysis 
Real-Time PCR results were expressed in relation to the control condition (having always 
the value 1) as folds mean ± standard error of the mean (SEM), including results from a minimum 
of n=3 different experiments, and analyzed using two-tailed Student’s t-test for paired samples. 
Results were considered as significant when p<0.05.  
 
b) Protein analysis of membrane antigens 
Immunogold and immunofluorescence images were captured by a video camera (ProgRes 
MF) and transferred to a personal computer with an automated image analysis system (Image J 
software, version 1.43m) for the evaluation of the density of gold particles (expressed as gold 
particles on covered surface), with the help of the threshold tool.  
 
c) Protein analysis regarding ECM activation 
c.1) Fluorescence micrographs were taken by a video camera (Leica, Germany) and 
densitometrically analyzed with the help of the Image J software, which is used to analyze/process 
all sorts of images in biology-related research. This software automatically analyzes the gray 
density of each pixel in a scale ranging from 0 (black) to 255 (white). The mean gray value in the 
control pictures was considered as one hundred per cent. Results are expressed as the percentage 
of the mean grey intensity increase of the covered surface over the control samples.  
 c.2) Blood perfusion images were captured by a video camera (Leica, Germany) and 
transferred to a personal computer with Image J for evaluation of the degree of platelet deposition 
on the perfused surface and evaluated en face by means of an automated method. Platelet 
adhesion on the ECM was selected from the background with the threshold tool, and the intensity 
was measured only in the selected area. The surface covered by platelets was expressed as a 
percentage with respect to the total area of the coverslip screened (%SC). 
 
 Data from experiments a) to c) are expressed as mean ± standard error of the mean (SEM), 
and analyzed using two-tailed Student’s t-test for paired samples. Results were considered as 
significant when p<0.05. 
 
d) Cytometry & ELISA 
 Flow cytometry and ELISA results were expressed as mean ± standard error of the mean 
(SEM), and analyzed using two-tailed Student’s t-test for paired samples. Results were considered 
as significant when p<0.05. 
 
e) GC-MS data analysis 
Due to the high difficulty of the metabolomic study analysis we performed the whole 
bioinformatics analysis with the help of the bioinformatics specialist from the metabolomic unit of 
our institution. The author of this thesis has participated to the analysis although not having 
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performed autonomous the procedure. 
 Raw GC/MS files were exported into the platform-independent netCDF (*.cdf) and loaded 
into XCMS software (version 1.6.1) based on R-program version 2.4.0, where peak finding, 
integration and alignment in the time domain were performed. XCMS data was exported to 
Matlab (version 6.5.1), where normalization to internal standard succinic acid-d4 was performed 
and the averaged integrated intensities for the three analytical replicates of each biological 
specimen were computed.  
 Secretome samples were compared based on either 6/21 multivariate or systematic 
multiple univariate statistical test performed 183 on XCMS-derived dataset. The false discovery 
rate (FDR) procedure described by Storey et al 336 was used to account for multiple testing. The 
AMDIS program (Automated Mass Spectral Deconvolution and Identification System) was run for 
peak deconvolution, and both the Fiehn GC/MS Metabolomics RTL Library and NIST mass spectral 
databases were used for identification.  Further data processing, analysis, and statistical 
calculations were performed using Matlab. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
IV. Results 
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1. Genetic expression in EC 
  
Gene expression analysis was conducted in order to assess the proinflammatory and 
prothrombotic changes introduced by the visceral adipose tissue’s secretome of morbid obese or 
morbid obese type 2 diabetic subjects treated with metformin on the EC. The related genes whose 
expression was analyzed in this thesis were VCAM-1, ICAM-1, von Willebrand Factor (VWF), tissue 
factor (TF) and the transcription nuclear factor-κB (NF-κB).  
 The expression of the adhesion molecules VCAM-1 (or CD106) and ICAM-1 (or CD54) is 
characteristic of the endothelium in that it indicates activation and the beginning and progression 
of inflammation, due to their participation in leukocyte migration on the endothelium and final 
diapedesis. NF-κB, implicated in various cell cycle processes, forms also part of the inflammatory 
cascade. The proteins VWF and TF are two major prothrombotic factors synthesized by endothelial 
cells and released to the subendothelial matrix in response to activation, playing a major role in 
atherothrombotic thrombus formation.   
 For the significant involvement of the above mentioned molecules in vascular damage, our 
study was preferentially focused on these very genes. 
 The duration of stimulation to evaluate gene expression was considered appropriate to 
last 24h after analyzing various studies from the literature with sera on HUVECs and performing 
time course studies. Results were obtained by Real-Time PCR gene expression analysis which 
(expression) was compared with a standard condition, that is, cDNA from cells having been 
stimulated in parallel to our conditions with regular growth medium, which we  named control 
medium (CM). 
 
 
1.1 Endothelial response to the stimulation with visceral simple obese (Ob) 
secretomes vs. secretomes of obese diabetic metformin-treated (DMO) patients 
 
1.1.1 Proinflammatory endothelial activation   
 
Endothelial cells exposed to the simple obese (Ob) or the diabetic obese (DMO) subjects 
presented a significant (between 3- to 8-fold) increase in the expression of VCAM-1, ICAM-1 and 
NF-κB as compared to the control medium (CM). 
The response of the ECs to the obese diabetic secretome (DMO) resulted in a high 
expression of VCAM-1. This effect was notably lower when stimulating the cells with the simple 
obese (Ob) secretome. As can be seen on Fig.19A, there was a statistically significant (p=0.03) 
difference in the gene expression between the two types of secretomes. ICAM-1, which is 
constitutively expressed in the endothelium under resting conditions,  increased three and two 
folds in response to the Ob and DMO secretomes, respectively, in comparison to VCAM-1. 
Nevertheless, ICAM-1 was expressed without significance between the two types of secretomes, 
but with a higher tendency at stimulation with the Ob secretome (Fig.19B). 
NF-κB expression was more similar to the levels of VCAM-1. Even more alike, the DMO 
secretome had a greater effect than the Ob on the ECs, inducing vascular damage as expressed by 
the more noticeable presence of NF-κB, with a p equal to 0.03 (Fig.19C). 
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Fig.19 Effects of the secretomes on proinflammatory genes on ECs. Expression of (A) VCAM-1, (B) ICAM-1 and (C) NF-κB 
genes in cells stimulated 24h with regular growth medium (control medium, CM), simple obese (Ob) and obese diabetic 
secretomes (DMO). Results obtained by Real-time PCR analysis. Bars representing fold change in respect to the control 
condition. Data are expressed as mean fold ± standard error of the mean (SEM). Ob n=6-9, DMO n=6. *p < 0.05, and ** p 
< 0.005 in CM vs. Ob and DMO, otherwise indicated.  
 
 
 
1.1.2 Prothrombotic response 
 
Ob and DMO induced a statistically significant increase in the expression of the genes of 
the prothrombotic factors VWF and TF. Endothelial cells did not respond in a diverse manner to 
stimulation with Ob and DMO secretomes, as far as the thrombosis markers were concerned. 
Therefore, although VWF and TF appeared at similar levels, VWF showed a tendency towards 
higher expression in the presence of the DMO secretomes, whereas we observed an opposite 
tendency for TF (Fig.20). Nevertheless, there was no statistical significance between the two 
conditions. 
 
1.1.1 - 1.1.2: Summary/Conclusions  
 
 Both secretomes of visceral Ob and DMO induce activation of the inflammatory and 
prothrombotic pathways, as demonstrated by comparison with the control condition (CM). In our 
experiments we observed that the secretomes from the adipose tissue of obese diabetic subjects 
seemed to activate the inflammatory cascade in a slightly greater degree than the secretomes 
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obtained by simple obese adipose tissues as marked by the higher expression of VCAM-1, NF-κB. 
VWF seems to increase slightly without reaching statistical significance. Although results of ICAM-1 
and TF are of opposite tendency, both are quite similar in both secretome groups. However, these 
results have to be regarded with precaution due to the high variability in the obese group. Overall 
we can conclude that the DMO secretome induces a slightly increased expression of the 
proinflammatory and prothrombotic genes studied, while both secretomes produce an important 
activation of endothelial cells with respect to the CM. 
 
 
 
Fig.20 Effects of the secretomes on prothrombotic genes on ECs. Expression of (A) VWF and (B) TF genes in cells 
stimulated 24h with regular growth medium (control, CM), simple obese (Ob) and diabetic obese secretomes (DMO). 
Results obtained by Real-time PCR analysis. Bars representing fold change in respect to the control condition. Data are 
expressed as mean fold ± SEM. Ob n=7, DMO n=6. **p < 0.005 in CM vs. Ob and DMO, otherwise indicated. 
 
 
1.2 Stimulation with simple Ob secretomes supplemented with  insulin 
 
Hyperinsulinemia is a common feature of type 2 diabetes mellitus associated to obesity 
and there persists still debate about its effects on the endothelium. The prothrombotic and 
proinflammatory potency of visceral obese adipose tissue secretomes on endothelial cells has 
been previously reported and published (previous results from our group). Therefore we decided 
to evaluate in our in vitro experimental model the complementary effect on endothelial cells of 
pathophysiological concentrations of insulin to the one induced by the Ob secretomes. 
 
1.2.1 Proinflammatory endothelial activation 
 
VCAM-1 and ICAM-1 expression remained unchanged at the presence or not of insulin at 
physiological to pathophysiological concentrations in the secretomes (0M, 10-11 M, 10-9 M), being 
around 3- and 15-fold higher than the control condition, respectively. The pathological 10-7 M 
insulin level induced an increased VCAM-1 expression as compared to the 10-9 M insulin condition 
(p=0.05). Expression of ICAM-1 under the same 10-7 insulin condition presented the same 
tendency, although not reaching statistical significance. Obviously, the highest constant effect 
observed equally in all conditions was due to the obese secretomes themselves (Fig.21A and B).  
Regarding NF-κB, insulin addition to the obese visceral secretome at 10-11 M and 10-9 M did 
not result in any significant fold change of NF-κB between the Ob conditions, whereas insulin at 10-
7 M showed a capacity to increase NF-κB expression in comparison to the lower insulin 
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concentrations (p<0.05). All secretome-related expressions were around 2-fold elevated in respect 
to the control condition (Fig.21C).  
 
 
 
Fig.21 Effects of insulin on proinflammatory genes on ECs. Expression of (A) VCAM-1, (B) ICAM-1 and (C) NF-κB genes in 
cells stimulated 24h with regular growth medium (control, CM) and simple obese secretome (Ob), alone (Ob i0) or 
supplemented with insulin at 10-11 M, 10-9 M and 10-7M (correspondingly symbolized as Ob i10-11, Ob i10-9, Ob i10-7). 
Results obtained by Real-Time PCR analysis. Bars representing fold change in respect to the control condition. Data are 
expressed as mean fold ± SEM. n=4-5 for VCAM-1, n=5-6 for ICAM-1, n=4 for NF-κB.  In ICAM-1 *p < 0.05 where 
indicated, and, in ICAM-1 regarding the rest of the conditions, and in NF-κB regarding the rest of the Ob conditions. ** p 
< 0.005 with respect to the rest of the conditions. 
 
 
1.2.2 Prothrombotic endothelial  response 
 
Results referring to thrombogenicity (Fig.22) revealed the ability of insulin to tend towards 
downregulating the gene expression of the VWF gradually in parallel with the increase in insulin 
concentration, until to reach statistical significance at the highest one (10-7 M), compared to the 
simple secretome stimulation (p=0.02). The same pattern was observed for TF although not 
reaching statistical significance probably due to the variability between samples. (Fig.22B). 
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Fig.22 Effects of insulin on prothrombotic genes on ECs. Expression of (A) VWF and (B) TF genes in cells stimulated 24h 
with regular growth medium (control, CM) and simple obese secretome (Ob), alone (Ob i0) or supplemented with insulin 
at 10-11 M, 10-9 M and 10-7M (respectively symbolized as Ob i10-11, Ob i10-9, Ob i10-7).  Results obtained by Real-Time PCR 
analysis. Bars representing fold change in respect to the control condition. Data are expressed as mean fold ± SEM. n=3-
5. n=4-5 for VWF, n=4 for TF. *p < 0.05, and ** p < 0.005 in CM vs. Ob conditions, except from comparison with Ob i10-7 
in the TF. 
 
 
1.2.1 - 1.2.2: Summary/Conclusions 
 
 Here we observed that simultaneous stimulation of ECs with insulin and secretome for 24h 
induced only at the very high level of 10-7 M an increased expression of the adhesion molecules 
VCAM-1, ICAM-1 and of the transcription factor NF-κB. Curiously, these changes were not 
paralleled by the changes in the expression of the genes of the prothrombotic factors VWF and TF, 
which may suggest to have a protective antithrombotic effect. 
 
 
1.3 Stimulation with simple Ob secretomes supplemented with glucose 
 
Next, in order to perform an overall evaluation of a glucose additive effect on the 
endothelium to the one induced by the obese secretomes, we concomitantly added glucose in 
increasing concentration to the endothelial cells while a 24h-stimulation with the secretome was 
performed.  
To fulfill this purpose, we employed in our experiments the normal, basal glucose state of 
HUVECs culture, namely 5mM, which was the one generally present in the simple visceral obese 
secretomes, and two pathophysiological conditions of glucose: 11mM and 16mM. 
 
1.3.1 Proinflammatory endothelial activation 
 
Supplementing the secretomes with the glucose concentrations of 11mM and 16mM for 
24h did not provoke changes in the gene expression. No statistically significant differences were 
observed in the fold change of the proinflammatory genes VCAM-1, ICAM-1 and NF-κB between 
the glucose conditions.  
Interestingly, glucose at its highest concentration (16mM) presented a tendency to 
diminish the gene’s expression of VCAM-1 and ICAM-1 in comparison with the lower ones. 
(Fig.23A, B) while the expression of NF-κB was quite equal between conditions (Fig.23C).  
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Fig.23 Effects of glucose on proinflammatory genes on ECs. Expression of (A) VCAM-1, (B) ICAM-1 and (C) NF-κB genes 
in cells stimulated 24h with regular growth medium (control, CM) and the obese simple secretome which  contained 
glucose 5mM (Ob g5) or supplemented with glucose at 11mM and 16mM (respectively symbolized as Ob g11, Ob g16). 
Results obtained by Real-Time PCR analysis. Bars representing fold change in respect to the control condition. Data are 
expressed as mean fold ± SEM. n=3-4. *p < 0.05 where indicated. 
 
 
1.3.2 Prothrombotic endothelial response 
 
Maintaining the same pattern as for the proinflammatory genes, the prothrombotic gene 
expression was not modified with the increasing glucose (Fig.24). To note that interpretation of 
the results regarding the expression of TF was difficult to be done, due to the high variability 
between samples.  
 
1.3.1 - 1.3.2: Summary/Conclusions 
 
Increasing concentration of glucose does not seem to result in any proinflammatory or 
prothrombotic additional damage to that already induced by the obese visceral secretome. 
However, results are difficult to evaluate due to the great variability. There was a tendency to peak 
for glucose at 11mM for ICAM-1 and TF genes, thereafter descending to the values of simple obese 
secretomes. Further increase in the number of experiments could lead to more relevant results.  
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Fig.24 Effects of glucose on prothrombotic genes on ECs. Expression of (A) VWF and (B) TF genes in cells stimulated 24h 
with regular growth medium (control, CM) and simple obese secretome (Ob g5) supplemented with glucose at 11mM 
and 16mM (respectively symbolized as Ob g11, Ob g16). Results obtained by Real-Time PCR analysis. Bars representing 
fold change with respect to the control condition.  Data are expressed as mean fold ± SEM. n=4. *p < 0.05 where 
indicated. 
 
 
1.4 Stimulation with control medium (CM) supplemented with insulin 
 
In order to investigate the 24h-effect of insulin on ECs, we stimulated for the same period 
of time ECs growing in regular medium supplemented with the corresponding insulin 
concentrations.  
 
1.4.1 Proinflammatory response 
 
 Inflammation-related genes were not induced by insulin, with the only exceptions being 
ICAM-1 at the 10-9 M condition, and NF-κB at the lowest insulin condition. On the contrary, there 
seemed to be a slight protective effect of the hormone, causing a decrease in the gene expression 
of all proinflammatory genes quantified, although reaching statistical significance only for the gene 
expression of ICAM-1 for insulin at 10-9 M, and for the transcription factor NF-κB for insulin at 10-11 
M (Fig.25). 
 
1.4.2 Prothrombotic response  
 
Results regarding the expression of the prothrombotic factors VWF and TF were 
heterogeneous. Generally insulin at 10-11 M and 10-9 M seemed to induce again a certain 
protection, while at the pathological concentration of 10-7 M to increase the expression of VWF 
(Fig.26).  
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Fig.25 Effects of insulin on proinflammatory genes on ECs. Expression of (A) VCAM-1, (B) ICAM-1 and (C) NF-κB genes in 
cells stimulated 24h with regular growth medium (control, CM) alone, or supplemented with insulin at 10-11 M, 10-9 M 
and 10-7M (respectively symbolized as CM i10-11, CM i10-9, CM i10-7). Results obtained by Real-time PCR analysis. Bars 
representing fold change in respect to the control condition. Data are expressed as mean fold ± SEM. n=3. *p < 0.05 
where indicated. 
 
 
 
Fig.26 Effects of insulin on prothrombotic genes on ECs. (A) Expression of VWF and (B) TF genes in cells stimulated 24h 
with regular growth medium (control medium, CM) alone, or supplemented with insulin (concentrations 10-11 M, 10-9 M 
and 10-7M). Results obtained by Real-time PCR analysis. Bars representing fold change in respect to the control 
condition. Data are expressed as mean fold ± SEM. n=4.  
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1.4.1 - 1.4.2: Summary/Conclusions 
 
 Insulin has a heterogeneous action on the expression of proinflammatory and 
prothrombotic factors with a slight decrease for the low concentration and a tendency to increase 
for high insulin concentrations, presenting the highest effect at 10-7 M in the VWF.  
 
 
1.5 Stimulation with control medium (CM) supplemented with glucose 
 
 Verification of the effect of glucose on endothelial cells was applied also in this case, 
keeping the same stimulation time and conditions. 
 
1.5.1 Proinflammatory response 
 
Glucose did not affect at all the gene expression of VCAM-1, ICAM-1 and NF-κB (Fig.27). 
 
 
 
Fig.27 Effects of glucose on proinflammatory genes on ECs. Expression of (A) VCAM-1, (B) ICAM-1 and (C) NF-κB genes  
in cells stimulated 24h with regular growth medium (control, CM g5) or supplemented with glucose at 11mM and 16mM 
(respectively symbolized as CM g11, CM g16). Results obtained by Real-time PCR analysis. Bars representing fold change 
in respect to the control condition. Data are expressed as mean fold ± SEM. n=3. 
 
1.5.2 Prothrombotic response  
 
 Results regarding glucose influence on a possible prothrombotic reaction were not 
encouraging, either (Fig.28). 
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Fig.28 Effects of glucose on prothrombotic genes on ECs. Expression of (A) VWF  and (B) TF genes in cells stimulated 24h 
with regular growth medium (control, CM g5) or supplemented with glucose at 11mM and 16mM (respectively 
symbolized as CM g11, CM g16). Results obtained by Real-time PCR analysis. Bars representing fold change in respect to 
the control condition. Data are expressed as mean fold ± SEM. n=3. 
 
 
1.5.1 – 1.5.2: Summary/Conclusions 
 
Glucose was unable to provoke cell damage when added to regular growth medium, in 
normal to very high glucose concentrations, confirming our first results.    
 
 
 
2. Protein expression in EC 
 
 Changes in gene expression were necessary to be confirmed at the protein level. In 
previous pages was made reference on VCAM-1 and ICAM-1 as molecules present on the surface 
of the endothelium, participating in the adhesion of the leukocytes to the vasculature and 
signalling among others the initiation of the inflammatory mechanism. Precisely, they are adhesion 
receptors on the endothelial cell membrane. 
 On the other hand, the genes for VWF and TF codify for proteins that leave the interior of 
the cell and are released to the extracellular matrix. From there they can take up action and carry 
out the thrombosis cascade. 
 Therefore, it was necessary to apply the appropriate technique in order to detect each 
protein. It was decided to perform immunogold labelling (IG) for the receptor detection, and carry 
on with immunofluorescence (IF) for the detection of the proteins of the extracellular matrix. 
Receptor’s expression was quantified after 24h of stimulation, whereas the expression of 
the ECM proteins was quantified after 7 days of coculture, time requested for their expression on 
the subendothelium. Due to the complexity of the technique, endothelial cells were exposed to 
the extreme conditions of our experimental design, respectively to basal and maximal 
concentrations of insulin and glucose. 
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2.1 Visceral simple obese (Ob) secretomes vs. the secretomes of diabetic obese 
(DMO) subjects treated with metformin 
 
2.1.1 Adhesion receptor expression on EC: Ob secretomes vs. DMO 
 
 Stimulation of the cells with DMO secretomes for 24 hours did present a discrete decrease 
in the expression of the adhesion receptors VCAM-1 and ICAM-1 as compared to the ones exposed 
to the Ob secretomes. Both types of secretomes induced on ECs a significantly increased 
expression of VCAM-1 and ICAM-1 in comparison to the control condition (Fig.29). 
 
 It will be noticed in- and referred to- upcoming pages that the expression of the VCAM-1 
protein was not studied any more. This was due to the fact that the present experiment was 
performed in an early time point compared to the rest; meanwhile the commercial company 
retired the antibody and thereby new immunocytochemistry methods are at the time evaluated 
for the quantification of this antibody in our laboratory.  
 
 
A) 
 
B) 
 
Fig.29 (A) Expression of VCAM-1 and ICAM-1 in EC stimulated for 1 day with control medium (CM), simple 
obese (Ob) and diabetic obese secretome (DMO). Characteristic images representative for both CAMs. (B) 
Quantification of obtained images: bars representing % surface covered in respect to the control. Data are 
expressed as mean fold ± SEM. n=6. **p < 0.005 in the control compared to the conditions. Pictures obtained 
by immunogold assay.  
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2.1.2 Prothrombotic proteins expression in the ECM after exposure to DMO vs. Ob 
secretomes 
 
VWF expression in the ECM after a week’s stimulation was significantly higher when cells 
got stimulated with the Ob and DMO secretomes than with the regular growth medium (Fig.30), 
but there was no difference in the degree of the outcome, whether it was one or the other type of 
secretome.  
 
 
A) 
 
B) 
 
Fig.30 (A) Expression of VWF in EC stimulated for 7 days with control medium (CM), simple obese (Ob) and 
diabetic obese secretome (DMO). (B) Quantification of obtained images: bars representing % surface covered 
in respect to the control. Data are expressed as mean fold ± SEM. n=6. *p < 0.05 and **p < 0.005. Pictures 
obtained by immunofluorescence assay. 
 
 
2.1.3 Thrombogenicity of the subendothelial cell matrix: Platelet adhesion on the ECM 
created from EC, after exposure to DMO vs. Ob secretomes 
 
The ECM was synthesized by incubation of the HUVECs under the conditions of interest for 
one week. Then it was perfused under mentioned conditions with blood from healthy subjects, 
and the platelet adhesion, as final consequence of the thrombogenicity of the subendothelial 
matrix, was detected. 
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Again, endothelial cells formerly stimulated with both the obese or diabetic obese 
secretomes presented an increased platelet adhesion with respect to the control condition 
(Fig.31).The Ob secretomes induced a statistically significant increased platelet adhesion while 
platelet adhesion to the ECs exposed to the DMO presented an intermediary level, higher than the 
control medium but lower than the diabetic secretome. 
 
 
A) 
    
 
 
 
B) 
 
Fig.31 (A) Platelet adhesion in HUVECs after perfusion of citrated blood (800s-1, 5min) in HUVECs cultivated 
for 7 days in control condition (CM), simple obese (Ob) and diabetic obese (DMO) secretome. (B) 
Quantification of platelet deposition. Data are expressed as mean fold ± SEM as % of change regarding the 
control. n=6. *p < 0.05. Pictures obtained by blood perfusion assay.  
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2.1.4 Summary Ob vs. DMO 
 
 Ob and DMO secretomes acted in a similar way on endothelial cells at stimulation, 
regarding the expression of the adhesion receptor proteins VCAM-1 and ICAM-1 and the 
expression of the subendothelial prothrombotic protein VWF. Subendothelial thrombogenicity, as 
quantified by platelet adhesion, was lower in the secretomes of the diabetic metformin-treated 
subjects. The observed behavior was higher compared to the control condition. 
 
2.2 Ob secretomes supplemented with insulin or glucose 
 
2.2.1 Adhesion receptor expression on ECs: simple obese secretomes supplemented 
with various concentrations of insulin or glucose 
 
Tracking the expression at 24h of the surface receptors of ICAM-1 on HUVECs by 
immunocytochemistry, we observed macroscopically a significant augmentation in their 
expression in EC exposed to the Ob secretomes as compared with the ones exposed to the control 
medium.  Regarding data obtained after the addition of insulin or glucose at maximal 
concentrations to the secretomes, results showed no significant differences between ICAM-1 
expression in EC exposed to the Ob secretomes alone or in the presence of glucose/insulin.  (Fig.32 
results for ICAM-1). Besides direct optic microscopy analysis, results were confirmed by the 
computed quantification analysis. 
 
 
A) 
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B) 
 
Fig.32 (A) Expression of ICAM-1 membrane receptors in cells stimulated 24h with control medium (CM) and simple 
obese secretome, alone (Ob), with high insulin at 10-9 M (Ob+ins) or high glucose concentration at 16mM (Ob+gluc).  (B) 
Quantification of obtained images: bars representing % total surface covered. Data are expressed as mean fold ± SEM. 
n=4. *p < 0.05 for CM in respect to Ob+gluc and **p < 0.005 for CM in respect to the other conditions. Images obtained 
by Immunogold assay performance.  
 
 
 
2.2.2 Thrombogenicity of the subendothelial matrix: Prothrombotic subendothelial 
response after exposure to simple obese secretomes supplemented with glucose 
or insulin 
 
In continuation we wanted to quantify the expression of the subendothelial VWF when 
cells were stimulated with simple obese secretomes supplemented with maximal concentrations 
of insulin and glucose. Their response to the simple obese secretome remained unchanged by 
addition of insulin at highest concentration. After exposure to glucose, endothelial cells presented 
a tendency to reduce the expression of the prothrombotic VWF (Fig.33). 
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A)  
 
 
B) 
 
Fig.33 (A) Expression of VWF in EC stimulated for 7 days with control medium (CM), simple obese secretome 
(Ob), obese secretome plus insulin at 10-7M (Ob + ins) and obese secretome plus glucose at 16mM (Ob + 
gluc). (B) Quantification of obtained images: bars representing % surface covered in respect to the control. 
Data are expressed as mean fold ± SEM. n=4. **p ≤ 0.005 where indicated. Pictures obtained by 
immunofluorescence assay. 
 
 
Although the TF gene analysis indicated an increased expression in response to the conditions 
under study, no changes were detected regarding the expression of this protein at the 
extracellular matrix level. These results suggest that TF is not released by endothelial cells under 
the conditions explored.  
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2.2.3 Thrombogenicity of the subendothelial matrix: Platelet adhesion on the ECM 
created from ECs after exposure to simple Ob secretomes complemented with 
insulin or glucose 
 
Blood perfusion of the ECM of HUVECs showed an equal platelet adhesion on the ECM 
generated from endothelial cells that had been cultured with the simple Ob secretomes and with 
or without insulin, in respect to the ones incubated with control medium (Fig.34). Interestingly, the 
ECM synthesized in the presence of glucose induced a significantly decreased platelet adhesion.  
 
 
 A) 
 
 
 B) 
 
Fig.34 (A) Platelet adhesion in HUVECs after perfusion of citrated blood (800s-1, 5min) in HUVECs cultivated for 7 
days in control condition (CM), simple obese secretome (Ob) stimulation and secretome plus insulin at 10-7 M (Ob + 
ins) or glucose at 16mM (Ob + gluc). (B) Quantification of platelet deposition. Results are expressed as mean fold ± 
SEM as % of change regarding the control. n=3. For CM, **p < 0.005 for the rest of the conditions. For Ob+gl, **p < 
0.005 for the rest of the conditions and CM.Pictures obtained by blood perfusion assay.  
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2.2.4 Summary Ob supplemented with insulin or glucose 
 
 Regarding the addition of insulin or glucose to the secretome, our results in general 
confirmed that insulin did not induce a surplus of injury on the endothelial cells, while very high 
concentrations of glucose provoked a significant decrease in platelet adhesion and a similar 
tendency in the expression of the VWF.  
 
 
 
3. Comparative analysis of the cytokines from simple Ob vs. DMO 
secretomes 
 
 The obtained results indicated that both the obese (Ob) and diabetic obese (DMO) 
secretomes from metformin-treated patients induced an increased proinflammatory and 
prothrombotic endothelial injury. For that reason, in order to understand the changes in cytokine 
composition of the secretomes of the DMO patients treated with metformin, we comparatively 
examined their pattern with the adipose tissue secretomes of the simple Ob subjects. To this 
purpose, we used a flow cytometry determination method  that was able to measure the levels of 
6 specific adipokines that have been previously reported to be associated with the 
atherothrombotic disease in obesity and in the general population: interleukin-8 (IL-8), interleukin-
6 (IL-6), interleukin-1b (IL-1b), tumor necrosis factor-alpha (TNF-α), interleukin-12 (IL-12) and one 
described as protective cytokine, respectively interleukin-10 (IL-10). 
 Moreover, in this experiment we used as negative internal control the secretomes of 
adipose tissue from normo-weight patients (CT).  
 Overall, adipokines were present in a very low level in the CT secretome samples. This 
concerns interestingly also IL-10 which seems to have a protective role on the endothelium.  
Except from IL-8, investigated adipokines were present in statistically significant greater 
amounts in the Ob secretomes as in the diabetic obese ones. IL-8 presented an opposite pattern, 
being considerably higher in the DMO secretomes. IL-12 level, although respecting the same 
pattern, did not reach statistical significance probably due to the high intersample variability 
(Fig.35).  
To note that IL-8 and IL-6 were found in very high levels in the secretomes. Inflammatory 
IL-1b and anti-inflammatory IL-10 were inside the detection limits of less than 100 pg/ml, whereas 
the inflammation indicators TNF-α and IL-12 were present at the lowest levels, that was, at less 
than 10 pg/ml (Fig.35). 
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Fig.35 Cytokines expression in secretomes of obese (Ob), diabetic obese (DMO) and lean/normo-weight (CT) patients. 
Data are expressed as mean of obtained values ± SEM, representative of n=7 individuals for Ob and DMO, and n=4 for 
CT. *p < 0.05 and **p < 0.005 wherever indicated but from IL-8 referring to all conditions. 
 
 
Summary/Conclusions 
  
 Compared to the diabetic obese secretomes originating from metformin-treated patients, 
the simple obese secretomes were, except from IL-8 and IL-12, the ones to have the majority of 
our studied cytokines elevated (including the protective IL-10). 
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4. Additional data concerning insulin uptake from the endothelial cells
  
As demonstrated above, insulin was not able to induce inflammatory and prothrombotic 
harm in the endothelial cells. In an attempt to find out about the grade of absorption of insulin 
from the medium by the endothelial cells, we performed an ELISA assay.  
Therefore, we left the endothelial cells in their growth medium (containing human serum), 
adding insulin at an elevated concentration (10-9M) on one hand and without addition on the 
other. Samples of the medium with and without insulin were obtained after 30 minutes, 3 hours 
and 24 hours, and measured with the ELISA method. 
 High insulin concentration was detected after 30 minutes of addition to the cells and 
declined with the pass of time (Fig.36), indicating its uptake by the endothelial cells. Insulin 
metabolism began after 30 min and reached the lowest level rapidly, at 3h.  
 Finally, this validated our decision to measure genetic expression after 24 hours of 
stimulation, since insulin starts to affect the cells at the beginning of its addition. 
 
 
 
Fig.36 Insulin presence in normal growth medium (CM) at time specific measurements: 30 minutes, 3 and 24 hours 
after its addition to HUVECs. Null addition of insulin (CM) and at 10-9M (CM i10-9). Data are expressed as mean of 
obtained values ± SEM. n=4-6. *p < 0.05 in comparison to 3h and 24h at 10-9M. 
 
 
Summary/Conclusions 
  
 Insulin is greatly consumed by the endothelial cells already after half an hour of addition.  
 
 
 
5. Metabolomics study of the obese adipose tissue secretomes 
 
 In the attempt to characterize the contribution of the obese adipose tissue secretomes to 
the metabolic systemic complications we performed a first metabolomic study of the visceral and 
subcutaneous obese adipose tissue secretomes in comparison with the ones from nonobese 
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subjects. The study of the diabetic obese secretomes is still under work and will not be subject of 
the present analysis.  
Therefore, in the investigation performed for this thesis we compared the metabolic 
profile of visceral (VIS) and subcutaneous (SC) adipose tissue secretomes from nonobese (BMI= 24-
26 kg/m2) and obese subjects (BMI > 40 kg/m2) with no other major metabolic risk factor than 
their own BMI.   
 
After raw data filtering, retention time correction, peak alignment in the time domain and 
peak integration, XCMS generates a table containing the resulting integrated intensities for each 
m/z-retention time pair spectral feature detected. A feature is defined as a molecular entity with a 
unique m/z and a specific retention time. This data table was scaled to unit variance and used to fit 
four different PCA (Principal Component Analysis) multivariate models aimed at investigating the 
effect of obesity and fat pad regional differences on the secretomes metabolic profiles.  
PCA is a method used for the unsupervised exploratory analysis of multivariate datasets 
deriving from high throughput analysis technologies. It involves a mathematical transformation of 
a number of possibly correlated input variables into a smaller number of uncorrelated variables 
called principal components. The projection of sample data into this new lower-dimensional 
variables subspace is called the PCA scores plot. Figure 37 shows the PC1/PC2 scores plots derived 
from the comparison of the obese and nonobese metabolic profile secretomes for either VIS-AT or 
SC-AT. This scatter plot provides a simplified qualitative overview on how secretome samples are 
related to each other in terms of their metabolic profiles i.e., similarity or dissimilarity among the 
metabolic profiles of secretome samples entering the study.  
 
 
 
Fig.37 Principal component analysis (PCA) scores plot resulting from either VIS- (left panel) or SC-AT (right panel) 
secretomes metabolic profile comparison. Each point in the plot represents an individual secretome sample 
measurement. Samples close to each other present similar metabolic properties whereas those far from each other are 
dissimilar in terms of their metabolic profile. n=8 for Ob and n=6 for NOb. 
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Therefore, secretome samples corresponding to obese subjects presented a prevailing 
trend to cluster altogether and apart from secretome samples belonging to nonobese individuals 
for either VIS-AT or SC-AT. Nevertheless, PCA scores plot did not reveal any trend when comparing 
VIS-AT and SC-AT fat depots neither for obese nor for nonobese subjects. This first overview 
already indicated in a qualitative manner that obesity induced differential secretory metabolic 
patterns, an effect which resulted more pronounced for the VIS-AT depot.  
We also analyzed the influence of obesity and the anatomical provenance of the fat pads 
on the metabolic profile of the secretomes from a univariate data analysis perspective. Thus, we 
applied multiple paralleled 2-way ANOVA on the entire list of metabolic features retrieved from 
XCMS. Data were rank-transformed before being submitted to 2-way ANOVA. After FDR correction 
for multiple testing, 31% and just 19% out of the initially detected features resulted significantly 
different due to obesity and regional fat origin, respectively.  
 
Overall, the results show that obesity induces higher metabolic variation in secretomes 
than the regional provenance of fat per se. Next, we focused on the identification of those 
metabolites responsible for the higher differences related to obesity. 
Obese and nonobese secretome samples from either VIS-AT or SC-AT were compared 
using the Mann-Witney test and FDR correction Features displaying significant differences were 
selected for further metabolite annotation.  
In the case of the SC-AT secretome, we observed significantly lower levels of 2-KIC (2-
ketoisocaproic acid) for the obese subjects as compared to the nonobese ones. Strikingly, all the 
other obesity-induced significant changes in the VIS-AT secretome were annotated as amino acids, 
namely essential ones (alanine, lysine, methionine, threonine), the branched-chain amino acid 
(BCAA) leucine, as well as glutamine and serine. We subsequently sought to determine the levels 
of the mentioned amino acids on the non-supplemented culture medium.  
It should be considered that, unlike proteomics, metabolomic analysis of secretomes 
presents inherent challenges since media per se contain up to several dozen different metabolites. 
Glutamine and alanine were exclusively determined on secretome samples and were not detected 
in the non-supplemented culture medium. Therefore, they were considered as a product of the fat 
pads.  
On the other hand, leucine, lysine, threonine, methionine and serine were detected in 
both the secretome and non-supplemented culture medium. Regardless of obesity, we 
consistently detected lower levels of these five amino acids in the secretomes as compared to the 
non-supplemented culture media, and we therefore considered them as uptaken metabolites.  
Metabolite identification parameters together with statistical analysis details are 
summarized in Table 12. 
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Table 12. Identification parameters and statistical summary for metabolites  
varying significantly in the Ob vs NOb comparison of VIS- and SC-AT secretomes‡ 
 Retention 
Time (min) 
Quantitative 
Ion (m/z) 
p-values q-values 
Fold Change 
Ob vs NOb 
Secreted Metabolites 
Alanine** 11.2 188 0.005 0.036 
2.1 
Glutamine** 14.4 246 0.022 0.081 
2.8 
2-KIC*, ** 9.1 216 0.020 0.082 
8.1 
Uptaken Metabolites 
Leucine** 8.3 188 0.008 0.047 
1.9 
Serine** 9.8 219 0.014 0.062 
1.6 
Threonine** 10.2 130 0.022 0.081 
2.2 
Methionine** 11.8 61 0.035 0.098 
1.5 
Lysine** 17.0 174 0.004 0.036 
3.1 
‡Fold changes were calculated considering intensities of each quantitative ion corrected by internal standard, as the 
ratio of the median corrected intensities in the Ob group (n=8) relative to the NOb (n=6) group median. Arrow ↑ 
indicates significantly elevated and arrow ↓ significantly low levels of the metabolites in the Ob group secretomes. 
*Statistical differences among groups for SC-AT, and **comparison of retention times and spectral data to the 
corresponding pure standard compounds. p < 0.05 and q < 0.1. 
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Fig.38 Significant metabolic changes detected in the VIS-AT secretomes of obese subjects. Red-underlined metabolites 
represent VIS-AT secretion and green-underlined metabolites represent VIS-AT uptake. For secreted metabolites, data is 
presented as mean ± SEM of the internal standard-corrected intensities for the corresponding quantitative ions. For 
uptaken metabolites, data is presented as mean ± SEM of the uptake percentage across all individuals in either Ob or 
NOb groups. The uptake percentage was calculated as the difference in percentage of the metabolite levels determined 
in the secretomes respective to the untreated media. Grey bars represent the obese group (Ob), and white bars 
represent the non obese group (NOb). n=8 for Ob and n=6 for NOb. 
 
 
An overview of the significant metabolic changes detected in the VIS-AT secretomes of 
obese subjects is depicted in Fig.38. Higher released levels of glutamine and alanine were detected 
in the VIS-AT depot of obese subjects. On the other hand, VIS-AT of obese subjects presented a 
lower net uptake of leucine, lysine, threonine, methionine and serine. 
 
 
Summary/Conclusions 
 
Obesity rather than fat regional origin affects the metabolic signature of adipose tissue 
secretomes, and visceral obese fat pads present the greatest differences in the metabolite pattern 
of adipose tissue secretomes.  
  
 
 
 
 
 
 
 
 
 
V. Discussion 
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The concept for the realization of this thesis was to further decipher the effect of the 
cytokines secreted by the visceral adipose tissue of obese individuals with type 2 DM on the 
endothelium, and moreover to contribute to the understanding of the complementary effect of 
hyperinsulinemia and hyperglycemia to this injury. As from ethical reasons it was not possible to 
obtain secretomes from diabetic patients before the initiation of their therapy, we have redirected 
our interest to patients treated with only metformin, the first line type 2 diabetes oral agent of 
worldwide use. Moreover, to a better understanding of the contribution of the adipose tissue’s 
secreted cytoadipokines to the metabolic disease, we performed for the first time the comparative 
metabolomic analysis of obese and lean adipose tissue secretomes, the next step of our future 
investigation being the comparison of secretomes of obese versus obese diabetic, metformin-
treated patients.    
During the investigation regarding this thesis I had the opportunity to be involved in a 
translational research and therefore to develop not only my technical skills in molecular biology, 
but also to be initiated in the clinical and physiopathological knowledge of human diseases. 
Moreover, through the participation in the metabolomics study, I had the chance to work in an 
emerging -omics science.  
Like in any scientific approach, the results presented have their own limitations and are 
open to debate. In the following pages I will discuss and decipher the major aspects and 
conclusions which emerge from the research we have done for this thesis.  
As a result to the work performed during the thesis, two scientific papers have emerged. 
The first one, regarding the metabolomics study, is under review. The second one, regarding the 
effect of secretomes of visceral adipose tissue from obese diabetic metformin-treated patients on 
the endothelium, is yet in manuscript form. 
 
 
1. Effect of the visceral obese adipose tissue secretomes of metformin-treated 
diabetic patients versus secretomes of simple obese subjects on the endothelial 
cells: is metformin changing the proinflammatory and thrombogenic effect of the 
obese adipose tissue secretomes? 
 
As described in the introduction, obesity is characterized as a chronic state of 
inflammation, which not only deals with the effects straightforwardly connected to that state, but 
also drags with itself a number of other comorbidities. One of the negative outcomes strongly 
associated to obesity is diabetes mellitus type 2, a chronic disease with long-term important 
macrovascular complications56.  
Being cardiovascular morbidity and mortality the first-line complications in type 2 DM and 
obesity, risk factors for cardiovascular disease are most important nowadays in the clinical 
observation and account for several surveys. Complications in the macroendothelium comprise a 
state that has to be looked into regularly with acute and chronic prognosis, and undeniably 
portrays a disturbed life quality as well as life expectancy in the affected population. 
We challenged ourselves in contributing to this field of investigation. The idea was to try to 
resemble situations where endothelial cells experience an obesogenic environment, alone, or 
accompanied by the diabetic state. Our laboratory had already introduced the concept of 
endothelial cell stimulation with the adipose tissue’s secretome for the conduction of similar kinds 
of experiments, and what we did with this assignment was to bring the investigation on the matter 
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a step further, comparatively analyzing the injury induced on endothelial cells of the obese versus 
obese diabetic secretomes. As mentioned in the aims, unfortunately, for ethical reasons, we 
couldn´t obtain secretomes of untreated diabetic obese subjects. Therefore, we reoriented our 
investigations with the goal to understand the glucose lowering and insulin sensitizer independent 
effect of metformin, the actual first-line worldwide employed oral medical drug in type 2 diabetes, 
on the endothelial proinflammatory and prothrombotic activation determined by the 
cytoadipokines secreted from the visceral obese adipose tissue. 
Metformin has been generally reported to reduce CV disease due to its proprieties to 
diminish endothelial oxidative stress, endothelial dysfunction, arterial stiffness and carotid arterial 
wall thickness 315,316. But in obesity-associated diabetes, the aggression of the arterial wall has a 
multifactorial etiology. The endothelial injury determined by cytoadipokines emerging from the 
inflamed obese visceral adipose tissue maintains a proinflammatory systemic ambient and is a 
chronic stimulus for further activation of endothelial inflammatory pathways. As previously 
reported206, cytoadipokines secreted from the obese adipose tissue directly determine the 
synthesis of adhesion molecules, prothrombotic factors and an increased platelet adhesion on the 
endothelium. In this sense, metformin has been reported to reduce systemic inflammation in 
obese insulin resistant and prediabetic patients 320,322,323 but controversy persists about its actions 
on inflammation and on the cardiovascular outcome in type 2 diabetic patients321,324,337. Metformin 
increases the fibrinolytic activity, slightly diminishes PAI-1 and decreases platelets’ response to 
proaggregating agents 296. In vitro, there is sustained evidence that metformin inhibits cytokine-
induced nuclear factor-κB activation via PI3K-dependent AMPK activation in all vascular wall cells 
(HUVEC, vascular smooth cells and macrophages) 308,310,311,313. Regarding its action on the synthesis 
and cytokine secretion of the obese adipose tissue’s proinflammatory and prothrombotic 
cytokines, there is evidence from studies in animal models and human adipose tissue that 
metformin diminishes the local oxidative stress and reduces local inflammation and expression of 
chemerin and MCP-1 by activating the local diminished AMPK 330,338,339. 
 
In our in vitro model we analyzed the proinflammatory and prothrombotic effect of the 
diabetic visceral obese adipose tissue secretomes, originating from metformin-treated patients, on 
the endothelium, compared to the exposure to secretomes of simple obese subjects.  
The important limitation of our study remains the fact that we do not have the possibility 
to apply our initially proposed study model to the secretomes of diabetic obese patients, that is, 
before receiving any treatment. In this sense, we´ve based our comparison on the reported 
research data present in the literature. There is no comparative report on cytokine secretion 
between visceral adipose tissue from obese versus obese diabetic subjects. On the contrary, there 
is a heterogeneous abundance of data suggesting that inflammation increases with the increase in 
tissue mass and that obese tissue inflammation and insulin resistance increase in the diabetic 
obese visceral adipose tissue 340. Moreover, data from various sera studies from type 2 diabetic 
patients report different serum profile of adipokines in function of the association with obesity or 
not 261,340,341,342,343. Maybe the more complete data arrive from the study of Doupis et al who 
reported that diabetes and obesity equally affect the endothelial cell function, while smooth 
muscle cell function is affected only by diabetes, probably due to the different observed sera 
profile of cytokines and growth factors in the two entities. Interestingly, the obese diabetic 
patients from that study, all with a significant lower BMI (36.4 versus 38.1kg/m2 for simple obese 
subjects) present, excluding IL-6 and IL-8 (probably due to the lower BMI and consequent visceral 
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adipose tissue), higher levels of all measured sera cytokines, like CRP, TNF-α, MCP-1, E-selectin, 
soluble (s) ICAM-1 and sVCAM-1 etc than the simple obese subjects. At the same time, the 
nonobese type 2 diabetic patients present, like in other studies, the lowest values of the 
mentioned markers 261,343. Therefore, it seems that, once initiated, diabetes and obesity potentiate 
their deleterious effect on inflammation.  
Regarding our clinical data from the obese diabetic patients treated with metformin, we 
observed that in this group the systemic inflammation parameter hs-CRP and the leukocyte count, 
although higher as in the obese group, were in fact lower than cumulative ones from BMI- and 
diabetes-expected values as compared to the study of Doupis mentioned above 261 (table 8). These 
lower values of hs-CRP can be due to the direct insulin sensitizer effect of metformin on the liver 
but can also reflect a lower hepatic cytoadipokine aggression in the metformin-treated obese 
patients.   
Concerning our in vitro experiments, the results regarding the expression and synthesis of 
proinflammatory adhesion receptors, after exposure to the secretomes of the obese versus  
metformin-treated diabetic obese visceral adipose tissue, indicate that although at gene 
expression level there is a tendency to an increased endothelial inflammatory injury in the 
endothelium exposed to the secretomes of the diabetic obese subjects treated with metformin, at 
protein level there are no significant changes. Intriguingly, NF-κB presents an increased expression, 
but this remains without echo at the synthesis level of proinflammatory adhesion molecules. 
Nevertheless, overall both types of secretomes induce a significantly increased activation of 
endothelial inflammatory pathways with respect to the control media.  
Expression and synthesis of prothrombotic subendothelial proteins present no differences 
between EC cultured with the distinct secretomes, remaining equally higher as compared to the 
control medium. Contradictorily, secretomes of diabetic obese subjects treated with metformin 
determine the synthesis of a less thrombogenic subendothelial matrix, as quantified by the 
reduced platelet adhesion, than the ones from simple obese individuals.  
 
To understand the biological relevance of this setting, we investigated the cytokine 
content of both types of visceral adipose tissue secretomes (the ones deriving from the visceral 
adipose tissue of obese diabetic patients treated with metformin and the ones deriving from 
simple obese subjects), by quantifying some of the cytokines most relevant to cardiovascular 
injury.  
Hence, we observed that metformin treatment had a heterogeneous effect on the 
cytokine profile of the obese adipose tissue, decreasing secretion of proinflammatory TNF-α, IL-12, 
IL-1b and IL-6 but also of the anti-inflammatory IL-10, while only increasing the synthesis of the 
deleterious IL-8. The same adipokines were, as predicted, very low or (nearly) absent in the 
secretomes originating from nonobese patients.  
 Generally we expected that proinflammatory cytokines would appear much more 
elevated in the secretomes of diabetic obese subjects, due to the deleterious supplementary effect 
of diabetes on obesity. In this meaning, our results are indicating that metformin determines a 
significant decrease in TNF-α, IL-12, IL-1b and IL-6, although IL-8 increases, maybe compensatorily. 
As mentioned above, it has been reported that in HUVECs metformin inhibits dose-dependently 
the TNF-α- and IL-1b- induced NF-κB activation, and IL-6 and IL-8 production. This effect takes 
place through the PI3K-dependent activation of AMPK, the basal mechanism of action of 
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metformin 317,318,319. Our data indicate that metformin has a distinct effect on the cytokine 
secretion of the obese adipose tissue than that on the endothelium in vitro under a specific 
proinflammatory stimulus. Therefore, despite low levels of TNF-α and IL-1b in the secretomes of 
obese diabetic metformin-treated patients, IL-8 was higher than in the simple obese secretomes, 
while IL-6 diminished. The decrease of IL-10 could be interpreted as consequence to the 
diminution of the defence of the adipose tissue in front of the longstanding local inflammation. 
Metformin-treatment diminished but did not completely inhibit the deleterious 
cytoadipokine secretion from the obese adipose tissue. Nevertheless, as repeated above, the 
cytoadipokines studied are only a representative selection of a higher amount of cytokines 
documented to be present in the obese adipose tissues’ secretomes. That means that there could 
have been discrepancies in the presence of the adipokines, like the boost of IL-8 in DMO, and in 
this way we can explain the differences in the maintained endothelial inflammatory injury 
observed in HUVECs exposed to the secretomes of the diabetic patients treated with metformin. 
This is also confirmed by the fact that NF-κB activation is still increased. Anyway, it is important to 
note that the observed endothelial injury is similar to the one induced by the simple obese 
secretomes, being lower than predicted by the BMI and the diabetic state of the researched 
subjects. It seems that the changes in the cytoadipokines’ pattern induced by metformin-
.treatment blocked the repercussion of the endothelial activation of NF-κB by the diabetic 
secretomes at the level of VCAM-1 and ICAM-1. Not to forget that the significant increase in NF-κB 
activation could be due to the action of other metabolites of the obese secretomes due to the fact 
that NF-κB is implicated also in other stress dependent proinflammatory cellular responses in 
obesity and type 2 diabetes 340,344,345,346. 
Corroborating the clinical and analytical data of the patients from our study with the 
experimental ones, our investigations are strongly indicating that metformin inhibits the secretion 
of a part of the deleterious cytoadipokines from the visceral obese adipose tissue, maintaining the 
proinflammatory endothelial activation as regarding proinflammatory adhesion receptors at the 
prediabetic obese level. 
 
Going back to, and associating the data regarding the effect of metformin on the 
thrombogenicity of the subendothelial matrix, we observed, interestingly, that the highest 
antithrombotic effect of metformin was detected in our investigation regarding the 
thrombogenicity of the subendothelial matrix synthesized under the influence of the secretomes 
of the diabetic obese patients treated with metformin. Thus, our work provides further evidence 
that metformin has a beneficial role on thrombogenicity, not only regarding platelet action and 
synthesis of PAI-1 as found in the literature, but also regarding the synthesis of a less 
thrombogenic subendothelial matrix, even lower than that induced by the simple obese 
secretomes. This observation is sustained from the recent evidence from in vivo sera studies that 
have reported that metformin ameliorates platelet volume and function in treated type 2 diabetes 
patients 305. The mechanism of this effect remains actually under study.   
 
In conclusion, metformin presents a partially beneficial action on the deleterious secretion 
of cytokines from the visceral obese adipose tissue of type 2 diabetic patients.  
Nevertheless, both secretomes of simple obese and diabetic obese patients treated with 
metformin induced a comparative inflammatory injury on endothelial cells, but the secretomes of 
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the obese diabetic patients treated with metformin induced the synthesis of a less thrombogenic 
subendothelial matrix.  
  
 
2.  Glucose and insulin proinflammatory and thrombogenic effect on the endothelial 
cells: is there an additional effect to the one induced by the visceral obese 
adipose tissue secretomes of simple obese subjects? 
 
2.1 Effect of insulin on the macroendothelial cell model 
 
In the last few years, the chronic low state of inflammation associated with obesity has 
emerged as a new risk factor for the obesity-associated cardiometabolic comorbidities. The debate 
about the role of inflammation versus hyperinsulinemia and insulin resistance in the genesis of 
macroendothelial injury is, as depicted in the introduction, despite the high number of studies 
performed on endothelial cells regarding the effects of hyperinsulinemia, still going on, as results 
have not been conclusive. Moreover, the consequences of hyperinsulinemia on a 
macroendothelial cell model, existing additionally in a high whole-adipogenic-derived 
inflammatory environment, has not been yet investigated in vitro. We attempted to enlighten the 
subject by studying the role of insulin in low to high concentrations in the complementary 
endothelial injury induced by the secretomes of the visceral adipose tissue, originating from 
morbidly obese patients. 
Here we observed that simultaneous stimulation of ECs with insulin and secretomes for 
24h induced only at the very high level of 10-7 M a slightly increased expression of the adhesion 
molecules VCAM-1, ICAM-1 and of the transcription factor NF-κB, with respect to the stimulation 
induced by the simple obese secretomes. Interestingly, these changes were not paralleled by the 
ones in the expression of the genes of the prothrombotic factors VWF and TF, as insulin appeared 
to have protective prothrombotic effects. Anyway, these results at gene expression level have not 
been confirmed at the protein synthesis level, as the synthesis of ICAM-1 was lower than in the ECs 
exposed only to the simple obese secretomes. Moreover, the synthesis of VWF and the platelet 
adhesion present equal levels between insulin supplemented or not to obese adipose tissue 
secretomes.    
As previously commented, the increase in the expression of the nuclear transcription 
factor-κB could be determined by insulin by the latter’s implication in other pathways than 
activation of cellular adhesion receptors.  
Our data are in contradiction with the ones emerging mostly from the group of Madonna 
et al regarding the proinflammatory role of insulin. Even so, our results are mostly in accordance 
with publications reporting that insulin can exert potential anti-inflammatory and antiatherogenic 
effects in clinical trials and in experimental models, hence likely to be cardioprotective and to 
improve clinical outcomes 243,245,347. 
To note that the kinetics of the experiments and the insulin concentration studies have 
been equivalent to the ones of Madonna et al, ranging from 10-11 to 10-7 mol/l which are extending 
from 1.7mU/l to 1.7x104mU/l, as mentioned before. This span covers from pathophysiological to 
pharmacological levels of insulinemia, and are far over the insulin concentrations in fasting and 
postprandial states of obese hyperinsulinemia in the presence of insulin resistance 332,333. 
Moreover, although the evidence of an endothelial cell-insulin receptor has been recognized long 
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before 333,334, we verified in our experimental model as earlier described the insulin uptake in 
HUVECs.  
 
Our conclusion is that insulin was not able to affect in a distinct degree the already high 
proinflammatory and prothrombotic response of the endothelium to the obese secretome.  
 
  
2.2 Effect of glucose on the macroendothelial cell model 
 
In the introduction we mentioned that hyperglycemia can be a reason for cardiovascular 
complications, but that its levels of adjustment are a subject that has not been resolved. Even if 
glycemic control prevents the onset of microvascular complications in diabetic patients, recent 
clinical trials reported that low glucose levels can result worthless for the vasculature. Moreover, 
high glucose variations and the metabolic memory seem to have more echo on the arterial 
outcome than individual values per se. Data from in vitro experiments regarding the capacity of 
glucose to induce the inflammatory activation of ECs are controversial, as presented in the 
introduction. 
Similarly as for insulin, we decided to make an evaluation of the effect of hyperglycemia on 
the activation of the endothelial injury mechanisms, in the presence of the deleterious 
cytoadipokines secreted from the obese adipose tissue. Therefore, we co-exposed ECs to the 
obese secretomes and glucose concentrations of 11 and 16mM, corresponding to 198 and 288 
mg/dl glucose and characterize states of hyperglycemia. 
 Increasing concentration of glucose seemed to not result overall in any proinflammatory or 
prothrombotic additional damage to that already induced by the obese visceral secretomes. In 
detail, there was a tendency for glucose to peak at 11mM for VCAM-1, ICAM-1 and TF genes but 
afterwards descending to the values of simple obese secretomes, while VWF gene expression 
remained unchanged. NF-κB expression remained also unchanged following concomitant exposure 
to glucose. Interpretation of results is challenging due to the high variations between samples. 
Maybe in order to quantify more precisely the effects of glucose, the number of samples should 
have been increased. Anyway there were no clear changes. 
 Results were paralleled at protein expression level with the absence of difference in ICAM-
1 in the presence of high concentration of glucose. As for the VWF, it seemed to display a tendency 
towards lowering down its expression with glucose. Intriguingly, platelet adhesion to the 
subendothelial matrix generated by the EC exposed to the secretomes and glucose was strongly 
diminished, less than the level of the control medium. Explication of this decreased platelet 
adhesion could be on one side a positive effect of glucose on EC, or, on the other, the fact that 
glucose exerts toxic effects on ECs determining the alteration of their normal growth. At optic 
microscopy level, ECs presented in both conditions a similar aspect, without changes in their 
morphology and without intracytoplasmic inclusions, reaching confluence after the same number 
of days in both conditions.  
Therefore our data are supporting previous ones from the literature that provide evidence 
about the fact that hyperglycemia is not sufficient to directly promote endothelial inflammatory 
activation 262,263,265-267. There are scarce data in the literature about the thrombogenicity of the 
macroendothelial ECM under hyperglycemic conditions (most researches concerning platelet 
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volume and reactivity), which seem not to be affected in type 2 diabetes. Anyway there have been 
made no studies about the impact of the glycemic control on this finding 348,349,350. 
 
 Our experiments brought us to the conclusion that high glucose was incapable of 
producing a surplus of inflammatory injury to the one determined by the cytoadipokines of the 
secretomes on the endothelial cells. Probably, endothelial damage of hyperglycemia is mediated 
predominantly through the oxidative stress generated by the advanced glycation end-products.  
 
 
3. Metabolomic comparative analysis of obese and lean visceral and subcutaneous 
adipose tissue secretomes:  is the metabolic obese secretome pattern of the 
visceral adipose tissue indicative of the implication of the adipose tissue-
emerged metabolites in the systemic metabolic disease?  
 
In order to understand the contribution of the obese adipose tissue-emerged metabolites 
to the systemic metabolic disease associated with obesity, we performed a comparative analysis of 
the secretomes of visceral and subcutaneous fat pads of obese and nonobese subjects, by applying 
an untargeted metabolomics approach. To our knowledge, this is the first comprehensive 
differential report on metabolomics of secretomes of different regional adipose depots isolated 
from obese subjects. Study participants presented no other metabolic disturbances than their BMI, 
and because of that, they presented signs of systemic inflammation, such as increased high 
sensitive C reactive protein, insulin resistance, and decreased adiponectin. The goal of our next 
investigation, actually under work, is to further decipher the comparative metabolomics of the 
secretomes of simple obese and diabetic obese subjects, but is not the topic of the actual thesis.  
Strikingly, although untargeted GC-MS-based metabolomics allows for the nonbiased 
screening of a wide range of chemical classes (sugars, short and medium chain fatty acids, steroids, 
amino acids or organic acids, among others), our results demonstrated that amino acids accounted 
for the main differences observed in the secretory pattern of visceral and subcutaneous fat depots 
of nonobese and obese individuals with no metabolic risk factors other than their own BMI. 
Supporting data from previous studies 351, our work reports significant differences in essential, 
branched-chain amino acids (BCAA) and nonessential amino acids, pointing out that obesity overall 
blunts amino acid metabolism in adipose tissue and profoundly affects BCAA catabolism. 
Moreover, our results demonstrate that the effect of obesity upon the secretory metabolic pattern 
of the adipose tissue is more profound than the effect of the regional provenance of the fat tissue, 
being the more affected the metabolism of obese visceral adipose tissue, in line with our 
previously reported results regarding holistic changes in obese adipose tissue 206.  
Already decades before, the obese state has been associated with an increased plasmatic 
level of amino acids 352. Recently the plasma amino acid profile has been found to be altered 
according to visceral fat accumulation 353. It is also a fact that amino acids contribute directly to 
hyperinsulinemia through direct pancreatic beta cell stimulation and gluconeogenesis 354,355,356. 
What is more, hyperaminoacidemia affects insulin action and glucose cellular uptake 
232,357,358,206,359,360.  Nowadays, it seems reasonable to conclude that the plasmatic amino acid excess 
in obesity is at least in part the consequence of widespread hyperproteic and hyperlipidic diet. At 
any rate, the role of chronic exogenous amino acid overload, with particular emphasis on the 
highly represented BCAAs in the etiopathogenesis of metabolic alterations associated with obesity, 
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has been under debate for decades 289,361. Recent metabolomic sera studies of obese individuals 
reported notable differences in the amino acid metabolic signatures between obese, mild insulin-
resistant but nondiabetic subjects and lean individuals 289, while a decrease in a cluster group of 
metabolites comprising BCAAs and related analytes predicts improvement in insulin resistance 
(HOMA-IR), independent of the amount of weight lost 362. Moreover, recent clinical evidence from 
the Framingham offspring study indicated increased levels of a group of five BCAA and aromatic 
amino acids (namely isoleucine, leucine, valine, phenylalanine and tyrosine) as candidate 
metabolic risk markers for diabetes in obesity, predating the clinical onset of diabetes by years 293. 
On the contrary, a low glutamate to glutamine ratio would exert a preventive role on the 
cardiometabolic status 294.   
Amino acids are not stored in the body. There is a highly active interorgan transport, and 
dietary amino acids in excess of those required for protein synthesis or gluconeogenesis, are 
rapidly catabolized 363. BCAA metabolism in adipose tissue has recently gained renewed interest, 
as it has been demonstrated that coordinated regulation of adipose tissue BCAA enzymes in 
fasting and in feeding may modulate circulating BCAA levels. In this sense, a transcriptional study 
on subcutaneous adipose tissue biopsies from a cohort of monozygotic twins discordant for 
obesity reported decreased mitochondrial BCAA catabolism for the obese twins in parallel with the 
onset of systemic and local adipose tissue inflammation. The down-regulation of BCAA oxidation 
enzymes was paralleled by decreased levels in plasma of 2-KIC acid and increased levels of leucine 
206,364. These changes correlated with elevated fasting insulin levels and insulin resistance 206,365. 
Contrarily, another recent study on type 2 diabetic and obese youth infirms these findings, 
indicating the presence of an adaptive metabolic plasticity in youth that equilibrates fatty acid and 
amino acid metabolism 366.  
We found both decreased secreted levels of 2-KIC and diminished leucine uptake in the 
obese subcutaneous or visceral fat depots, respectively. 2-KIC is the transamination product of 
leucine, i.e, a leucine breakdown product. This confirms data from indirect functional in vivo and 
ex vivo proteomic and transcriptional studies on adipose tissue in the fasting state 351,367,368. The 
dysregulation of leucine metabolism seems to be higher in the visceral obese adipose tissue, 
eluding the formation of 2-KIC.  
On the other hand, we have determined increased released levels of both glutamine and 
alanine in the obese visceral adipose tissue secretomes. Adipose tissue alanine and glutamine 
released in quantities sufficient to make a significant contribution to the whole body economy of 
these amino acids has been previously reported 369,370. Catabolic pathways of BCAA leucine 
through the KIC acid route involve the formation of important amounts of alanine, glutamine and 
glutamate. These pathways are the route for disposal of amino groups released in the 
transamination of BCAA232,289,206,369. Therefore, since alanine and glutamine are highly 
gluconeogenic amino acids, the increased amount of alanine released by the visceral adipose 
tissue to the systemic circulation could contribute to hyperinsulinemia and to the development of 
insulin resistance. 
 It is worth mentioning that in the visceral adipose tissue of obese subjects, the uptake of 
leucine and other reported glucogenic (methionine, serine, threonine) and exclusively ketogenic 
(leucine) amino acids was found to be diminished. This is indicative of profound deviations in local 
amino acid metabolism and results in increased release in the circulatory flux of amino acid 
metabolites with gluconeogenic potential, as well as unmetabolized BCAA with demonstrated 
direct insulin-resistant cellular consequences.  
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Altogether, our findings point to a blunted amino acid metabolism and overload of BCAA 
catabolism in the inflamed and lipid-overcharged obese adipose tissue. This would, in turn, 
independently if primary or secondary to the exogenous overload, essentially contribute to the 
altered and increased plasmatic amino acid metabolite pool, sustaining the deleterious actions of 
amino acids on the onset of metabolic carbohydrate disturbances in obesity.  
Our results demonstrate that the early stages of obesity, including the presence of 
systemic inflammation and insulin resistance, before the clinical onset of significant metabolic 
alterations other than the BMI, are characterized by a markedly affected adipose tissue- amino 
acid metabolism and secretion. Further combined functional and metabolomic approaches are 
awaited to understand the dynamic alteration of amino acid metabolism in the obese state and 
the specific contribution of the adipose tissue-emerged metabolites to the metabolic systemic 
disease.  
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
VI. Conclusions 
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Taking on account the results obtained from this thesis under the conditions applied, we 
conclude following: 
 
 
1. Treatment with metformin presents a partially beneficial action on the deleterious 
secretion of cytokines from the visceral adipose tissue of type 2 diabetic obese patients.  
Both secretomes of simple obese and diabetic obese patients treated with 
metformin induced a comparative inflammatory injury on endothelial cells, but the 
secretomes of the obese diabetic patients treated with metformin induced the synthesis of 
a less thrombogenic subendothelial matrix.    
 
2. Insulin does not increase the expression of proinflammatory adhesion molecules and the 
thrombogenicity of the subendothelial matrix of  HUVECs by the cytokines secreted from 
the obese visceral adipose tissue.  
Pharmacological levels of insulin induce the increased expression of NF-κB.   
  
3. Glucose does not determine an increase of the endothelial proinflammatory and 
prothrombotic injury provoked by the cytoadipokines of the visceral obese secretome in 
HUVECs.  
High levels of glucose, though, seem to decrease importantly the plaquetary adhesion 
capacity when acting in combination with the secretome. 
 
4. Obesity, more than the regional distribution of fat pads, markedly affects the metabolic 
profile of adipose tissue secretomes before the clinical onset of other significant 
metabolic alterations aside from BMI. Visceral obese adipose depots present the greatest 
alterations.   
Amino acid metabolism is blunted and BCAA catabolism overloaded in the obese 
adipose tissue. This may contribute to the altered and increased plasmatic amino acid 
metabolite pool, sustaining the deleterious actions of amino acids on the onset of 
metabolic carbohydrate disturbances in obesity.  
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Introducción 
 
1. La obesidad: una enfermedad en todo el mundo 
 
La obesidad se define como la acumulación de tejido adiposo excesivo o anormal que 
puede perjudicar la salud. El estado de obesidad designa un aumento desproporcionado de peso 
con respecto a la altura, el sexo y la edad. Una cuantificación simple de esta relación utilizada 
comúnmente para clasificar el sobrepeso y la obesidad es el índice de masa corporal (IMC), 
calculado dividiendo el peso de una persona en kilogramos (kg) por el cuadrado de su altura en 
metros (m) (IMC = kg / m2). 
Según la Organización Mundial de la Salud (World Health Organization, WHO), la obesidad 
en los seres humanos se clasifica en base a un IMC ≥ 30. La misma organización sostiene que el 
principal responsable de la obesidad es el desequilibrio energético entre las calorías consumidas y 
las calorías gastadas, aparte del impacto sobre este balance a los efectos dietéticos, económicos, 
psicológicos, reproductivos, cultural y farmacológicos. Se han reconocido más de 50 genes 
vinculados o no con la herencia de la obesidad, pero la obesidad sigue siendo predominantemente 
una enfermedad poligénica compleja. Además, la obesidad es atribuible también a los cambios 
epigenéticos. 
Sin dudas, la obesidad comenzó como un problema de salud pública en las sociedades con 
un alto estatus socioeconómico, principalmente los Estados Unidos y Europa. Pero tan pronto 
como los países en desarrollo experimentaron cambios en su dieta, la carga de la obesidad se 
desplazó hacia las sociedades más pobres.  Países tan diversos como México, China, Tailandia y 
Sudáfrica muestran aumentos espectaculares en la obesidad. Preocupante es también la 
incrementada prevalencia de sobrepeso en los jóvenes, alcanzando hasta el 25,6% en Estados 
Unidos y el 10-36% en el continente europeo. 
La distribución de la grasa es un factor importante a tener en cuenta, y la medición de la 
grasa visceral es un mejor factor de predicción de riesgos para la salud que la grasa corporal total. 
Muchas técnicas se han establecido para la medición de la distribución de la grasa corporal, 
incluyendo el IMC, la circunferencia de cintura, impedancia bioeléctrica, etc. 
Las comorbilidades asociadas a la obesidad son debidas al exceso de tejido adiposo en sí, y 
a las alteraciones metabólicas y / o psicosomáticas inducidas por el exceso de la masa adiposa. 
Reducen la esperanza de vida y suponen aumento en la hipertensión arterial, las enfermedades 
cardiovasculares (ECV), la dislipidemia y la diabetes . 
 
2. Diabetes Mellitus Tipo 2  
 
Según la Asociación de Diabetes Americana (ADA), diabetes mellitus (DM) se define como 
un grupo de trastornos metabólicos caracterizados por hiperglucemia crónica resultante de 
defectos en la secreción y/o acción de la insulina. Los criterios para el diagnóstico de la diabetes se 
basan en cifras de glucosa en plasma en ayunas ≥ 126 mg/dl. 
La diabetes tipo 2 representa el 90-95% de los casos de diabetes. Presenta una prevalencia 
creciente y subyacen defectos que pueden variar desde resistencia a la insulina predominante con 
deficiencia de insulina relativa, a un defecto predominante de secreción de insulina de las células 
beta con resistencia a la insulina. Se presenta con mayor frecuencia en los adultos que en los niños 
y aparece asociada a obesidad, falta de actividad física, en hipertensión, dislipidemia, etc. Se han 
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estudiado varios genes candidatos como posiblemente implicados en la etiología de la DM2, pero 
la evidencia actual indica que se trata de una enfermedad genética compleja. 
En las últimas tres décadas el número de personas con DM en todo el mundo se ha 
duplicado. La prevalencia mundial está aumentando rápidamente en poblaciones que han sido 
industrializadas en un corto período de tiempo. Asia se ha convertido en el "epicentro de diabetes" 
en el mundo, como resultado de su rápido desarrollo económico, seguida por la región del Golfo y 
África. La diabetes tipo 2 es cada vez más frecuente en adolescentes obesos. 25% de los niños y 
adolescentes de 21% con grado severo de la obesidad, independientemente de la etnia. En 
Europa, la prevalencia de la enfermedad en los países europeos también se estima que aumentará 
en los próximos 10 años. 
La DM tipo 2 es una enfermedad crónica con una alta morbilidad y mortalidad 
cardiovascular. Los pacientes tienen un mayor riesgo de retinopatías y nefropatías entre otras 
complicaciones. El tratamiento de la DM tipo 2 además de medicación requiere cambio en los 
hábitos de vida. Para el tratamiento farmacológico de DM tipo 2, se usan agentes orales, tales 
como las biguanidas (por ejemplo metformina), sulfonilureas, inhibidores de las alfa-glucosidasas, 
sensibilizadores de la insulina (como pioglitazona), inhibidores de DPP-IV y agentes miméticos de 
incretina. 
 
3. Aterotrombosis 
 
El endotelio vascular constituye el revestimiento interior celular de los vasos sanguíneos. 
Ha surgido como un regulador clave de la homeostasis vascular y alteraciones en su función 
pueden conducir a tales disfunciones. 
EL subendotelio subyace del endotelio e implica la matriz extracelular sintetizada por las 
células endoteliales, que contiene numerosas proteínas, como el colágeno, factor de von 
Willebrand (VWF, importante en la cascada de la coagulación), la laminina, metaloproteinasas 
(MMPs) y el factor tisular (TF, implicado en el mantenimiento de la hemostasis vascular). 
La adhesión celular es un proceso esencial necesario para el correcto funcionamiento de 
los organismos multicelulares. Moléculas de adhesión celular (CAMs) están involucrados en una 
variedad de procesos: la adhesión célula-célula y célula-matriz, la migración celular, la activación 
de los linfocitos y la iniciación de la respuesta inmune. La superfamilia Ig de receptores de 
adhesión consiste en las proteínas de la superficie celular que están implicadas en la fase final de 
la adhesión celular de los granulocitos y monocitos al endotelio. Los miembros de esta familia 
expresadas por las células endoteliales, implicadas en la adhesión de leucocitos, son las moléculas 
de adhesión intercelular (ICAM)-l y II-y la molécula de adhesión celular vascular-l (VCAM-1). 
 
El endotelio en la trombosis arterial 
Aterotrombosis arterial consiste en la disminución progresiva del calibre de la pared del 
vaso como consecuencia de la acumulación local de colesterol y la formación de las placas 
ateroscleróticas. La placa abruptamente puede romperse o el endotelio puede erosionar, lo que 
resulta en la exposición de material trombogénico, incluyendo FvW y TF, y la formación de un 
trombo en el lumen. Si el trombo es lo suficientemente grande, se bloquea la arteria induciendo 
un síndrome coronario agudo o infarto de miocardio o un accidente cerebrovascular. Si la placa no 
se rompe y la lesión continúa creciendo, la lesión puede invadir el lumen y consecuentemente 
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reducir la cantidad de sangre suministrada al tejido adyacente, lo que conduce a la hipoxia 
sintomática de este último. 
 
Papel de la inflamación en la aterogénesis 
La aterosclerosis hoy en día no es sólo debido a la hipercolesterolemia, sino también a 
complejidad de factores tales como la hiperglucemia crónica y la inflamación, local y sistémica. Las 
causas patógenas de la inflamación local y sistémica han sido subestimadas durante mucho 
tiempo, pero la presencia de inflamación sistémica es evidente incluso antes de la detección del 
infarto de miocardio. La inflamación inicia la lesión aterosclerótica y contribuye a la formación de 
la placa compleja, debilita la capa fibrosa (que causa la ruptura de la placa fácilmente) y mejora la 
trombogenicidad del núcleo lipídico. 
Como marcadores potencialmente útiles de la inflamación han sido reconocidos entre 
otros las CAMs, interleucinas (IL-6,-1β, -8, -10, -12), TNF-α, MCP-1 y biomarcadores de la matriz 
extracelular (VWF, TF). 
 
4. Los factores que contribuyen a la enfermedad cardiovascular en la obesidad y la diabetes 
mellitus tipo 2 
 
El tejido adiposo blanco es un sitio de almacenamiento de energía principalmente para 
triacilglicéridos. Hoy en día se ha demostrado poseer un papel metabólico complejo, que consiste 
en secretar y liberar una variedad de proteínas y biomoléculas, interaccionando con otros tejidos y 
órganos. Además, se le ha atribuido una actividad pro-inflamatória (secreción de citoquinas) que 
puede activar directamente los mecanismos de lesión endotelial. 
La obesidad es capaz de estimular tanto la inflamación crónica como el desarrollo de 
resistencia a la insulina. Sin embargo, la insulina se ha demostrado que tiene efectos anti-
inflamatorios, así como efectos proaterogénicos, proinflamatorios y otros. No obstante, el impacto 
de la hiperglucemia es objeto de controversia. En base a ello, investigar, como la glucosa, la 
insulina y la DM tipo 2 alteran el efecto de las adipoquinas secretadas por el tejido adiposo 
obeso, ha sido uno de los objetivos de esta tesis. 
 
La metabolómica, un método relativamente nuevo de la biología molecular, se centra en 
la medición del estado fisiológico de los metabolitos de un organismo causada por factores tales 
como la dieta, estilo de vida, ambiente, efectos genéticos y fármacos. Es principalmente funcional 
en fenotipificación, en el descubrimiento de biomarcadores, en el diagnóstico de enfermedades, y 
hasta la fecha, se sabe poco de su contribución a la caracterización de los metabolitos en suero, en 
la aparición de la diabetes y de la obesidad. 
 
5. El  papel de la metformina en el tratamiento de la diabetes tipo 2 
 
El principal modo de acción de la metformina -el fármaco de primera línea como 
antidiabético oral- es la supresión de la gluconeogénesis hepática. Esto reduce los niveles 
circulantes de glucosa, aumenta la sensibilidad hepática a la insulina, y reduce la hiperinsulinemia 
asociada con la resistencia a la insulina. 
El mecanismo molecular por el cual la metformina actúa es inhibir la producción de 
glucosa hepática celular mediante la activación de la proteína quinasa activada por AMP (AMPK), 
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una enzima hepática importante en la señalización de la insulina, en el balance de energía de todo 
el cuerpo y en el metabolismo de la glucosa y grasas . 
Como se sugiere por los datos de los ensayos clínicos, la metformina reduce la mortalidad 
cardiovascular y también la morbilidad cardiovascular, debido a su efecto reductor de glucosa. 
Además, la terapia con metformina también disminuye la sensibilidad a los agentes de agregación 
plaquetaria, probablemente debido a la reducción de los niveles de glucosa en la sangre. 
 
Objetivos 
 
Con el fin de avanzar en la comprensión de los procesos fisiopatológicos implicados en la 
aterotrombosis y la diabetes tipo 2 en la obesidad, hemos propuesto los siguientes objetivos: 
1. Investigar los efectos de las concentraciones fisiológicas y fisiopatológicas de insulina y 
glucosa en la lesión endotelial proinflamatoria y protrombótica inducida por las citoquinas 
secretadas por el tejido adiposo obeso visceral. 
2. Investigar el posible efecto protector de la metformina sobre la lesión endotelial, 
inducido por citoquinas provenientes del tejido adiposo visceral de los sujetos obesos con diabetes 
tipo 2 de diabetes establecida. 
3. Estudiar el impacto de la obesidad sobre el metabolismo de los depósitos de tejido 
adiposo regionales, o sea, visceral y subcutáneo, comparando el perfil metabólico de secretomas 
de tejido adiposo obeso visceral y subcutáneo con otros similares aislados de sujetos delgados. 
Debe considerarse que los pacientes obesos con diabetes establecida se han sometido a 
cirugía bariátrica sólo después de la iniciación del tratamiento con metformina. Por esta razón, el 
estudio de los secretomas de tejido adiposo visceral de los pacientes obesos con diabetes 
establecida sin ningún tratamiento fue, por razones éticas, no posible. 
 
Resultados 
 
1. Expresión génica en células endoteliales (CE) 
   
La expresión de genes se realizó con el fin de evaluar los cambios proinflamatorios y 
protrombóticos introducidos por el secretoma de tejido adiposo visceral de obesidad mórbida u 
obesidad mórbida de sujetos diabéticos tipo 2 tratados con metformina, en las CE. Los genes 
relacionados, cuya expresión se analiza en esta tesis, después de 24 horas de estimulación, son los 
VCAM-1, ICAM-1, FVW, TF y NF-κB. 
 
La respuesta endotelial a la estimulación con secretomas viscerales de pacientes con obesidad 
simple (Ob) vs. secretomas de obesos diabéticos tratados con metformina (DMO): 
Ambos secretomas Ob y DMO activaron las vías inflamatorias y protrombóticas, como se 
demuestra por la comparación con la condición del medio control (CM). En nuestros experimentos 
hemos observado que los secretomas del tejido adiposo de los sujetos DMO parecían activar la 
cascada inflamatoria en un grado ligeramente mayor que los obtenidos por secretomas de tejidos 
Ob, marcado por la mayor expresión de VCAM-1, NF-κB. FVW aumentó ligeramente sin alcanzar 
significación estadística. De todos modos los resultados de ICAM-1 y TF son opuestos, siendo 
bastante similares entre ambos grupos de secretoma, aunque este resultado debe tomarse con 
R e s u m e n | 173 
 
precaución debido a la alta variabilidad en el grupo de obesos. En general se puede concluir que el 
secretoma DMO provoca una ligera expresión aumentada de los genes proinflamatorios y 
protrombóticos estudiados, mientras que ambos secretomas inducen una activación importante 
de las CE con respecto al CM. 
 
La estimulación con secretomas Ob suplementados con insulina: 
La hiperinsulinemia es una característica común de la DM tipo 2 asociada a la obesidad y 
todavía persiste el debate sobre sus efectos sobre el endotelio. La potencia protrombótica y 
proinflamatoria de secretomas obesos viscerales de tejido adiposo en CE ha sido descrita 
anteriormente y publicada (resultados previos de nuestro grupo). Por lo tanto hemos decidido 
evaluar en nuestro modelo experimental in vitro el efecto complementario sobre las CE de las 
concentraciones de insulina fisiopatológicas inducido por los secretomas Ob.  
Hemos observado que la estimulación simultánea de las CE con insulina y secretoma 
durante 24 horas indujo (sólo en concentraciones de 10-7 M) un incremento en la expresión de las 
moléculas de adhesión VCAM-1, ICAM-1 y el factor de transcripción NF-κB. Curiosamente, estos 
cambios no fueron acompañados por cambios en la expresión de los genes protrombóticos FVW y 
TF, ya que parecían tener efectos protectores protrombóticos. 
 
Estimulación con secretomas Ob suplementados con glucosa: 
Con el fin de realizar una evaluación global de un efecto aditivo de la glucosa en el 
endotelio a uno inducido por los secretomas obesos, se añadió glucosa en forma concomitante. 
Hemos empleado en nuestros experimentos el estado de glucosa basal en el cultivo de HUVECs, o 
sea, 5 mM, y dos condiciones fisiopatológicas de la glucosa: 11 mM y 16 mM. 
El aumento de la concentración de glucosa parece no producir ningún daño adicional 
proinflamatorio o protrombótico a los que ya inducidos por la obesidad del secretoma Ob. De 
todos modos los resultados son difíciles de evaluar debido a la gran variabilidad observada.  
 
2. Expresión de proteínas en CE 
 
La expresión de genes era necesario ser confirmada en la proteína. La expresión del 
receptor se cuantificó después de 24 horas de estimulación, mientras que la expresión de las 
proteínas ECM se cuantificó después de 7 días de cocultivo, el tiempo requerido para la expresión 
en el subendotelio. Debido a la complejidad de la técnica, las CE fueron expuestas a las 
condiciones extremas de nuestro diseño experimental,  a las concentraciones basales y máximas 
de insulina y glucosa, respectivamente. 
Secretomas Ob y DMO actuaron de una manera similar sobre las CE, con respecto a la 
expresión de los receptores de proteínas de adhesión VCAM-1 e ICAM-1 y a la expresión del 
subendotelial protrombótico FVW. La trombogenicidad subendotelial, cuando se cuantificó por la 
adhesión de plaquetas, fue menor en los secretomas de los sujetos diabéticos tratados con 
metformina. La respuesta observada fue superior al de la condición control.  
En cuanto a la adición de insulina o de glucosa al secretoma, nuestros resultados 
confirmaron que la insulina no indujo un excedente de lesión en las CE, mientras que 
concentraciones muy altas de glucosa provocaron una disminución significativa en la adhesión de 
las plaquetas y una tendencia similar en la expresión del FVW. 
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3. Análisis comparativo de las citoquinas de secretomas Ob vs DMO 
 
Con el fin de entender los cambios en la composición de citoquinas de los secretomas de 
los pacientes DMO tratados con metformina, se examinó su patrón con los secretomas de tejido 
adiposo de los sujetos Ob. En comparación con los secretomas DMO procedentes de pacientes 
tratados con metformina, los secretomas obesos eran, excepto para IL-8 e IL-12, los que tenían la 
mayoría de citoquinas elevadas (incluyendo la protectora IL-10). 
 
4. Estudio metabolómico de los secretomas de tejido adiposo obesos 
 
En el intento de caracterizar la contribución de los secretomas de tejido adiposo obeso en 
la aparición de las complicaciones sistémicas metabólicas, se realizó un primer estudio 
metabolómico de secretomas de tejido adiposo obeso visceral y subcutáneo en sujetos obesos y 
no obesos. De acuerdo con nuestros resultados, la obesidad per se, y no la grasa de origen 
regional, modificó la firma metabólica de secretomas de tejido adiposo, y los especímenes de 
grasa visceral obesa presentaron las mayores diferencias en el patrón de metabolitos en los 
secretomas del tejido adiposo. 
 
Discusión 
 
Esta tesis pretende avanzar en el intento de descifrar el efecto de las citoquinas secretadas 
por el tejido adiposo visceral de los individuos obesos con DM tipo 2 sobre el endotelio y a su vez 
contribuir a la comprensión del efecto complementario de la hiperinsulinemia y la hiperglucemia 
en este tipo de lesiones. 
 
En nuestro modelo se analizó in vitro el efecto proinflamatorio y protrombótico en el 
endotelio de los secretomas DMO procedentes de pacientes tratados con metformina, frente a 
secretomas Ob. Dado que no era posible obtener secretomas de pacientes DMO antes de recibir 
cualquier tratamiento, basamos nuestra comparación en los datos descritos en la literatura. Hay 
una abundancia heterogénea de datos, lo que sugiere que la inflamación aumenta con el aumento 
de la masa del tejido y que la inflamación del tejido obeso y la resistencia a la insulina aumentan 
en los tejidos adiposos DMO viscerales. Por otra parte, datos de estudios de diversos sueros de 
pacientes diabéticos tipo 2 reportan un perfil diferente de adipoquinas en el suero, en función de 
la asociación con la obesidad o no.  
Nosotros esperábamos que las citoquinas proinflamatorias estuvieran mucho más 
elevadas en los secretomas DMO, debido al efecto deletéreo complementario de la diabetes en la 
obesidad. Nuestros datos indican que la metformina tiene un efecto distinto sobre la secreción de 
citoquinas del tejido adiposo obeso y su impacto sobre el endotelio del que se describe en la 
literatura,y ello a pesar de los niveles generales más bajos de las citoquinas en los secretomas 
DMO. La disminución de la IL-10 podría interpretarse como consecuencia de la disminución de la 
defensa del tejido adiposo frente a la inflamación local de larga duración. Sin embargo, los 
citoadipocinas estudiadas son sólo una selección representativa de una mayor cantidad de 
citoquinas documentadas que puede estar presentes en secretomas de tejidos adiposos obesos. 
Los secretomas DMO indujeron una expresión ligeramente mayor de los genes 
proinflamatorios y protrombóticos estudiados, mientras tanto secretomas Ob y DMO indujeron 
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una activación importante de las CE con respecto al medio de control. Además, nuestro trabajo 
proporciona evidencia adicional de que la metformina tiene un papel beneficioso en la 
trombogenicidad, no sólo con respecto a la acción plaquetaria y la síntesis de PAI-1 (datos de la 
literatura), sino también con respecto a la síntesis de una matriz subendotelial menos 
trombogénica. 
 
Estimulación simultánea de las CE con insulina y secretomas durante 24 horas indujo a 
altas concentraciones de insulina una expresión ligeramente mayor de VCAM-1, ICAM-1 y de NF-
κB, con respecto a la estimulación inducida por los secretomas Ob . Sin embargo, la insulina parece 
tener efectos protectores protrombóticos. De todos modos, estos resultados en la expresión 
génica no han sido confirmados a nivel de síntesis protéica. 
Nuestros datos están en contradicción con los emergentes en su mayoría del grupo de 
Madonna et al sobre el papel proinflamatorio de la insulina. Aún así, los resultados de la mayoría 
de publicaciones sugieren que la insulina puede ejercer potenciales efectos anti-inflamatorios y 
antiaterogénicos en ensayos clínicos y en modelos experimentales, por lo es un tanto probable 
que sea cardioprotector y mejore los resultados clínicos. 
 
De manera similar a la insulina, co-expusimos CE a secretomas Ob y concentraciones 
hiperglucémicas de 11 y 16mM. El aumento de la concentración de glucosa no provocó daño 
adicional proinflamatorio o protrombótico al ya inducido por los secretomas Ob. En algunos casos, 
la interpretación de los resultados fue difícil debido a las variaciones entre las muestras.  
Por lo tanto, nuestros datos apoyan los anteriores de la literatura que proporcionan 
evidencia sobre el hecho de que la hiperglucemia no es suficiente para promover directamente la 
activación inflamatoria endotelial. Existen pocos estudios en la literatura sobre la trombogenicidad 
macroendothelial de la matriz extracelular endotelial bajo condiciones de hiperglucemia, que 
parecen no verse afectados en la diabetes tipo 2. No obstante no se ha realizado ningún estudio 
sobre el impacto del control glucémico en este descubrimiento. 
  
Con el fin de comprender la contribución de los metabolitos surgidos del tejido adiposo 
obeso a la enfermedad metabólica sistémica asociada con la obesidad, se realizó un análisis 
comparativo de los secretomas de especímenes grasos viscerales y subcutáneos de los sujetos 
obesos y no obesos, mediante la aplicación de un enfoque metabolómico. 
En conjunto, nuestros resultados apuntan a un metabolismo elevado de aminoácidos y a 
una sobrecarga del catabolismo de aminoácidos BCAA en el tejido adiposo obeso inflamado. Esto, 
a su vez, independientemente, contribuye a la alteración y el aumento de aminoácidos 
metabolizados, sosteniendo las acciones perjudiciales de los aminoácidos en la aparición de 
complicaciones en la obesidad.  
Nuestros resultados demuestran que las primeras etapas de la obesidad, incluyendo la 
presencia de inflamación sistémica y la resistencia a la insulina, antes de la aparición clínica de 
importantes alteraciones metabólicas, se caracterizan por un incremento en el metabolismo de 
aminoácidos y su secreción. Además, gracias a la combinación de análisis funcionales y 
metabólicas se espera comprender la alteración dinámica del metabolismo de aminoácidos en el 
estado de obesidad y su contribución específica de sus metabolitos en la enfermedad sistémica 
metabólica. 
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Conclusiones 
 
Teniendo en cuenta los resultados obtenidos en esta tesis y bajo las condiciones aplicadas, 
se concluye lo siguiente: 
1. El tratamiento con metformina, un método ampliamente utilizada para normalizar la 
glucosa de pacientes afectos de diabetes tipo 2, actúa sólo de manera parcial en la 
reducción de las citoquinas nocivas secretadas por el tejido adiposo visceral de pacientes 
diabéticos tipo 2. 
2. La insulina, añadida al secretoma obeso visceral, no amplia ni reduce el daño inducido en 
el endotelio por el propio secretoma. 
3. La glucosa no es capaz de inducir un incremento en la lesión endotelial, adicional al daño 
inducido por las citoadipoquinas del secretoma obeso visceral. 
4. La huella metabólica de los secretomas del tejido adiposo se ve alterada por el estado de 
la obesidad en general. Los depósitos viscerales obesos presentan las mayores diferencias 
en el patrón de metabolitos de los secretomas. Las etapas tempranas de la obesidad, 
incluyendo la presencia de inflamación sistémica y la resistencia a la insulina, se 
caracterizan por una alteración en el metabolismo y la secreción de aminoácidos por el 
tejido adiposo. 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
